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Natural products have been exploited by humans as the most consistently reliable 
source of medicines for hundreds of years. Owing to the great diversity in chemical 
scaffolds they encompass, these compounds provide an almost limitless starting 
point for the discovery and development of novel semi-synthetic or wholly synthetic 
drugs. In Africa, and many other parts of the world, natural products in the form of 
herbal remedies are still used as primary therapeutic interventions by populations 
far removed from conventional healthcare facilities. However, unlike conventional 
drugs that typically undergo extensive safety studies during development, traditional 
remedies are often not subjected to similar evaluation and could therefore harbour 
unforeseen risks alongside their established efficacy. 
 
A comparison of the ‘drug-like properties’ of 335 natural products from medicinal 
plants reported in the African Herbal Pharmacopoeia with those of 608 compounds 
from the British Pharmacopoeia 2009 was performed using in silico tools. The data 
obtained showed that the natural products differed significantly from conventional 
drugs with regard to molecular weight, rotatable bonds and H-bond donor 
distributions but not with regard to lipophilicity (cLogP) and H-bond acceptor 
distributions. In general, the natural products were found to exhibit a higher degree 
of deviation from Lipinski’s ‘Rule-of-Five’. Additionally, these compounds possessed 
a slightly greater number of structural alerts per molecule compared to conventional 
drugs, suggesting a higher likelihood of undergoing metabolic bioactivation.    
 
A combination of CYP450 enzyme inactivation assays and reactive metabolite 
trapping experiments was used to evaluate in vitro bioactivation of 15 natural 
product and natural product-derived compounds. Gedunin, Justicidin A and 
Jamaicin were found to be potent inhibitors of the main drug metabolizing isoform 
CYP3A4. Gedunin also exhibited potent inhibition of CYP2C19. The inhibition of 
CYP3A4 was, however, not time-dependent and therefore unlikely to be due to 
reactive metabolite-mediated inactivation of the enzyme. Inhibition of the other 
 
vi 
main drug metabolizing isoforms, CYP1A2, CYP2C9 and CYP2C19 was markedly less 
pronounced. 
 
Direct assessment of the formation of electrophilic reactive metabolites was carried 
out by incubating 11 of the 15 compounds in hepatic microsomal preparations 
fortified with nucleophilic trapping agents. Using methoxylamine as a trapping agent, 
incubations of the monosubstituted furan ring-containing compounds Gedunin and 
the tetraol DC3 were found to contain components strongly suspected to be trapped 
reactive metabolites. None of the compounds tested formed detectable adducts 
when incubated in the presence of either reduced glutathione or potassium cyanide. 
 
The cross-reactivity of eight chemical inhibitors commonly used in early CYP450 
phenotyping assays revealed the relatively low selectivity of ticlopidine and 
diethyldithiocarbamate. These assays also highlighted the particularly low potency of 
diethylthiocarbamate as the routinely preferred inhibitor for determining the 
contribution of hepatic CYP2E1 to xenobiotic metabolism. The data obtained 
provided ample evidence for the need to identify and characterise a superior 
replacement inhibitor for CYP2E1 phenotyping.  
 
The determined cross-reactivity values of different inhibitors were used to formulate 
a mathematical strategy to compensate for cross-inhibition in CYP450 enzyme 
phenotyping calculations. Recalculation of previously obtained CYP3A4 phenotyping 
data using the new strategy appeared to improve the correlation between 
fm,CYP3A4 values determined using different phenotyping approaches. A similar 
effect on phenotyping data from other CYP450 enzymes could not be established 
owing to a limitation in the size of the pre-existing dataset. 
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CHAPTER ONE:  
INTRODUCTION AND LITERATURE REVIEW 
1.1 Summary 
In this Chapter, the role played by natural products as a well established resource 
from which drugs have been discovered is discussed. Metabolism of xenobiotic 
compounds through different enzymatic systems in man is highlighted as a primer to 
more detailed discussions on metabolism-mediated adverse reactions to 
xenobiotics. The potential for natural products to cause adverse reactions in humans 
resulting from their metabolic bioactivation is discussed with reference to specific 
examples cited in the literature. The different approaches used to predict, detect 
and mitigate against undesirable toxicity arising from metabolism of xenobiotics in 
the early stages of the drug development process are covered. The research 
question to be answered, study justification and specific objectives of this work are 
highlighted at the conclusion of the Chapter. 
 
1.2 Natural Products 
In medicinal chemistry, the term ‘natural product’ is used to describe a low 
molecular weight chemical compound, usually excluding proteins and nucleic acids, 
produced or extracted from living organisms. Natural products are therefore 
obtained from terrestrial plants, microbes, marine organisms and animals.1,2 In many 
instances, natural products are sometimes referred to as secondary metabolites, 
usually because the exact physiological or biochemical role(s) they play in the source 
organism is often unknown. In plants, however, some natural products are known to 
play a variety of functions, including providing defence mechanisms against 
predators or pathogens, or acting as chemo-attractants of pollinators and seed 
dispersers.3,4 Microbes on the other hand are known to synthesize natural products 
that kill or inhibit the growth of sensitive strains of the same or related microbial 
species in their immediate environment.5  
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Although not usually essential for the survival of the host organisms, natural 
products confer an evolutionary advantage that boosts chances of survival in 
adverse environmental conditions. 
1.3 Natural Products as Sources of Drugs 
1.3.1 Historical Perspective 
Since antiquity, natural products have been used, usually in crude form, as a key 
component of ancient yet sophisticated traditional medicine systems to combat 
disease.6 Paleoanthropological field studies have uncovered evidence suggesting 
that prehistoric Neanderthal man may have been aware of the medicinal properties 
of some plants more than 60,000 years ago. Records from ancient civilisations in 
Mesopotamia, Egypt and Greece provide documented proof of the systematic use of 
natural products in medicine in meticulously detailed pharmacopoeia dating back 
many centuries before the current era. Traditional Chinese Medicine (TCM) and 
Indian Ayurvedic therapies still in widespread use today both rely heavily on natural 
product-derived remedies, which have been in use for hundreds of years.7 
For centuries, natural products were used for therapeutic purposes in their crude 
forms, usually as combinations of both pharmacologically active and inactive 
compounds. In the early 1800s, however, the laboratory isolation of morphine as the 
first pure natural compound by the German pharmacist Friedrich Wilhelm Adam 
Sertürner opened a new age of medicinal natural product chemistry.8,9 Following this 
discovery and subsequent commercialization of morphine by the pharmaceutical 
company E. Merck, focus on natural products gradually shifted towards the 
identification of active compounds, their isolation, purification and characterization 
from crude preparations. By 1820, for example, isolation of the antimalarial drug 
quinine from the bark of Cinchona species had been reported by Pierre Joseph 
Pelletier and Joseph Bienamié Caventou.10 Yet another shift in the paradigm to 
natural products chemistry was realized in the mid-nineteenth century. Although the 
bark of the willow tree (Cortex salicis) had been used as early as 400 B.C. by the 
Greeks and Romans to alleviate pain, its natural product active ingredient, salicin, 
was only identified in the 1800s. Degradation of salicin yields salicylic acid, which has 
superior analgesic and antipyretic properties. The German chemist, Hermann Kolbe, 
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reported the successful total synthesis of salicylic acid in 1859, the earliest recorded 
instance of a natural product-derived medicinal compound being prepared in the 
laboratory. Chemical modification of salicylic acid to the better tolerated acetyl 
salicylic acid by Felix Hoffmann led to large scale manufacture and commercialization 
of the drug Aspirin® by Bayer in 1899.11 Thus, the age of commercial drug discovery 















Figure 1.1 Earliest examples of drugs isolated from or inspired by natural products 
Natural products have contributed to the development of new drugs in mainly three 
ways: (1) By serving as active medicinal compounds in their free unmodified state, as 
illustrated by both morphine and quinine; (2) acting as chemical starting points or 
building blocks for the synthesis of more complex molecules. For example, diosgenin 
is used as the starting material for the synthesis of steroidal contraceptive drugs; (3) 
providing insights into new modes of pharmacological action and paving way for the 
preparation of novel or wholly synthetic analogues.2 
Due to technical improvements in screening programs as well as in separation, 
purification and characterization techniques, more than 1,000,000 natural 
compounds have been discovered since the early efforts of Sertürner. An estimated 
50 - 60% of these compounds are produced by plants while about 5% are of 
microbial origin. Of all reported natural products, approximately 20 - 25% exhibit 
some kind of biological activity.12 
 
1.3.2 Drugs from Plant Natural Products 
Plants are the oldest sources from which natural product-based remedies have been 
obtained. It is, therefore, unsurprising that more than half of the natural products 
successfully developed into medicines are derived from plants. Although 
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approximately 250,000 unique higher plant species have been identified to-date, 
only about 5 - 15% of these have been investigated chemically and 
pharmacologically. Considering the known potential for plants to produce hundreds 
of secondary metabolites unique to certain species or genera, the possibilities of 
sourcing still more novel medicinal compounds from such an array would appear 
almost unlimited. The chemical diversity of plant-derived natural products is well 
illustrated by the sheer volume of chemical scaffolds they encompass, including but 
not limited to alkaloids, terpenoids, lignans, flavanoids, tannins and phytosteroids.13  
This diversity in chemotypes has resulted in the isolation and development of 
compounds that are used to treat a wide spectrum of medical conditions as briefly 
summarized in Table 1.1.14,15 
 
Table 1.1: Examples of drugs obtained from plant derived natural products 
Drug Chemical Class Plant source Therapeutic use 
Artemisinin Sesquiterpene Artemisia sp. Antimalarial 
Atropine Alkaloid Atropa belladonna Anticholinergic 
Digitalin, Digitoxin Cardiac glycosides Digitalis purpurea Cardiotonic 
Ephedrine Phenylpropanolamine Ephedra sinica Sympathomimetic 
Galanthamine Alkaloid Galanthus sp. Anti-Alzheimer 
Paclitaxel Taxane diterpene Taxus brevifolia Antineoplastic 
Podophyllotoxin Lignan Podophyllum peltatum Antiviral 
Quinidine Alkaloid Cinchona ledgeriana Antiarrhythmic 
Vincristine, 
Vinblastine 
Vinca alkaloids Catharanthus roseus Antineoplastic 
 
Plant-derived natural products have been particularly successful as sources of 
antitumour and anti-infective agents. Of all drugs approved for the treatment of 
cancer between 1940 and 2002, 40% were derived directly from or inspired by plant-
based natural products.16 This relatively high proportion may be partly explained by 
the concerted efforts of the US National Cancer Institute to screen large numbers of 
plant-based natural products for anti-tumour activity over the last 60 years. Between 
1960 and 1982, over 35,000 plant samples mostly from temperate regions of the 
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world were collected randomly, from which more than 114,000 plant extracts were 
screened for anti-tumour activity. It is from these efforts that anticancer drugs such 
as paclitaxel and camptothecin were ultimately developed.17,18  
In the treatment of malaria too, plant natural products play a central role in 
chemotherapy. Quinine is still used as the drug of choice in the management of 
severe complicated P. falciparum malaria while artemisinin derivatives are currently 
recommended as first line treatments for uncomplicated P. falciparum malaria in the 
form of artemisinin-based combination therapies.19  
 
1.3.3 Drug Discovery from Microbial Natural Products 
The discovery of the prototype antibiotic penicillin by Alexander Fleming from a 
mould in 1929 and its subsequent commercialisation in the 1940s revolutionalized 
the practice of medicine and ushered in the age of antibiotic drug discovery.20–22 Due 
to the astounding impact of penicillin, pharmaceutical companies embarked on 
concerted efforts to discover new antibiotics from microbial sources over the 
following decade. This resulted in the discovery of such compounds as streptomycin 
in 1943,23 chlortetracycline in 1945,24 chloramphenicol in 1947,25 cephalosporins 
such as cephalosporin C in 1949, erythromycin in 195226 and vancomycin in 1953.27 
Most of these compounds are still used clinically as drugs today. 
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Figure 1.2: Prototype antibiotics of different classes isolated from microbial sources 
 
Microbes, especially fungi and actinobacteria, are perhaps the richest source of 
drugs currently used as antibiotics in the treatment of infectious diseases as briefly 
summarized in Table 1.2. 
Table 1.2: Examples of natural product antibiotics from microbial sources in current clinical use 
Compound Chemical Class Microbial source Species 
Benzylpenicillin Penicillin Fungi 
Penicillium spp e.g. P.  
chrysogenum 
Griseofulvin Antifungal Fungus Penicillium griseofulvum 
Rifampicin  Rifamycin Actinobacteria Amycolatopsis mediterranei 
Gentamycin Aminoglycoside Actinobacteria Micromonospora purpurea 
Oxytetracycline Tetracycline Actinomycete Streptomyces rimosus 
Vancomycin Glycopeptide Actinobacteria Amycolatopsis orientalis 
Daptomycin Lipopeptide Actinobacteria Streptomyces roseosporus 
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Compound Chemical Class Microbial source Species 
Erythromycin Macrolide Actinomycete Saccharopolyspora erythraea 
Lincomycin Lincosamide Actinobacteria Streptomyces lincolnensis 
Bacitracin Polypeptide Bacteria (Gram+) Bacillus subtilis 
Mupirocin Carboxylic acid Bacteria (Gram-) Pseudomonas fluorescens 
Microbial natural product-derived drugs have also been licensed for use in the 
treatment of non-infectious diseases. For example, the fungal metabolite mevastatin 
is the natural-product inspiration behind the development of cholesterol lowering 
statin drugs such as lovastatin, atorvastatin and rosuvastatin.28,29 Anthracycline 
antibiotics such as the natural product daunorubicin and its semi-synthetic derivative 
doxorubicin are clinically used as antineoplastic agents for the treatment of cancer 
while the macrolide rapamycin (sirolimus) is used as an immunosuppressant to 




















































Figure 1.3: Drugs derived from microbial sources used for treatment of non-infectious diseases 
 
1.3.4 Drug Discovery from Animal-Derived Natural Products 
Compared to plants and microbes, the animal kingdom has been relatively neglected 
as a source of natural product-derived drugs.32 Nevertheless, some notable examples 
of clinically used compounds from different animal species exist, mostly having been 
developed from animal toxins, venoms or hormones. For instance, the discovery and 
development of angiotensin converting enzyme (ACE) inhibitors such as captopril 
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and later analogues such as enalapril, ramipril and lisinopril was inspired from a 
nonapeptide found in venom obtained from the Brazilian pit viper (Bothrops 
jararaca).33 Since their launch in the early 1980s, ACE inhibitors have become some 
of the most widely used drugs in the management of cardiovascular diseases 































Figure 1.4: ACE inhibitors developed from an animal derived natural product 
 
The antidiabetic drug exenatide obtained from the hormone exendin-4 found in 
saliva of the Gila monster (Heloderma suspectum) is another drug from an animal 
derived natural product currently in clinical use. Other examples of drugs developed 
from animal-derived natural products include the antiplatelet compounds 
eptifibatide, derived from the peptide barbourin found in the venom of the south-
eastern pygmy rattlesnake (Sistrurus barbouri) and bivalirudin, engineered from 
hirudin present in the saliva of leeches (Haementeria officinalis).35,36  
 
 
Figure 1.5: Gila monster. Source of exendin-4, precursor of antidiabetic drug exenatide 
 
1.3.5 Marine Invertebrates 
Considering that oceans and seas make up almost 70% of the earth’s surface and are 
home to an enormously rich biodiversity, the marine environment has been 
comparatively frugal in yielding natural products that have been successfully 
developed into drugs.37  Among the factors that have contributed to the relatively 
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low return in marine drug discovery may be the fact that a vast expanse of the 
world’s oceans and seas still remains unexplored. Another challenge lies in the 
reality that many of the rich sources of marine natural products, such as sponges and 
their fauna, survive exclusively in marine environments and are virtually 
uncultureable.38 Nevertheless, advances in marine research technology and 
exploration have gradually made this environment more accessible and resulted in a 
steady increase in the number of novel marine natural products isolated and 
reported in the literature over the past 30 years as periodically reviewed by Faulkner 
and Blunt et al. 39–45 A common feature that has raised interest in marine natural 
products as potential sources of drugs is the extremely high potency exhibited by 
many of the bioactive marine compounds thus far isolated. This characteristic is 
thought to be most likely a means of circumventing the inevitable dilution of 
secondary metabolites produced by marine organisms necessitating such high 
potency for efficacy.46 
The first drugs to be developed and licensed from marine natural products were the 
anti-leukaemic compound cytarabine and the antiviral vidarabine in 1969 and 1976, 
respectively. These drugs were developed from the nucleosides spongouridine and 
spongothymidine isolated from the demosponge Techtitethya crypta found in the 
Caribbean sea.47,48 
Thereafter, the next marine-derived compound to receive marketing approval in the 
USA was the potent non-opioid analgesic ziconotide isolated from a cone snail 
species and which was only licensed as recently as 2004. Ziconotide is used for the 
management of severe chronic pain and was developed as a synthetic form of the 
hydrophilic conopeptide ω-MVIIA obtained from the venom of the Pacific fish-
hunting snail, Conus magus. This drug is the prototype in a new class of selective N-
type voltage sensitive calcium channel blockers.49  
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Figure 1.6: Fish-hunting cone snail (Conus magus)
49 
 
The drug trabectedin (ET-743) is another marine natural product that has been 
successfully developed into a clinical anticancer agent for treatment of soft tissue 
sarcomas and ovarian cancer. This compound was initially isolated from aqueous 
extracts obtained from the sea squirt Ecteinascidia turbinata in the Caribbean, and 
found to be a potent cytotoxic agent having good stability and relatively high natural 
abundance.50 Trabectedin was licensed for clinical use by the EMA in 2007. 
Another marine-derived anti-cancer agent, eribulin, was approved by the US FDA for 
clinical use in the treatment of intractable metastatic breast cancer in 2010. 
Although eribulin is a fully synthetic compound, its development was inspired from 
the polyether macrolide natural product halichondrin B, originally isolated from the 
marine sponge Halichondria okadai. Halichondrin B has extremely potent anticancer 
activity, and acts through tubulin binding similar to that exhibited by the vinca 
alkaloid antineoplastic agents vinblastine and vincristine. Eribulin was developed 
from halichondrin B as a structurally simplified and pharmaceutically optimized form 
of this compound for clinical use.51  
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Figure 1.7: Examples of marine natural product derived drugs. The portion of Halichondrin B from 
which the drug eribulin was developed is circled for ease of reference. 
 
Marine-derived natural products that have been advanced to various stages of 
clinical trials for different applications in recent years are summarized in Table 
1.3.52,53 
 









III Tetrodotoxin Tetrodotoxin Tetraondontiformes Analgesic 
II-III Plitidepsin Plitidepsin Aplidium albicans Anticancer 
II XEN-2174 χ-conotoxin MrIA Conus marmoreus Analgesic 
II Kahalalide F Kahalalide F Elysia rufescens Anticancer 
II Plinabulin Halimide Aspergillus spp. Anticancer 
II DMXBA Anabaseine Marine worms Schizophrenia 
II PM1004 Jorumycin Joruna funebris Anticancer 
I-II PM-10450 Jorumycin Joruna funebris Anticancer 
I Leconotide ω-conotoxin CVID Conus catus Analgesic 
I Marizomib® Salinosporamide A Salinispora tropica Anticancer 
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1.3.6 Other Potential Sources of Natural Product-Derived Drugs 
It has been estimated that the chemical space occupied by organic compounds, 
including natural products, having a molecular weight of less than 500 extends to 
approximately 1060 compounds.54  It is therefore, perhaps not an understatement to 
claim that despite a significant number of drugs in clinical use having been derived 
from natural products, these represent only a small fraction of the vast drug 
discovery opportunities yet to be exploited. 
Based on the success of drugs from animal natural products, one area that has been 
proposed for potential exploitation is the field of venomics, involving drug discovery 
from building and screening venom libraries obtained from both terrestrial and 
marine organisms.55  
Natural products obtained from organisms that inhabit and thrive in extreme 
environments have also attracted growing interest in recent years. Extremophilic 
microbes such as acidophiles, alkaliphiles, halophiles, piezothermophiles, 
hyperthermophiles or psychrophiles56 are increasingly being evaluated as sources of 
novel secondary metabolites and possible drug leads.57 For example, the 
extremolyte ectoine found in many halophilic microbes that survive in high salt 
concentration environments has been investigated as a cytoprotectant and protein 
stabiliser with potential application in treatment of conditions such as Alzheimer’s 
disease.58,59   
Organisms that inhabit the deep sea environment are highly adapted to survive in a 
habitat characterized by intensely high pressures, low temperature, oxygen and light 
concentrations as well as scarce nutrients. Under such conditions, these organisms 
have evolved unique primary metabolic pathways resulting in the production of 
entirely novel secondary metabolites. With advances in marine exploration 
equipment enabling greater access to this largely unexplored habitat, deep sea 
marine organisms continue to attract greater study and have yielded a growing 
number of unique bioactive natural products.60 Deep-sea hydrothermal vents have 
been identified as habitats occupied by invertebrates capable of surviving and 
thriving under possibly the harshest conditions on earth. Though such organisms are 
not known to produce natural products, most survive through symbiotic associations 
with micro-organisms that do produce secondary metabolites. The first true new 
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natural products isolated from deep-sea hydrothermal vents were the ammonificins 
and loichichelins reported in 2009. These may represent the first in a possibly rich 





















































Loihichelin A  
Figure 1.8: Natural products isolated from organisms that inhabit extreme environments 
 
1.4 Past Decline, Current Status and Future Prospects of Natural Product-Based 
Drug Discovery 
Despite the numerous successes in obtaining drugs from natural products, there has 
been a gradual de-emphasis in natural product drug discovery by most of the major 
pharmaceutical companies over the last 20 years. Several factors have led to this 
shift, including a greater investment in newer drug discovery approaches based on 
synthesis and high throughput screening of large libraries of synthetic compounds 
created using combinatorial chemistry. Although the success-rate of drug discovery 
using such methodology is lower than that based on natural products, it possesses 
the key advantage of speed. Since the compounds screened are already known, the 
time and effort needed to characterise and identify them is eliminated, whereas in 
natural product-based drug discovery, such technical aspects take up considerable 
time and effort. Furthermore, synthetic compounds are much more easily packaged 
CHAPTER 1: INTRODUCTION AND LITERATURE REVIEW 
 
NICHOLAS M. NJUGUNA - Ph.D. THESIS 2014 
 
14 
into physical libraries for large-scale high throughput screening for biological activity 
compared to natural products.62 
The reviews published by Newman and Cragg, however, provide compelling 
evidence that natural products have been the single-most successful source of 
approved drugs over the last 30 years.63–66 Thus, despite the challenges often 
encountered in obtaining drugs from nature, the advantages they possess have been 
successfully circumvented in those compounds advanced to clinical use. Factors that 
might explain these successes include increased access to natural products through 
(1) Exploration and research into new environments; (2) advances in compound 
separation, isolation and characterization techniques often employing coupled 
technologies such as liquid chromatography coupled to solid-phase extraction and 
nuclear magnetic resonance67–69 (3) more sensitive and accurate analytical 
equipment allowing ease of characterization using non-destructive techniques and 
minute quantities of material, for example, multidimensional NMR spectroscopy 
using cryoprobes and advances in high resolution mass spectroscopy 
instrumentation.70 
Additionally, in many cases, natural products possess certain advantages over 
synthetic compounds that have distinguished them as more reliable sources of 
drugs:71 
1. Unmatched diversity and chemical complexity. Chemical scaffolds that would be 
virtually impossible or extremely difficult to replicate in the laboratory even using 
modern chemical synthetic techniques (e.g. due to presence of numerous chiral 
centres, and unusual bond patterns are often commonly encountered in nature. 
Even where such synthesis is possible, it may not be amenable to large scale 
application necessary for commercial drug manufacture. 
2. Natural products tend to occupy a complementary chemical space to that of 
conventional drugs, and many quite often violate what are considered to be the 
rules of ‘drug-likeness’ yet still possess desirable chemotherapeutic profiles.72 
3. Most natural products are the result of thousands of years of evolutionary 
development representing optimized output that has been perfected over 
countless generations. Thus, unlike synthetic drugs that usually need to undergo 
numerous iterative improvements to enhance their pharmacological profiles 
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prior to attaining the desired properties, many natural products, such as 
antibiotics from microbes, are often produced in a form ready for direct 
exploitation. 
 
The paradigm shift of drug discovery driven through wholly synthetic combinatorial 
chemistry has not had the anticipated returns in terms of yielding large numbers  of 
block-buster drugs despite enabling the screening of vast libraries of compounds in 
short time-frames. Considering the successes of natural-product driven drug 
discovery on the other hand, it appears that an approach that embraces a 
combination of both aspects offers the best option for future drug-discovery 
programs.73 For example, it has been proposed that natural products could be used 
as a basis for creating combinatorial libraries of synthetic compounds, either as a 
source of chemical scaffolds or as an inspiration towards natural-product-like 
synthetics.74,75 Alternatively, generation of natural product analogues using 
biosynthetic enzymes or genetically altered microorganisms may provide an avenue 
for accessing unique derivatives of natural product hits, circumventing the 
challenges associated with synthetic chemical modification.76 To counter the 
problem of limited quantities of rare natural products, bioengineering easily cultured 
heterologous microbial vectors to produce the desired compound or its synthetic 
intermediate(s) could become commonplace. This approach has been successfully 
demonstrated in the production of artemisinic acid, a precursor of the plant derived 
sesquiterpene antimalarial artemisinin, using yeast cells.77 Related to this is the 
application of metagenomic techniques involving the isolation and identification of 
genes present in the environment directly without the need to identify their source 
organisms beforehand and producing secondary metabolite natural products by 
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1.5 Metabolism of Xenobiotics 
To maintain chemical and functional homeostasis in all body tissues upon exposure 
to chemical challenges, most organisms have evolved elaborate metabolic systems. 
In man, metabolic transformation of xenobiotics is performed by a diverse array of 
proteins, collectively referred to as drug metabolizing enzymes. These convert 
chemicals present in food, the environment, pollutants, toxins, cosmetics and drugs 
into compounds that can be more readily eliminated from the body. The enzymes 
also often catalyse the transformation of endogenous substrates such as steroids, 
hormones, and neurotransmitters into active or inactive forms for elimination.80  
Metabolism of xenobiotics has traditionally been classified as occurring in phases. 
Phase I metabolism involves functionalization reactions on substrates resulting in the 
introduction or unmasking of chemical functional groups such as hydroxyls, amines, 
carboxylic acids or thiols. Phase II metabolism involves synthetic conjugation 
reactions in which the functionalized xenobiotic metabolite is chemically bound to a 
polar endogenous substrate. Although phase II metabolism often involves the 
product formed from phase I reactions, it can also take place directly on the parent 
substrate.The overall goal of xenobiotic metabolism is to transform foreign 
compounds into more polar, water soluble forms that can be more readily 
eliminated from the body. 
Phase I metabolic reactions introduce or unmask a functional group in the xenobiotic 
substrate to provide a chemical site for subsequent conjugation reactions. Several 
enzymes are involved in these reactions which chemically broadly encompass 
aliphatic and aromatic hydroxylations usually through monooxygenation reactions, 
reductions and hydrolysis of esters and amides. In most cases, phase I metabolism 
results in only a slight increase in substrate hydrophilicity.  
The cytochrome P450 (CYP450) superfamily of enzymes is a class of oxidoreductases 
coded for by 57 genes and 58 pseudogenes in humans which are the most important 
group of drug metabolising enzymes in man.81 These enzymes are monooxygenases 
that catalyse the chemical addition of a single oxygen atom to a vast array of both 
endogenous and xenobiotic substrates in a general reaction simplified thus: 
O2 NADPH H
+ NADP+ H2OR OHR H  
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Structurally, CYP450 enzymes are haemoproteins with an average molecular weight 
of approximately 50,000 Da.82 At their active sites, they contain a prosthetic 
ferroprotophyrin IX ring at the centre of which a reduced iron (Fe) atom is bound to 
four nitrogen atoms and has two free coordination sites for bonding to a conserved 







O OH OHO  
Figure 1.9: Structure of chain A of human CYP3A4 enzyme. (The prosthetic iron protoporphyrin IX ring 
system is clearly visible at the active site of the enzyme). 
 
Intracellularly, CYP450s are bound to the membrane of the smooth endoplasmic 
reticulum in close proximity to cytochrome P450 reductase and cytochrome b5 which 
are both important components in the CYP450 oxidation cycle. CYP450s are also 
found in mitochondrial membranes but in this case having their globular domain 
oriented towards the lumen.84 
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CYP450s are distributed in virtually all body tissues but occur at their highest 
concentrations in the liver. Other organs in which the enzymes are present in 
significant concentrations include the respiratory tract, kidneys, gastro-intestinal 
tract, brain, heart and skin.86 Some isoforms are present in varying concentrations in 
all these different sites, while others are known to be preferentially expressed only 
in certain tissues or stages of embryonic development. For example, CYP3A7 is 
expressed abundantly in the endometrium and fetal liver during pregnancy but its 
concentration and activity rapidly decline after birth and the isoform is virtually 
absent in adult tissue. On the other hand, all other CYP isoforms are only present at 
extremely low concentrations in fetal liver but gradually increase after birth.87 
 
 




A few CYP450 enzymes belonging to the families CYP1, CYP2 and CYP3 have been 
identified as being involved in the metabolism of xenobiotics. Of these, five specific 
isoforms (CYP1A2, 2C9, 2C19, 2D6 and 3A4) contribute to the metabolism of 
approximately 95% of drugs that are metabolized by the CYP enzyme system, 
representing approximately 75% of all clinically used drugs.89 
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Oxidation of substrates by CYP450s is a complex multistep process involving the 
enzyme, reduced nicotinamide adenine dinucleotide phosphate (NADPH) as the 
electron donor and flavin adenine dinucleotide (FAD)-containing P450 reductase 
serving as the electron transfer bridge as illustrated in Figure 1.13.85 
 
Figure 1.13: Simplified catalytic cycle illustrating substrate oxygenation by CYP enzymes
85
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In addition to catalyzing classical and relatively direct monooxygenation reactions, 
CYP450s have been found to mediate more complex transformations such as 
chlorine oxygenation, aromatic dehalogenation, ring expansion and ring formation,  
as well as cleavage of amino oxazoles and the 1,2,4-oxadiazole ring.91,92 
Genes encoding for CYP450s belonging to the families CYP1, CYP2 and CYP3 are 
polymorphic. However, the phenotypic importance of the variant alleles in terms of 
catalytic activity and protein expression differs. Of the major drug metabolising 
isoforms, CYP2C9, CYP2C19 and CYP2D6 in particular are well known to exhibit 
pronounced polymorphism, which often translates to significant inter-individual or 
inter-population variations in how these enzymes metabolize xenobiotics.93 Such 
variation can have a major impact on the therapeutic efficacy of drugs metabolised 
predominantly by these isoforms as well as on their potential toxicity due to 
phenotypic variability in metabolism-mediated  detoxification and elimination.94  
 
Table 1.4: Summary of other non-CYP450 enzymes involved in metabolism of xenobiotics  




Complementary redox system to CYP450s in drug 




Aldehyde oxidase and xanthine 
oxidoreductases 
Molybdenum hydroxylases involved in oxidation of 
aromatic azaheterocyclic xenobiotics and  





Key in metabolism of endogenous catecholamine 
neurotransmitters; inhibitors used clinically as 
antidepressants and in Parkinson’s disease
99–102
 
Alcohol and aldehyde dehydrogenases 
Extensively diverse superfamilies of polymorphic 















Uridine glucuronosyl transferases  
Principally conjugative enzymes that couple 
xenobiotics or their Phase I metabolites to an 
endogenous substrate donated by cofactors such as 
uridine 5’-diphosphoglucuronic acid (UDPGA), 3’-
phosphoadenosine-5’-phosphosulfate (PAPS), 
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1.6 Classification of Metabolites 
Regardless of the route through which xenobiotic substrates are metabolized, the 
net result is the formation of metabolic species that may be broadly classified based 
upon chemical reactivity as stable or reactive. 
1.6.1 Stable Metabolites 
1.6.1.1 Biologically inactive stable metabolites 
In many instances, the chemical modification of xenobiotics by metabolic enzymes 
results in a total or significant loss of pharmacological activity due to changes in their 
chemical properties and ability to interact with therapeutic targets in vivo. When 
designing drugs, emphasis is often placed on developing compounds that possess 
optimal metabolic stability to allow for convenient dosing. In some cases, however, 
drugs may be intentionally designed to be readily metabolised to inactive species in 
a predictable and controllable manner after exerting their therapeutic activity by 
incorporating metabolic hotspots in the molecule. This ‘soft drug’ design is 
particularly useful in developing medicines that have minimal adverse effects arising 
from their interaction with off-target receptors or due to biotransformation to 
multiple metabolic products.122  
 
1.6.1.2 Biologically active metabolites 
Conversely, metabolism of the xenobiotic substance may result in products that 
possess pharmacological activity of equal, lesser or greater magnitude than the 
parent. Active metabolites are thus be defined as metabolic products of 
biotransformation that have pharmacological activity against the same 
pharmacological target as the parent drug molecule.123 The phenomenon of active 
metabolite formation is sometimes utilized in the formulation of medicines as 
prodrugs which are inherently inactive but designed to undergo metabolic 
biotransformation to yield therapeutically active metabolites. The prodrug approach 
is useful in allowing for the design of compounds that possess optimized 
physicochemical properties such as membrane permeability, aqueous solubility or 
chemical stability and enhanced pharmacokinetic profiles.124,125 
Most active drug metabolites arise from phase I metabolism, but some medicines 
are known to yield both active and inactive phase II metabolites. For example, 
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morphine-6-glucuronide is known to possess even greater analgesic activity than its 
parent morphine, whereas morphine-3-glucuronide has been shown to be a potent 
opioid antagonist in animal models and somewhat paradoxically, also appears to 
enhance pain through unknown mechanisms.126,127 
Figure 1.14: Glucuronide metabolites of morphine having different pharmacological activities 
 
1.6.2 Reactive Metabolites 
Reactive metabolites were first recognized in work reported in the 1940s when 
James and Elizabeth Miller investigated the metabolism in rats of the carcinogenic 
dye 4-dimethylaminoazobenzene (DAB) formerly used as a food coloring agent.  
They observed that liver proteins of animals treated with DAB became permanently 
yellow colored. Upon treatment with alkali, these proteins released 3-methylthio-N-
methyl-4-aminoazobenzene, suggesting that covalent binding involved modification 
of protein methionine residues by an “active form” of a mono-demethylated 
metabolite of the dye.128 Reactive metabolites are unstable and chemically reactive 
products of metabolism capable of reacting with endogenous macromolecules in 
their immediate environment, including the enzymes responsible for their formation. 
These metabolites may be classified into two broad categories: electrophiles - which 
may be further classified as being either alkylating or acylating agents and free 
radicals. Alternatively, electrophiles may also be classified as being soft or hard 
species. The classic soft electrophiles include epoxides, α,β-unsaturated carbonyls, 
quinones, quinone imines, quinone methides, imine methides, isocyanate, 
isothiocyanates, aziridinium and episulfonium ions. Aldehydes and iminium ions are 
regarded as being hard electrophiles.129 Electrophiles vary in their selectivity for 
biological nucleophiles but in general, mainly target cysteine, methionine, lysine, 
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histidine and to a lesser extent glutamate and aspartate amino acid residues on 
proteins. 
 
Figure 1.15: Generalised classification of reactive metabolites  
 
Reactive metabolites are difficult to isolate or characterize and their chemical 
structures can only be inferred from trapped products. Even in the cases where they 
can be synthesized, these compounds are stable only in aprotic solvents and cannot 
be administered to animals to study their in vivo effects directly.130 
 
1.7 Metabolism-Mediated Xenobiotic Toxicity  
Metabolism of xenobiotics is usually a detoxification process. In some instances, 
however, metabolism may lead to formation of the reactive metabolites alluded to 
previously causing deleterious effects due to their interaction with endogenous 
macromolecules. The mechanisms through which reactive metabolites cause toxicity 
are complex but generally involve covalent binding of such metabolites to enzymes, 
membrane proteins or nucleic acid bases in DNA or RNA.131–133 Covalent binding may 
result in sufficient structural modification of the endogenous target causing it to lose 
its primary biological function. In the case of enzymes, inhibition of catalytic activity 
may occur, while for DNA and RNA, disruption of genetic material may result in 
mutations and possibly carcinogenesis. In addition to binding directly to cellular 
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targets, reactive metabolites may undergo chemical transformation to yield highly 
reactive oxygen species or radicals that trigger damaging oxidative stress in target 
tissues.134  
It is now almost universally accepted that idiosyncratic adverse reactions (IADRs) to 
xenobiotics are mediated through reactive metabolites interacting with 
macromolecular targets in vivo.135 Among the mechanisms proposed that lead to 
such idiosyncratic reactions is an immune response triggered by covalent binding of 






Idiosyncratic adverse reactions are particularly difficult to predict during drug 
development because they are unrelated to the known pharmacology of the 
compound, are usually not dose-dependent and since they only occur only rarely, 
might not be observed in the relatively small number of patients monitored during 
clinical trials. Additionally, these reactions cannot easily be studied using animal 
models during preclinical development since their occurrence in such models is often 
idiosyncratic as well.137 
  
1.7.1 Metabolism-Mediated Toxicity of Conventional Drugs  
Numerous examples of drugs withdrawn from the market or whose clinical use is 
restricted due to toxicity arising from metabolic biotransformation exist. 
Paracetamol is one of the most widely used over-the-counter analgesic-antipyretic 
Figure 1.16: Relationship between metabolism and toxicity 
136 
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medications worldwide with a good safety profile when administered at therapeutic 
doses. However, in overdose, paracetamol is a potent hepatotoxin due to its 
metabolism to a reactive quinone-imine intermediate that covalently binds to 
hepatocellular proteins resulting in necrosis and acute liver failure.138,139 At normal 
doses, CYP450-mediated quinone-imine biotransformation is a minor metabolic 
pathway with most of the drug undergoing glucuronidation and sulfonation as the 
preferred routes of metabolism. At high drug concentrations, however, quinone-
imine formation may occur at a rate that exceeds the capacity of normal glutathione-
mediated detoxification leading to the toxic effects observed clinically.140 
 
 
Figure 1.17: Metabolism and bioactivation of paracetamol 
 
The antipsychotic drug clozapine is another example known to exhibit reactive 
metabolite-mediated drug toxicity. Clinically, clozapine is associated with adverse 
incidences of agranulocytosis in about 0.8% of patients characterised by depletion of 
neutrophil counts triggered by the formation of a reactive nitrenium or iminium ion 
metabolic intermediate.141 Clozapine toxicity appears to affect neutrophils most 
because they express high levels of myeloperoxidases, which are the enzymes 
thought to be responsible for the formation of the reactive metabolic intermediates. 
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Further evidence that clozapine toxicity is mediated via iminium intermediates is 
provided by the fact that the structurally analogous drugs quetiapine and loxapine in 
which the diazepine ring is replaced by thiazepine and oxazepine rings respectively, 
are devoid of similar adverse effects.142 Absence of the bridging N atom required to 
form an iminium ion in both cases supports the proposed bioactivation theory. 
 
Figure 1.18: Bioactivation of clozapine. (The non-reactive intermediate forming analogues quetiapine 
and loxapine are illustrated for structural comparison). 
 
As illustrated with paracetamol, for many compounds, toxicity due to reactive 
metabolite formation is partly influenced by the dose of the drug administered. A 
survey published in 2011 by Stepan et al. found that 84% of drugs withdrawn from 
the market due to IADRs associated with reactive metabolites had daily doses 
greater than 100 mg compared to none administered at doses less than 10 mg and 
only 6% administered at 10 – 50 mg daily. Similar trends were observed for 
marketed drugs whose use is restricted by so-called “black-box” warnings. In this 
case, 81% have typical daily doses greater than 100 mg, 11% are administered at 50 
– 100 mg while none administered at less than 10 mg fall under such restrictions.143 
 
1.7.2 Metabolism-Mediated Toxicity of Natural Products 
Natural products that cause toxic effects in humans mediated through metabolic 
biotransformation have been widely reported. Aflatoxin B1 is a long established 
thermo-labile hepatotoxin produced by the fungal species Aspergillus flavus and A. 
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parasiticus commonly found as contaminants in poorly stored mouldy grains such as 
maize or wheat.144 The mechanism by which aflatoxin B1 causes toxicity involves 
initial formation of a highly reactive exo-epoxide resulting from oxidative 
metabolism of the parent. The epoxide intermediate reacts with DNA, specifically 
binding to the N7 atom of guanine residues, thereby causing defects in the DNA 
sequence. Although the epoxide can also bind directly to amino acid residues in 
proteins, this process usually involves initial acid-catalysed hydrolysis of the epoxide 
to aflatoxin B1 dihydrodiol followed by base-catalysed conversion to aflatoxin B1 
dialdehyde. The dialdehyde form then attacks lysine residues present in hepatocyte 
proteins, disrupting their 3D structure and functionality and resulting in toxicity.145 
 
Figure 1.19: Metabolic bioactivation of aflatoxin B1 and formation of DNA and protein adducts 
 
Aristolochic acids are nitrophenanthrene carboxylic acid natural products present in 
plants of the genus Aristolochia. In incidences first reported in 1993, when 
components of these plant species were inadvertently included in herbal 
preparations used as weight loss agents in Belgium, cases of terminal renal failure 
resulted in patients.146 It has since been established that aristolochic acids are 
metabolized to reactive intermediates implicated in causing nephropathies 
characterised by renal fibrosis and development of urothelial cancer.147,148 Metabolic 
bioactivation of aristolochic acids involves the initial reduction of the nitro group 
catalysed by CYP1A1, CYP1A2 or COX-I followed by condensation resulting in 
formation of a lactam ring. Oxidation of the lactam at the N atom forms the N-
hydroxide which is transformed to a reactive cyclic nitrenium ion in a reaction 
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possibly mediated by sulphotransferases.149–151 The nitrenium ion intermediate 
covalently binds with adenosine and guanine residues in DNA leading to mutations 
that trigger carcinogenesis in renal tissue where the enzymes responsible for 
reactive intermediate formation appear to have high activity.152  
 
Figure 1.20: Bioactivation of aristolochic acids and binding to DNA residues 
 
The botanical dietary supplement kava derived from Piper methysticum contains the 
natural products kawain and methysticin as the main active ingredients thought to 
be responsible for its sedative, anxiolytic, muscle relaxant, anaesthetic and 
anticonvulsant properties.153 Reports of hepatotoxicity associated with kava use 
have been linked to the bioactivation of methysticin in vivo. The proposed 
mechanism for bioactivation involves initial CYP450-catalysed conversion of the 
benzodioxole ring in methysticin to a catechol metabolite that undergoes further 
oxidation to form the electrophilic ortho-quinone which may react with glutathione 
or covalently bind and modify hepatic proteins.154 
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Figure 1.21: Proposed bioactivation of methysticin in kava preparations 
 
Other natural product metabolites exert their toxic effects indirectly through drug 
interactions with conventional medicines. A well documented example of this is the 
interaction of grapefruit juice and numerous drugs, first reported with the 
antihypertensive calcium channel blocker felodipine.155 Components in grapefruit 
juice have been shown to be potent inhibitors of enterocyte CYP3A4, which is 
responsible for presystemic metabolism of many orally administered drugs in the 
GIT.156   The enzyme inhibition is mechanism-based and for drugs such as felodipine, 
may result in a clinically significant increase in the amount of drug absorbed from the 
GIT and its subsequent plasma concentrations. Enzyme inhibition and reactive 
metabolite studies have shown that the main component in grapefruit juice 
responsible for CYP3A4 inhibition is the furanocoumarin bergamottin acting via 
bioactivation to a reactive epoxide intermediate.157,158 
 
Figure 1.22: Proposed bioactivation of bergamottin by intestinal CYPs and resultant CYP3A4 inhibition 
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1.8 Profiling ADME Properties in Early Drug Discovery 
Prior to 2000, the majority of drug candidates progressing through to clinical trials 
but which failed to receive marketing approval were mainly unsuccessful due to poor 
absorption, distribution, metabolism, excretion (ADME) and toxicology properties or 
drug metabolism and pharmacokinetic (DMPK) profiles.159,160 To avert such high 
attrition rates, pharmaceutical companies began to increasingly conduct ADME 
studies much earlier in the drug discovery process as part of rational drug design.161–
163 This shift has had a dramatic effect in reducing the percentage of drug candidates 
that fail to meet regulatory requirements due to ADMET/DMPK liabilities over the 
last decade.  Despite these changes in emphasis, however, drug toxicity and lack of 
efficacy are still the leading causes of attrition during late stage drug development or 
withdrawal of marketing approval for already licensed drugs.164 
 
 




1.8.1 Computational Tools in ADMET Profiling 
Computational tools are an integral part of modern drug discovery and are employed 
in virtually all aspects of development from initial hit identification to marketing 
authorisation.165 They are used to help predict ADMET properties of drug candidates 
early in the development cycle to minimise the costs and time taken to determine 
such profiles experimentally. In silico tools are used to calculate or predict structure-
based physicochemical parameters such as acid dissociation constants (pKa), 
lipophilicity, aqueous solubility, H-bonding, polar surface area and other so-called 
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“Lipinski Rule of Five” descriptors for drug-likeness on which ADMET properties 
largely depend.166,167 Additionally, actual ADMET properties may be predicted based 
on combinations of  the physicochemical data generated and simulated models using 
mathematical algorithms based on experimental data from real drugs. Predicting 
ADMET properties such as absorption, which are dependent on both known 
characteristics such as compound solubility, lipophilicity, and polar surface area but 
also on unknown parameters such as active transport is challenging even using 
computational tools. Consequently, many software applications differ in the 
algorithms and statistical approaches they use to predict these properties, usually 
incorporating numerous property descriptors and assigning different weights to 
them in overall property calculations.168–170 Despite this, however, predictive 
computational tools for ADMET profiling are never 100% accurate with models and 
simulations being highly dependent upon the quality of the real-world experimental 
data used to build them.171,172  
Prediction of compound metabolism using in silico tools uses several approaches, 
usually combinations of rule-based and structure-based QSAR models often relying 
on known 3D structures  or protein homology models of enzymes to calculate the 
probability and magnitude of interactions between compounds and enzymes using 
ligand docking simulations.173,174 These tools are typically designed to predict the 
most likely site(s) of metabolism on test molecules and the chemical species likely to 
arise from transformation at the identified sites by specific xenobiotic metabolizing 
enzymes.175–177  
Apart from the prediction of metabolism and toxicity, computational tools are also 
used to profile other ADMET properties such as compound absorption, oral 
bioavailability and distribution in vivo, particularly for drugs intended to exert their 
effects in specific target organs such as the CNS.178,179 At present, however, success 
in accurate prediction of metabolism using current in silico tools remains still 
somewhat limited. 
 
1.8.2 Metabolic Stability and Enzyme Phenotyping 
A key determinant of the rate at which drugs are cleared from the body and 
therefore their therapeutic effectiveness is the ability to resist metabolic 
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transformation. For compounds that are metabolised to toxic species, ease of 
biotransformation may be an important factor in determining the magnitude or risk 
of toxicity in vivo. In vitro metabolic stability assays are therefore conducted in early 
ADME profiling to provide data for use in predicting or extrapolating in vivo intrinsic 
clearance rates and possibly to identify the relative contribution of different organs 
or tissues to compound clearance.180 
Experimental in vitro metabolic stability data is obtained by incubating compounds in 
a variety of metabolism systems most commonly, microsomal fractions from liver, 
kidney, lung or intestines, fresh or cryopreserved hepatocytes, liver slices, as well as 
plasma and S9 fractions.181,182 In addition to using human tissue, metabolic systems 
from animal models such as mice, rats, dogs and primates are also used to conduct 
these assays. Data from in vitro metabolic stability experiments is used to 
extrapolate the in vivo metabolic disposition of compounds in both humans and 
animals and provides information for prioritising compounds to be advanced to 
more capital intensive and technically involving preclinical in vivo pharmacokinetic 
assays. Identification of the metabolites formed from such stability assays also 
provides information on the metabolic hotspots in the substrates and insights on 
how such can be modified through medicinal chemistry efforts if necessary.183 
Enzyme phenotyping assays are performed to identify the specific enzymes involved 
in any transformation observed from metabolic stability assays and the individual 
contribution of these enzymes to overall compound disposition. Phenotyping assays 
provide an early indication of compounds whose disposition in different patient 
populations may vary significantly because their main route of metabolism is 
mediated by genetically polymorphic enzyme isoforms. Since CYP450s are the 
enzymes known to metabolize the vast majority of drugs in clinical use, in vitro 
CYP450 phenotyping assays are by far the most commonly performed in early 
ADMET profiling. Enzyme phenotyping may be carried out by incubating test 
substrates in different individual isolated purified recombinant enzymes and 
subsequently determining the relative contribution of each to metabolism. 
Alternatively, compounds may be incubated in microsomes which typically contain a 
mixture of enzyme isoforms and the individual contribution of each to metabolism 
determined by adding specific inhibitors of the different isoforms then calculating 
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the difference in metabolism observed in either case.184 Enzyme inhibitors used in 
the latter approach are usually specific chemicals and drug compounds, or 
alternatively, poly- or monoclonal antibodies that bind and inhibit specific enzyme 
isoforms.185 
These techniques have inherent shortcomings that often lead to poor correlation 
between enzyme phenotyping data generated using the two methods for the same 
compound. For instance, CYP450 phenotyping using liver microsomes and specific 
chemical inhibitors is often confounded by the fact that the inhibitors used exhibit 
some degree of cross-reactivity with different isoforms. Use of specific antibodies in 
place of chemical inhibitors may minimize unwanted cross-reactivity effects but 
introduces higher costs and experimental complexity.  On the other hand, CYP450 
phenotyping using recombinant enzymes expressed from heterologous systems such 
as E. coli or yeast is often affected by the fact that activity of the enzymes may vary 
widely owing to differences in CYP450 protein:NADPH reductase: cytochrome b5 co-
expression ratios.186  
 
1.8.3 Predicting Formation of Reactive Metabolites from Structural Alerts 
Structural alerts are chemical functional groups in xenobiotics that may undergo 
metabolic bioactivation to reactive intermediates that result in toxicity. These groups 
are sometimes referred to as toxicophores. The presence of structural alerts is, 
however, not always definitive proof of bioactivation to form reactive metabolites. 
Many drugs that possess structural alerts are devoid of reactive metabolite 
formation liabilities and exhibit good safety profiles. Nevertheless, in early drug 
discovery ADME profiling, structural alerts are often flagged and used as a basis for 
‘go-no go’ decisions (Figure 1.24) based on the existing body of evidence supporting 
their involvement in formation of toxic reactive metabolites and covalent protein 
binding.187 
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Figure 1.24: Example of possible decision scheme for handling bioactivation data at different stages of 
drug development. Scheme (a):  Reactive metabolite data from early drug design and optimization; 
Scheme (b): Covalent binding data in late preclinical or early clinical research (CRM: Chemically 




Established toxicophores whose presence in drug design is avoided as much as 
possible include anilines, quinones, quinone methides, monosubstituted furan and 
thiophene rings, benzodioxoles, α,β-unsaturated carbonyls, terminal alkenes, 
terminal and ω-1 alkynes, cyclic tertiary amines, aldehydes and epoxides, among 
others.188  
 




Detection of structural alerts when conducting early ADME profiling on potential 
drug compounds may involve simple unaided visual inspection of molecular 
structures when working with small compound libraries or, more commonly, the use 
of software to screen large compound sets.190 Apart from allowing faster screening 
of compounds, computational tools have the advantage of being programmable for 
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detection of structural alerts that might be ‘masked’ within complex chemical 
structures and thus not immediately obvious to the inexperienced eye. 
 
1.9 In vitro Determination of Reactive Metabolite Formation 
1.9.1 Enzyme Inhibition Assays 
Enzyme inhibition assays using substrates that generate metabolites which can be 
monitored through relatively simple detection techniques such as 
fluorospectrometry are routinely used for high throughput compound screening for 
assessing potential drug-drug interaction. In these screens, the test compounds are 
incubated in purified recombinant enzymes or microsomal proteins in the presence 
of probe substrates of the drug metabolizing enzyme(s) to be monitored for 
inhibition.191 Comparison of the rate or extent of probe substrate metabolism in 
incubations containing the test compound against those without the test compound 
provides an indication of how strongly enzyme activity is inhibited. Detection 
techniques such as fluorimetry may be used to quantify enzyme inhibition if the 
metabolites generated are fluorescent compounds.192  
A modification of the enzyme inhibition assay that determines if inhibition of enzyme 
activity is time-dependent involves first incubating the test compound with the 
enzyme in the presence and absence of co-factors before adding the probe 
substrate. If enzyme inhibition is observed to be significantly higher following pre-
incubation with the test compound compared to no pre-incubation, this is strongly 
indicative that the formation of reactive metabolites may be responsible for the  
observed inhibition.193,194 
Enzyme inhibition assays in early drug discovery are typically aimed at screening a 
large number of compounds in a short time and are usually carried out in 96-well 
microplates to increase throughput. At this stage, emphasis is placed more on 
approximating the relative enzyme inhibition potential of different compounds for 
purposes of ranking. Detailed inhibition assays are only being carried out later to 
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1.9.2 Reactive Metabolite Trapping Assays 
In vitro reactive metabolite trapping experiments are perhaps the most common 
technique for detecting electrophilic reactive metabolic intermediates in early drug 
discovery. While time dependent enzyme inhibition assays are typically used to 
screen large volumes of compounds in a short time, in most cases they do not 
provide data related to the actual intermediate or species responsible for any 
observed inhibition, thus the need to carry out trapping experiments. 
The general procedure in these assays involves the incubation of test substrates in a 
suitable metabolic system, most commonly human hepatic microsomes with the 
necessary cofactors included and in the presence of a nucleophilic trapping agent 
capable of forming stable covalent adducts with any reactive metabolites formed. In 
the case of reactive metabolites arising from oxidative bioactivation reactions, in 
vitro assay systems that make use of electrochemical oxidation cells in place of 
biological systems such as microsomes have been reported.195,196 The ideal choice of 
trapping agent used to capture reactive metabolites depends on the reactivity of the 
metabolites formed. Soft electrophilic reactive metabolites are most commonly 
trapped using reduced glutathione (GSH) or glutathione analogues such as 
glutathione ethyl ester. Hard electrophiles such as iminium ions may be too reactive 
to be effectively trapped using GSH but ideal for trapping using cyanide ions. 
Reactive aldehyde metabolites are similarly best trapped using amines such as 
methoxylamine and semicarbazide.197 Stable isotope radiolabelled analogues and 
fluorescent dansylated derivatives of glutathione have also been reported to 
improve sensitivity in detecting trapped reactive metabolites.198–200 
Highly sensitive analytical techniques are required to detect trapped intermediates 
from these in vitro assays due to the typically low concentrations of the metabolites 
formed and also the need to have structural data that can be used in adduct 
identification. At present, liquid chromatography coupled to tandem mass 
spectrometry (LC-MS/MS) offers the best analytical option by allowing for the 
separation of analytes from the often complex biological sample incubation matrix 
and subsequent identification of trapped metabolites based on their mass/charge 
(m/z) ratios and fragmentation patterns.201,202 
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1.9.3 Covalent Binding Studies 
Covalent binding studies are usually only conducted in the later stages of reactive 
metabolite profiling of drug leads because they require the use of radiolabelled test 
compounds. Due to the relatively high costs, hazards and technical expertise 
involved in synthesizing radiolabelled substrates, these studies are only performed 
on compounds already in fairly advanced phases of preclinical drug development.203 
In these assays, the general procedure involves incubation of the radiolabelled drug 
in a metabolising system, usually microsomal proteins, in the presence of the 
necessary cofactors. At the end of the incubation, microsomal proteins are 
precipitated, centrifuged and washed to remove any unbound drug or metabolites. 
The washed proteins are then digested and residual radioactivity measured as an 
indicator of the radiolabelled drug or metabolite covalently bound to the proteins. 
Nucleophilic trapping agents such as reduced glutathione may also be incorporated 
in the incubation to determine their influence on the extent of any covalent binding 
observed.204 
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1.10 Research Program 
1.10.1 Study Justification 
Toxicity of drug candidates is a major cause of attrition of promising compounds in 
drug discovery. Only about 11% of compounds entering clinical development ever 
reach the market - more than a third are withdrawn due to reasons related to 
toxicology and clinical safety.205 Although overt toxicity studies are often conducted 
in vitro alongside assays to determine pharmacological activity on drug candidates 
from synthetic or natural product origin, these studies are often not equipped to 
predict toxicity arising from in vivo metabolism of the test compounds. Numerous 
drugs have been developed, licensed and marketed but subsequently discovered to 
cause IADRs mediated through metabolic intermediates that have significant toxicity 
profiles leading to their withdrawal from the market. Even in situations where the 
drug is not withdrawn, severe limitations in its therapeutic application may have to 
be implemented in the form of “black box” warning labels that restrict its use. 
From a drug development perspective, such scenarios greatly undermine the time, 
effort and cost involved in developing a compound for therapeutic use in patients. 
To minimize these situations, ADME profiling studies are increasingly being 
incorporated early in the drug discovery process. 
Drugs from natural sources are often considered to be safer and less likely to cause 
toxicity compared to synthetic compounds. While this assumption may be true for 
many natural products, it does not apply universally. In many third world countries, 
access to medicine and healthcare services is an unmet need to the majority of the 
population. Consequently, natural product-based alternative and traditional herbal 
medicines play an important role in providing remedies to ailments and are often 
used by patients alongside conventional medicines.206 The WHO estimates that in 
Africa alone, 80% of the population relies on traditional medicines for their 
healthcare needs, while in China, these remedies account for about 40% of all 
healthcare delivered.207 
As observed with some synthetic drugs, components of natural product remedies 
may interact unfavourably with conventional medicines or other natural products if 
co-administered. Additionally, like conventional medicines, some natural products 
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may undergo metabolic transformation to form reactive metabolites that trigger 
toxic outcomes or IADRs. 
Because traditional natural product medicines are not subjected to the same 
rigorous studies and safety profiling assessments typically accorded to conventional 
drugs, they may pose a potentially greater risk of causing adverse reactions. 
Therefore, investigating the potential of natural products used as remedies for 
treatment of disease to undergo undesirable metabolic bioactivation would allow 
early discovery of toxic liabilities prior to the exploitation of these compounds as 
possible leads in drug discovery programs.  
 
1.10.2 Aims and Objectives 
The main objective of this study was to determine the physico-chemical and 
metabolic properties of natural products with respect to druggability, potential to 
form reactive metabolites and inhibit major drug metabolising CYP450 enzymes.  
A secondary objective was to identify the cross-inhibitory effects of chemical 
inhibitors routinely employed in early CYP450 pehnotyping assays using human liver 
microsomes. 
 
1.10.3 Specific Aims 
The specific aims of this research project are: 
1. To create a software database containing data on pure African natural products 
isolated from multiple sources. 
2. Use commercially available in silico tools to mine the database created and map 
the chemical space of the natural products in comparison with that of clinically 
used conventional medicines. 
3. Conduct in vitro studies on selected natural products to determine the formation 
of reactive metabolites through enzyme inhibition and reactive metabolite 
trapping assays. 
4. Determine the cross-reactivity of chemical inhibitors commonly used in 
performing early CYP450 phenotyping assays in the pharmaceutical industry. 
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CHAPTER TWO:  
IN SILICO PROFILING OF NATURAL PRODUCT CHEMICAL SPACE 
 
2.1 Summary 
In this Chapter, the use of computational tools to design, create and populate a 
database of natural products is described. The chemical space occupied by the 
natural products with specific regard to their predicted physico-chemical properties 
for ‘drug-likeness’ is determined using software. Statistical analysis of the chemical 
space data of the natural products compared to that of conventional drugs is 
performed to determine the significance of any similarities or differences in the 
properties of both data sets. An analysis of structural alerts present in the natural 
products compared to those present in conventional drugs is carried out to predict 
the relative predilection of these compounds to undergo metabolic bioactivation. 
 
2.2 General Introduction 
Computational tools are now considered virtually indispensible integral components 
of the drug discovery process. They are used for virtual screening of large compound 
libraries to identify potential drug hits either through structure-based or ligand-
based screens typically at the very onset of drug discovery programs.1–3 Their use has 
become more common-place following  the realization that traditional high-
throughput screening (HTS) assays on combinatorial chemistry compound libraries 
often yielded large proportions of false positive ‘non-drug-like’ hits that could be 
easily identified and excluded computationally by applying property filters.4 
Computational tools are used to predict the ‘drug-likeness’ of compounds in 
chemical libraries based on calculation of both simple 1D, 2D and more complex 3D 
property descriptors.  
Virtual compound libraries in the form of in silico databases containing large volumes 
of information on thousands and sometimes millions of both real and hypothesized 
combinatorial compounds are now freely or commercially available for high-
throughput drug discovery screening. At present, many of these depositories can be 
accessed through the world-wide-web as online databases in which data is 
continuously updated and new compounds uploaded. An example of such online 
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databases is ZINC,5–7 which at present contains freely accessible records of more 
than 35 million compounds. Although ZINC is mainly populated with synthetic 
compounds, it also contains a sizeable collection of natural products and provides 
links to other online databases which specifically contain only natural product 
collections.  For example, a library of more than 1000 natural products from African 
Medicinal Plants christened AfroDb is entirely housed within the ZINC database.8 In 
general, however, discovery of bioactive natural products using computational tools 
has been hampered by a relative dearth in the availability of good quality publicly 
accessible natural product databases.9 
 
2.3 Natural Product Database  
2.3.1 Database Design 
A compound database containing data on natural products was designed and 
created using commercially available off-the-shelf software (Microsoft® Office 
Access 2003 Service Pack 3, Microsoft Corporation, WA, USA). The database was 
created on a HP Pavilion® dv9925nr stand-alone notebook PC running on a dual-core 
2.0 GHz AMD Turion® T60 microprocessor, equipped with 4.0 GB RAM and a 250 GB 
(5400 rpm) primary storage hard-disk. The operating system platform was a 64-bit 
version of Windows Vista® Home Premium.  
The relational database comprised the following tables: 
1. African Herbal Pharmacopoeia: Containing data on herbal products from 
monographs published in the African Herbal Pharmacopoeia (AHP)10 including: 
the herbal product name, natural botanical source, reported ethno-botanical 
uses, experimentally determined pharmacological activities and chemical 
constituents isolated from the product. 
2. AHP Chemical Constituents: This table contained data on the chemical 
compounds from the AHP monographs, specifically: their common chemical 
name, chemical structure appended both as OLE (Object Linking and Embedding) 
objects created using a different software application as well as conventional 
molecular text notation. 
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3. ICIPE Compounds: Containing similar information as the AHP Chemical 
Constituents table but only for natural products available from the International 
Centre of Insect Physiology and Ecology (ICIPE) based in Nairobi, Kenya. 
4. Conventional BP 2009 Drugs: This table contained the international non-
proprietary names (INN) and chemical structures of conventional drugs in current 
clinical use published in the British Pharmacopoeia 200911 for comparison against 
the natural product sets. This dataset contained only small molecule drug 
compounds and not components of biological formulations such as 
immunoglobulins, anti-toxins, plasma proteins or vaccines whose monographs 
were also present in BP 2009. 
The design structure of the Natural Product database is summarised in Table 2.1. 
Different text notations for compound structures were included to provide an option 
for importing and/or exporting chemical structures to other software platforms 
easily without having to redraw them. In this case, the notations used were SMILES 
(Simplified Molecular Input Line Entry System),12 SLN (SYBYL Line Notation)13 and the 
IUPAC InChI (International Chemical Identifier)14. These three were selected because 
they are currently the most widely used molecular text notation systems capable of 
interpretation by the vast majority of molecule manipulation software. Text notation 
of the molecular structures of the chemical constituents also reduced the amount of 
physical digital storage space taken up by such data for purposes of transfer when 
copying or moving between different software applications. Another advantage of 
incorporating the text notations was that they provided the possibility for indexing 
of the database, thereby allowing compound searches to be performed faster while 
at the same time avoiding redundancy through inadvertent capture of the same 
compound details more than once especially in cases of compounds having more 
than one common name. 
 
Table 2.1: Natural Product Database Structure  
Data Table Data Fields Data Field Type (Size) 
African Herbal 
Pharmacopoeia 
Monograph number Numeric Integer 
Herbal Product Text (50 characters) 
Natural source Text (50 characters) 
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Data Table Data Fields Data Field Type (Size) 
Ethnobotanical use (x3) Text (50 characters) 
Pharmacological properties (x3) Text (50 characters) 




Common chemical name Text (50 characters) 
Chemical structure OLE Embedded Object 
SMILES notation Text (255 characters) 
SLN notation Text (255 characters) 
InCHI notation Text (255 characters) 
ICIPE Compounds 
Common chemical name Text (50 characters) 
Chemical structure OLE Embedded Object 
SMILES notation Text (255 characters) 
SLN notation Text (255 characters) 
InCHI notation Text (255 characters) 
British Pharmacopoeia 
2009 Drugs 
Common drug name Text (50 characters) 
SMILES notation Text (255 characters) 
 
The possibility of data redundancies through accidental entry of the same chemical 
compound more than once into any of the three compound tables was avoided by 
indexing the SMILES notation field and forbidding entry of replicate data. 
2.3.2 Data Entry 
To ease capture of data into the tables described above and ensure consistency by 
minimizing errors, computerized data entry forms were designed. For entering data 
into the AHP Chemical Constituents and ICIPE Compounds tables, an identical form 
was created as illustrated in Figure 2.1.  
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Figure 2.1: Screenshot of AHP Chemical Constituents and ICIPE Compounds Data Entry Form 
 
To capture molecular structures of each new compound into the database, the form 
was designed to link with ChemDraw Ultra software ver. 11.0 (ChembridgeSoft, MA, 
USA). This link also allowed for the editing of already captured chemical structures 
using the ChemDraw molecule editor. ChemDraw was also used to generate the 
SMILES, SLN and InChI notations for each compound for entry into their 
corresponding data fields. 
The information entered into the African Herbal Pharmacopoiea Table was a 
composite of data already captured in the Chemical Constituents Table (i.e. chemical 
constitutents’ common names) and other data to be extracted from each product 
monograph (e.g. ethnobotanical use and pharmacological activity). To input this 
information, a separate data entry form (Figure 2.2) incorporating drop-down lists 
that allowed for entry of the chemical constituents from the pre-existing table was 
designed. This helped to minimize errors and avoid repetition through entry of data 
that had already been captured previously. 
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Figure 2.2: Screenshot of African Herbal Pharmacopoeia Table Data Entry Form 
 
2.3.3 Summary Statistics 
The complete database comprising the tables, data entry forms and records 
described above occupied 105 megabytes of hard-disk space. The data captured was 
fully transferable and could be freely copied and accessed using any Windows-based 
PC in which Microsoft Access® 2003 or newer versions was installed.  
In total, data from all 51 monographs in the African Herbal Pharmacopoeia were 
captured into the database. 335 Unique compounds identified as components of the 
natural products in the AHP were input into the Chemical Constituents Table, 
representing an average of 6.6 compounds per monograph. By comparison, the ICIPE 
list of chemical compounds comprised a total of 297 natural products isolated from 
an undisclosed number or variety of sources while the BP 2009 table contained a 
total of 608 unique drug entities. 
 
2.4 In silico Chemical Space Property Calculations and Predictions 
It is generally accepted that natural products occupy a different chemical space to 
that of conventional drugs with regard to the physicochemical properties considered 
most critical in conferring drug-likeness. For example, natural products tend to have 
more oxygen and fewer nitrogen atoms per molecule compared to synthetic organic 
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compounds and drugs. They also tend to possess a greater number of stereogenic 
centres.15  
The chemical constituents captured from the African Herbal Pharmacopoeia were 
evaluated using MarvinSketch software ver. 5.5.1.1 (ChemAxon Kft, Budapest, 
Hungary) to predict values for the four ‘Rule-of-Five’ parameters described by 
Lipinski as significantly influencing the absorption and permeability properties of 
orally administered drugs. According to the ‘Rule-of-Five’, the majority of orally 
active drugs tend to have molecular weights less than 500, LogP values not greater 
than 5.0 in addition to having no more than 5 H-bond donors or 10 H-bond 
acceptors.16 In addition to these, the number of rotatable bonds in the molecules 
was also calculated as another critical determinant for oral bioavailability in drug-like 
compounds as proposed by Veber et al.17 Most oral drugs have less than 10 
rotatable bonds and besides contributing to bioavailability, their presence also 
influences ligand affinity to drug targets.18 
Frequency distribution histograms and pie charts of the values predicted or 
calculated for these five parameters are illustrated in Figures 2.3 – 2.7. For 
comparison of the natural product values against conventional medicines in current 
clinical use, the same parameters were determined for the drug molecules captured 
from the British Pharmacopoeia 2009. 
 
2.4.1 Molecular Weight 
79.1% of the AHP compounds had molecular weight (mwt) < 500 with most (60.3%) 
ranging from 200 to 450. Only slightly more than 1% had mwt greater than 750 and 
none had a value below 100. The mean molecular weight for all 335 compounds was 
376.6 (sd 162.3) with a median of 338.3.  
In contrast, 95.4% of the B.P. compounds had molecular weights below 500 (78.5% 
ranging from 200 to 450). No compound had molecular weight less than 100 and 
only 0.8% had molecular weights in excess of 700. The mean value for B.P. drugs was 
316.9 (sd 106.5) with a median of 307.4.  
For the ICIPE compounds, 94.3% had mwt less than 500, with those ranging from 51 
to 250 accounting for the majority (67.3%). This relatively high proportion of low 
molecular weight compounds was due to the fact that many of the ICIPE compounds 
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were small mono- and sesquiterpene components of essential oils extracted from 
plants. This fact was further reflected in the average molecular weight for the data 
set which was significantly lower than that for the AHP and BP drugs at 245.0 (sd 
129.1) with a median value of 204.0. Five compounds (1.7%) had mwt less than 100 




2.4.2 Predicted cLogP 
Estimated octanol/water partition coefficient values for the AHP compounds ranged 
from -5.02 to +10.0 with a mean of 2.70 and median value of 2.60. BP drugs had 
cLogP values ranging from -3.5 to +11.2 with a mean of 2.33 and median of 2.41. In 
both cases, compounds mostly clustered within the -1.0 to 5.0 cLog P range with 
approximately 60% having values lying between 0 and 5.0.  
By contrast, the ICIPE compounds exhibited a bi-modal distribution with cLogP 

















































































Percentage Distribution of ICIPE Compounds 
Molecular Weights
Figure 2.3: Pie charts of molecular weight distributions for the three compound datasets 
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notably higher than that for the AHP and BP compounds at 3.49 indicating a higher 
proportion of more lipophilic compounds in this collection. This could be attributed 
to the fact that the terpenes mentioned previously as comprising a significant 
portion of this dataset are largely simple hydrocarbons devoid of heteroatoms or 
functional groups that might confer reduced lipophilicity. 












































































































































Figure 2.4: Frequency distribution histograms of predicted cLogP values for compounds in the three 
datasets 
 
2.4.3 Rotatable Bonds 
Veber et al proposed that in addition to the four physicochemical parameters 
highlighted in Lipinski’s ‘Rule-of-Five’ for good bioavailability, most orally-active drug 
compounds appear to possess 10 or fewer rotatable bonds. The natural products 
from the AHP and B.P. 2009 drug molecules both exhibited similar distributions in 
this property with 94.9% and 93.6% of AHP and BP compounds respectively having 
10 or less rotatable bonds. Notably, more than 11% of the AHP compounds but only 
about 4% of the BP drugs were totally devoid of rotatable bonds.  
The ICIPE compounds presented a similar profile with 93.3% falling within the 10-
bond limit. Two thirds of these compounds had 3 or fewer rotatable bonds with 
12.1% lacking any at all. 
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Figure 2.5: Frequency distribution histograms for number of rotatable bonds in the database 
compounds 
 
2.4.4 Hydrogen Bond Donors and Acceptors 
The ability to form hydrogen bonds is a key requirement for drug-like compounds to 
be orally active, since such bonds enhance aqueous solubility and also partly because 
they facilitate substrate-target interactions at the sub-cellular active sites of most 
drugs. However, the ideal H-bond number in a drug-like molecule must strike an 
optimal balance since too high a value might inadvertently limit compound 
permeability. The ‘Rule-of-Five’ specifies that the ideal number of H-bond donors in 
a drug-like molecule should be less than or equal to 5, while H-bond acceptors must 
not ideally exceed 10. In general, the majority of AHP, ICIPE and BP chemical 
constituents complied with this rule (82.4%, 97.0% and 97.9% respectively). The 
ICIPE compounds were particularly unique in having a very high proportion of 
molecules lacking H-bond donors (49.2%) which indicated a high incidence of 
molecules devoid of hydroxyl, amine or carboxylic acid functional groups in this data 
set. The average number of H-bond donors for the AHP, ICIPE and BP compounds 
was 2.69, 1.04 and 1.73 and corresponding median values of 2, 1 and 1 respectively. 
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Figure 2.6: Frequency distribution histograms of H-bond donors in the database compounds 
 
The average number of H-bond acceptors was 5.25, 2.38 and 4.86 for AHP, ICIPE and 
BP compounds respectively. While only 75.2% of the AHP compounds had 10 or 
fewer H-bond acceptors, the ICIPE and BP compounds had 98.3% and 96.9% 
respectively. All three compound groups presented a distribution skewed to the right 
(Figure 2.7) indicating higher incidence of fewer H-bond acceptors in general, with 
this characteristic being markedly pronounced with the ICIPE molecules in which 
more than 75% had three or less acceptors. 




























Figure 2.7: Frequency distribution histograms of H-bond acceptors in the database compounds 
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Table 2.2: Mean values of ‘Rule-of-Five’ properties 
 
Mean calculated values 
AHP Natural Products 
(n = 335) 
ICIPE Compounds 
(n = 297) 
BP 2009 Drugs 
(n = 608) 
Molecular weight 376.6 245.0 316.9 
cLogP 2.7 3.5 2.3 
Rotatable bonds 3.7 3.5 5.1 
H-bond donors 2.7 1.0 1.7 
H-bond acceptors 5.2 2.4 4.9 
 
2.5 Statistical Evaluation and Comparison of Compound Datasets 
Using SPSS19 statistics software, the Kolmogorov-Smirnov and Shapiro-Wilk tests 
were applied across the three compound datasets to determine if the predicted and 
calculated values for the ‘Rule-of-Five’ and rotatable bond parameters exhibited 
normal frequency distributions.  In all cases, the calculated p-values (0.000) were less 
than 0.05 at the 95% confidence level (Table 2.3), indicating that the data did not 
exhibit a normal distribution and could not therefore be reliably compared using 
standard parametric tests such as the Student’s t-test.  
 
Table 2.3: Results for statistical tests for normal distribution of data 
 
Kolmogorov-Smirnov Test Shapiro-Wilk 
Statistic df p-value Statistic df p-value 
Mwt .080 1240 .000 .934 1240 .000 
cLogP .049 1240 .000 .988 1240 .000 
Rotatable Bonds .163 1240 .000 .884 1240 .000 
H_Donors .224 1240 .000 .793 1240 .000 
H_Acceptors .150 1240 .000 .910 1240 .000 
 
The Mann-Whitney-Wilcoxon non-parametric statistical comparison test was 
therefore used to determine if there were significant differences in the respective 
chemical space profiles of the AHP, BP and ICIPE compounds. In this case, the 
variance in median values of the parameter distributions (Table 2.4) were used as a 
more robust variable for comparison of the different compound sets. 
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Table 2.4: Median values of ‘Rule-of-Five’ properties 
 
Median values 
AHP Natural Products 
(n = 335) 
ICIPE Compounds 
(n = 297) 
BP 2009 Drugs 
(n = 608) 
Molecular weight 338.3 204.0 307.4 
cLogP 2.60 3.21 2.41 
Rotatable bonds 3 3 4 
H-bond donors 2 1 1 
H-bond acceptors 4 2 4 
 
The null hypothesis (Ho) for the Mann-Whitney-Wilcoxon statistical comparison of 
the similarity in the values of the datasets was that no significant difference exists in 
the chemical space parameters of the AHP, ICIPE and BP compounds. The test was 
carried out by comparing two of the datasets against each other in turns as 
independent sample sets for each of the 5 parameters and determining the p-value 
at the 95% confidence level (Table 2.5). The significance value of the calculated 
statistic was 0.05, therefore, for all comparisons in which the determined p-value 
was less than this cut-off, the null hypothesis was rejected. Conversely, p-values 
greater than 0.05 meant that the null hypothesis could not be rejected and that 
consequently, the differences between the datasets were not statistically significant. 
 
Table 2.5: Mann-Whitney-Wilcoxon independent samples comparison test results 
 Mwt cLogP Rot. Bonds HBD HBA 
 p Ho p Ho p Ho p Ho p Ho 
AHP vs BP 0.000  0.114  0.000  0.000  0.709  
ICIPE vs BP 0.000  0.000  0.000  0.000  0.000  
AHP vs ICIPE 0.000  0.000  0.389  0.000  0.000  
Note:  indicates failure to reject the null hypothesis; indicates rejection of the null hypothesis 
 
AHP compounds were found to share strong similarities with conventional BP 2009 
drugs in the distribution of cLogP and H-bond acceptors. On the other hand, 
molecular weights, number of rotatable bonds and H-bond donors were significantly 
different between the two datasets.  
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In contrast, the ICIPE compounds were found to be significantly different from the 
BP 2009 drugs in each of the 5 parameters evaluated, strongly suggesting that this 
dataset appeared to consist largely of compounds devoid of drug-like characteristics. 
Comparison between the ICIPE and AHP compound sets also revealed that these two 
groups were largely dissimilar, with only the number of rotatable bonds in the 
molecules of either set not being significantly different from each other. 
 
2.6 C-Lab Chemical Space Prediction and Principal Component Data Analysis 
In addition to predicting the five chemical space parameters described above using 
MarvinSketch, the 3 data-sets were analyzed using the AstraZeneca in-house C-Lab 
ADMET property prediction service designed to calculate, using models, a much 
larger array of physicochemical and ADMET properties.20 Using this package, it was 
possible to compute values for 196 related compound parameters broadly falling 
into the six categories summarized in Table 2.6 below. 
 
Table 2.6: Categorization of physico-chemical descriptors predicted using C-Lab Platform 
Category Parameters predicted 
Lipophilicity 6 
Hydrogen Bonding 29 
Molecular Size and Shape 22 
Molecular Charge/Polarity 75 
Atom Counts 37 
Molecular Topology 27 
TOTAL 196 
   
This multiplicity in prediction was due to the fact that many physicochemical 
properties are typically estimated in silico using mathematical formulas or models of 
which there might be several variations. For example, to estimate cLogP for each 
compound, the C-Lab platform calculated values using 3 different and widely 
recognized approaches, each yielding, in most cases, a different albeit closely 
approximating result. In this case, cLogP values were variously predicted based on 
calculations using Ghose/Crippen atom types;21 a neural network approach on 
Ghose/Crippen atom types and prediction using the Daylight/Biobyte approach. 
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Using C-Lab, the 196 descriptors generated for each compound in all three datasets 
rendered simple analysis of the data to determine chemical space trends extremely 
challenging. To simplify this task, a different statistical application software was used 
to carry out multivariate component analysis aimed at reducing the complex data 
into a format that could be more easily interpreted. For this, SIMCA-P+ ver. 12.0.1 
(Umetrics AB, Umeå, Sweden) was used. Data analysis using SIMCA again involved 
comparing the descriptors predicted for the conventional BP 2009 drugs as the 
reference against those for compounds from the AHP and ICIPE datasets. The results 
were plotted on 2-D principal component analysis (PCA) scatter plots (Figure 2.8) 

















DivDataset_AZdescriptors080812+comps110825.M1 (PCA-X), all AZdescriptors, PS-Conv_Drugs_AZdescr_Oct11
tPS[Comp. 1]/tPS[Comp. 2]
R2X[1] = 0.304779            R2X[2] = 0.271129            
Ellipse: Hotelling T2 (0.95) SIMCA-P+ 12.0.1 - 2011-10-04 13:12:21 (UTC+1) 
 
Figure 2.8: 2-D PCA scatter plot of predicted chemical space parameters of BP 2009 drugs (black 
triangles) and AHP chemical constituents (red diamonds, outliers highlighted in blue and red boxes). 
 
PCA plots of the physicochemical descriptors of AHP compounds against BP 2009 
drugs revealed a significant degree of overlap in compound properties but with two 
distinct groups of non-overlapping compounds as illustrated. The first and larger 
group comprising 79 compounds was clustered to the left of the main BP 2009 drugs 
body of plots (2nd and 3rd quadrants of the 2-D scatter plot) while the second smaller 
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cluster to the lower right (4th quadrant) of the BP 2009 drugs plots and comprised 12 
compounds. Based on the predictions from MarvinSketch for these 91 outlying 
compounds, 75 (82.4%) were later found to violate one or more of the Lipinski rules 
while the remaining 16 were fully compliant. Of note, however, was the fact that 
these latter 16 compounds consisted almost entirely of the molecules in the 4th 
quadrant outlier zone for which the data collated indicated they were the lowest 
molecular weight compounds of the entire data set with values less than 250. 
A similar comparison of the ICIPE compounds C-Lab predicted properties against 
those of BP 2009 drugs using SIMCA-P+ yielded the results illustrated in Figure 2.9. In 
this case, a much larger proportion of compounds did not overlap with the BP drugs 
with the most prominent cluster located to the lower right hand side of the 
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Ellipse: Hotelling T2 (0.95) SIMCA-P+ 12.0.1 - 2011-10-04 13:03:03 (UTC+1) 
 
Figure 2.9: 2-D PCA scatter plot of predicted chemical space parameters of BP drugs (black triangles) 
and ICIPE compounds (red diamonds). Outliers are highlighted in red boxes.  
 
A total of 145 compounds could be distinctly identified in the outlier group with a 
few other compounds noted in different non-overlapping areas of the scatter plot. A 
review of the predicted physico-chemical properties of the main group of outliers 
revealed that these compounds when compared to the original entire ICIPE dataset: 
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a) Had a markedly lower mean molecular weight (175.8 vs 245.0); 
b) Had slightly higher mean cLogP values (3.95 vs 3.49); 
c) On average, had significantly fewer rotatable bonds, H-bond donors and 
acceptors (i.e. 2.59 vs 3.55, 0.23 vs 1.04 and 0.78 vs 2.38 respectively). 
Unlike the case with the AHP compounds where there appeared to be a good 
correlation between outliers and deviation from the ‘Rule-of-Five’, with the ICIPE 
dataset, only 44 of the 145 outliers (i.e. 30.3%) were found to deviate from the rules.  
 
From these observations, it appeared that principal component analysis using 
SIMCA-P+ could be used as an easy and fairly accurate method for screening large 
datasets of compounds likely to vary significantly in physico-chemical  properties 
from those of conventional drugs. On the basis of the SIMCA-P+ projections, the 
ICIPE compounds could be considered to be not particularly promising as potential 
drugs - a conclusion that was supported by the fact that the vast majority of these 
compounds were simple hydrocarbon components of essential oils and other 
secondary metabolites of plant origin. 
 
2.7 Overall Compliance with ‘Rule-of-Five’  
Compliance of compounds in the three datasets with the ‘Rule-of-Five’ is 
summarized in Table 2.7. A total of 104 out of the 608 BP 2009 drugs (17.1%) failed 
to comply with at least one of the ‘Rule-of-Five’ parameters. 76 of these (i.e. 73.1% 
of non-compliant compounds) did not comply with 1 rule while 15 (14.4%), 10 (9.6%) 
and 3 (2.9%) failed to adhere to 2, 3 and 4 rules respectively. The most frequently 
violated rule was that for cLogP where 49 (47.1%) of the 104 drugs exceeded the 
+5.0 limit followed by rotatable bonds where 39 (37.5%) drugs fell outside the 
prescribed limit.  
For the AHP constituents, 135 of the 335 compounds in the dataset (40.3%) violated 
one or more of the Lipinski rules. Among these, the proportion of multiple deviations 
was as follows: 1 rule - 72 compounds (53.3%), 2 rules - 33 compounds (24.4%), 3 
rules - 21 compounds (15.5%) and 4 rules - 9 compounds (6.7%). Most frequent 
deviation occurred in the limit for molecular weight where 70 compounds (51.8%) 
exceeded 500. H-bond donors and cLogP were violated by an almost identical 
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proportion of the compounds (43.7% and 40.7% respectively) while only 17 
compounds (12.6%) flouted the rule on number of rotatable bonds. 
In contrast, only 85 of the 297 ICIPE compounds (28.6%) violated any of the rules 
with cLogP being the most prone to deviation (89.4% of the failures). 23.5% and 
20.0% of the deviating compounds exceeded the limits for rotatable bonds and 
molecular weight while 10.6% and 5.9% of the deviants exceeded the requirements 
for H-bond donors and H-bond acceptors respectively. 60 of the 85 compounds 
failed in only one parameter while 11 deviated in both two and three of the rules. 
Only three compounds failed to adhere to four of the rules. In none of the three data 
sets was any compound found to flout all five of the Lipinski rules. 
 
Table 2.7: Summary of compound deviations from ‘Rule-of-Five’ 
 Compound Dataset 
AHP (%) 
n = 335 
ICIPE (%) 
n = 297 
BP Drugs (%) 
n = 608 
1 Parameter  72 (21.5) 60 (20.2) 76 (12.5) 
2 Parameters 33 (9.8) 11 (3.7) 15 (2.5) 
3 Parameters 21 (6.3) 11 (3.7) 10 (1.6) 
4 Parameters 9 (2.7) 3 (1.0) 3 (0.5) 
TOTAL 135 (40.3) 85 (28.6) 104 (17.1) 
 
2.8 In silico Screening for Time Dependent Enzyme Inhibition Structural Alerts 
A software script designed to detect functional groups associated with Time 
Dependent Inhibition (TDI) of CYP450 enzymes was used to screen the compounds in 
the data set. The script worked by identifying text fragments within the SMILES 
notations for each compound indicating the presence of structural alert groups and 
was designed to pick out any of 25 possible alerts, including, but not limited to: 
1. 5 membered heterocyclic aromatic rings; 
2. Conjugated unsaturated alkyl chains and carbonyl groups; 
3. Terminal (ω) and penultimate carbon (ω-1) acetylenes; 
4. Exocyclic and multi-halogenated alkenes, epoxides and thioethers; 
5. Isothiocyanates, thioamides and dithiocarbamates; 
6. Phenols, acetates and peroxides. 
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Table 2.8: Summary of number of TDI structural alerts detected per dataset 
 Compound Dataset 
 AHP ICIPE Cmpds BP Drugs 
None Detected 88 135 183 
1 Detected 127 121 279 
2 Detected 92 37 123 
3 Detected 28 3 19 
4 Detected 0 1 3 
5 Detected 0 0 1 
Average structural alerts per compound 1.18 0.70 0.99 
The AHP natural products were noted to possess the greatest number of potential 
toxicophores per compound (1.18) compared to the ICIPE and BP drugs. The ICIPE 
compounds had the fewest number of potential time dependent enzyme inhibitors 
while the BP drugs averaged almost 1 structural alert per compound. In the three 
data sets, only one compound was found to contain as many as five (5) different 
structural alerts (Figure 2.10 - Cefixime from BP 2009 drugs). Ironically, however, this 
highlighted the fact that presence of structural alerts alone is not necessarily always 
definitive indication of compound toxicity since cefixime, an orally active third 
generation cephalosporin, belongs to a class of antibiotic compounds with a 
generally low toxicity index in humans. The major side effect associated with 
cephalosporins in general is the possibility of hypersensitivity reactions in individuals 
allergic to this class of β-lactam antibiotics. Inhibition of CYP450 enzymes by 
cephalosporins has rarely been reported in the literature with cefixime in particular 
reported as being non-inhibitory against the major drug metabolizing hepatic 
CYP450 isoforms in vitro.22 
 
Figure 2.10: Cefixime - Five structural alerts but low toxicity in vivo 
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A virtual database of natural products and conventional clinically used drugs was 
successfully designed, populated and mined for data that allowed statistical 
comparison across different data sets. Evaluation of the in silico predicted physico-
chemical properties in particular with regard to the Lipinski ‘Rule-of-Five’ parameters 
highlighted broad differences between natural products and the mainly synthetic 
conventional BP 2009 drug compounds. 
As expected, a greater proportion of the natural products in the database did not 
comply with one or more of the Lipinski parameters compared to the BP2009 
dataset. In the case of the latter group, the non-compliance rate of approximately 
17.1% was thought to have been largely due to the fact that this dataset had not 
been filtered beforehand to remove drugs administered through non-oral routes, or 
whose oral absorption was largely dependent on active transporters in vivo. 
Although the database created as described in this Chapter is relatively modest in 
terms of the number of compounds contained, particularly when compared to 
commercially available or online databases, it possesses the advantage of containing 
a large proportion of natural products from medicinal plants unique to the African 
continent. As such, it may conceivably be populated with compounds possessing   
unique chemical scaffolds that may lend themselves to useful ligand-based or target 
structure-based in silico virtual screening. 
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CHAPTER THREE:  
IN VITRO EVALUATION OF NATURAL PRODUCT BIOACTIVATION 
 
3.1 Summary 
In this Chapter, a panel of in vitro experimental techniques employed to investigate the 
possible bioactivation of a selection of natural products is described in detail. The natural 
products selected for in vitro studies are described with particular emphasis on their 
potential or reported biological or medicinal properties. The evaluation strategy employed 
to systematically investigate the potential bioactivation of these selected natural products is 
highlighted. Results from both the preliminary screening as well as details of how in vitro 
trapping experiments were conducted on the selected natural products possessing different 
structural alerts using different trapping agents are presented. An overview of the rationale 
for using different LC-MS detection modes to aid in data analysis as well as interpretation of 
data collected from analysis of the test samples to determine which compounds appeared 
to form reactive metabolic intermediates is included. 
 
3.2 General Introduction 
As previously highlighted in Chapter 1, toxicity of drugs and natural products may arise from 
their inadvertent metabolic bioactivation into reactive metabolites, which are suspected to 
disrupt normal biochemical processes through irreversible covalent binding to sub-cellular 
components.1 
The ability to predict which compounds have the potential to undergo undesirable 
bioactivation during early drug discovery is hampered by many factors, including the fact 
that animal studies cannot be used to determine this and that idiosyncratic adverse 
reactions only occur in  a small percentage of the population. In some cases, however, the 
potential for reactive metabolite formation may be highlighted by the presence of 
functional groups, or structural alerts, known to undergo metabolic bioactivation to reactive 
electrophilic intermediates.2,3 However, the presence of structural alerts is rarely conclusive 
evidence that a drug candidate will have a definite liability through formation of reactive 
metabolites. Many drugs in clinical use that have excellent safety profiles are known to 
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possess structural alerts that do not appear to result in the formation of toxic reactive 
metabolites.4 
At present, the most reliable in vitro experimental technique for detecting the formation of 
reactive metabolites involves determination of covalent binding of test compounds to 
microsomal or hepatocellular proteins after co-incubation. This requires the use of radio-
labelled test compounds and is based on determination of the residual radioactivity after 
incubation of compounds with microsomes and subsequent ‘wash-out’ of the test 
substrates. Radiation readings from the components left behind after removal of the 
substrate are considered evidence of covalent binding of the radiolabelled drug or its 
metabolites to proteins in the incubation matrix. The extent of covalent binding can be 
quantified from the magnitude of radiation detected in the sample. Thus, this technique 
allows for comparison of the relative risk of covalent binding by different compounds or 
their metabolites and may be used to rank them for purposes of lead optimization. The 
main drawback to this methodology is the need to incorporate radioisotopes into the test 
compounds, which may not be practically feasible in the early stages of drug discovery 
particularly when dealing with natural products. Consequently, such assays are only 
performed on a routine basis at later stages of the drug discovery cycle.5 
An alternative, cheaper, and more universally applicable in vitro method to investigate 
covalent binding of compounds resulting from their metabolic bioactivation involves 
trapping of reactive metabolic intermediates using nucleophilic trapping agents. Successful 
application of such methods is, however, dependent on the availability of highly sensitive 
analytical and detection techniques since due to their reactive nature, the reactive 
intermediates are very short-lived and typically only generated in minute quantities. LC-MS 
detection is the most widely applied technique for analysing in vitro metabolite trapping 
incubation samples, providing high sensitivity and the ability to yield information that is 
useful in elucidating the structures of the  reactive intermediate.6–8  
 
CHAPTER 3: IN VITRO EVALUATION OF NATURAL PRODUCT BIOACTIVATION 
 
NICHOLAS M. NJUGUNA - Ph.D. THESIS 2014 
 
86 
3.3 Bioactivation Evaluation Strategy 
To investigate the possible bioactivation of natural product constituents present in 
plant- or microbe-derived preparations used in both conventional and traditional 




3.4 Selection of Natural Products 
A total of twelve purely natural product compounds and three semi-synthetic natural 
product derivatives were sourced for experimental evaluation of metabolic 
bioactivation leading to formation of reactive intermediates. The following key 
considerations were made in selecting specific compounds to study: 
i. The compounds are known or reported to possess biological activity of 
potential medicinal benefit. Alternatively, the compounds are known  
chemical constituents of ethnobotanical preparations reported to possess 
such biological activity;  
ii. The compounds all contained an overt structural alert in their molecular 
structures that might potentially undergo metabolic bioactivation; 
iii. The compounds were readily available in sufficient quantities to facilitate 
comprehensive in vitro testing; 
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iv. Chemical structural diversity i.e. efforts were made to ensure that the 
compounds chosen belonged to different chemical scaffolds. In some cases, 
however, semi-synthetic analogues were also selected for testing to 
investigate the effect of minor changes in parent natural chemical structure 
on possible bioactivation. 
 
3.4.1 Gedunin 
Gedunin (GEDN) is a triterpenoid limonoid isolated from 
plants of the family Meliaceae.9 It is present in extracts 
prepared from the leaves and seeds of the Neem tree 
(Azadirachta indica), a well-known and widely used 
medicinal plant native to India and Burma but also 
common in tropical parts of West and East Africa. The 
medicinal properties of the Neem tree have been exploited for many years along the 
East African coast, where the plant is considered to be a virtual cure-all for treating 
diverse medical conditions – hence its Swahili name “Mwarubaini” (meaning reliever 
of forty disorders). GEDN has also been reported to be a constituent in preparations 
from other plant species including Melia azedarach, Xylocarpus granatum, X. 
obovatus, Cedrela odorata, C. sinensis, Entandrophragna angolense, E. delevoyi, 
Khaya grandifolia and Carapa guainensis. 
GEDN is the most potent naturally occuring antiplasmodial limonoid identified to-
date. MacKinnon et al. reported its in vitro antiplasmodial IC50 values as 39 ng/mL 
and 20 ng/mL against the chloroquine sensitive (CQ-S) P. falciparum D6 and resistant 
(CQ-R) W2 clones, respectively, comparable to those of quinine (14.8 ng/mL and 34.9 
ng/mL).10 Similar results had earlier been reported by Khalid et al but in this case, the 
strain of P. falciparum used in the study was not indicated.11 An even more recent 
study by Chianese et al. reported the antiplasmodial activity of GEDN and other 
limonoids isolated from fruits of the neem tree, in which the potency of the 
compound against the CQ-R P. falciparum W2 strain was again noted to be greater 
than against the CQ-S D10 strain.12 
Apart from its antiplasmodial activity, GEDN has also been reported to possess 
antitumor activity in vitro. For example, it was found to be a moderately potent 
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growth inhibitor of CaCo-2 colon cancer cells at IC50 16.83 µM.
13 GEDN and some of 
its semi-synthetic derivatives have also been reported to exhibit antiproliferative 
activity against MCF-7 and SkBr3 breast cancer cell lines in vitro, acting via inhibition 
of 90kDa heat shock protein (Hsp90), a validated target for new anticancer drugs.14   
In addition to its antiplasmodial and cytotoxic activities, GEDN has also been 
reported to possess inhibitory activity against H+ K+ - ATPase (gastric proton pump) in 
rats and guinea pig models comparable to the anti-ulcer drug omeprazole.15 
The sample of GEDN used for all in vitro experiments in this work was purchased 
from Tocris Biosciences (Ellisville, MO, USA).    
 
3.4.2 Justicidin A 
Justicidin A (JSTN) is an aryl naphtholignan first isolated 
from the plant Justicia procumbens. In Traditional Chinese 
Medicine, J. procumbens is used as a folk remedy in the 
treatment of fever, pain due to pharyngolaryngeal swelling 
and cancer.16 JSTN is also present in other plant species, 
and has been isolated from members of the Geraniaceae 
family, in particular, Monsonia angustifolia. 
JSTN has been reported to possess in vitro antiviral, antiplatelet and particularly 
cytotoxic activity against different human cancer cell lines.16–19 For instance, the 
compound has been found to cause apoptosis in HT-29 and HCT116 human 
colorectal cancer cells and markedly suppressed the growth of HT-29 cells 
transplanted into an immunodeficient (NOD-SCID) mouse model upon oral 
administration.20 JSTN has similarly been reported to inhibit the growth of 
hepatocellular carcinoma cells in vitro and also in mice via a mechanism thought to 
involve activation of caspase-8 leading to apoptosis in addition to disruption of 
mitochondrial function in the cancer cells.21 Very recently, JSTN and other aryl 
naphtholignans from M. angustifolia have been patented for potential application in 
the treatment of erectile dysfunction and libido enhancement.22 
The sample of JSTN used for all in vitro experiments in this work was obtained from 
the Council for Scientific and Industrial Research (CSIR), Pretoria, South Africa.  
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3.4.3 Dehydrobrachylaenolide  
Dehydrobracylaenolide is a eudesmane-type sesquiterpene 
lactone (SQTL) originally isolated from the plant Brachylaena 
transvaalensis from which its name is derived.23 The structure 
of SQTL was elucidated from NMR data  reported by Bohlmann 
& Zdero and the  absolute stereochemistry confirmed by chemical synthesis of the 
natural product by Higuchi et al.24 More recently, the X-ray crystal structure of this 
compound has been reported by Rademeyer et al.25  
SQTL has also been isolated from roots of the plant Dicoma anomala, a grassland 
herb species that is widely distributed in sub-Saharan Africa. This plant is reported to 
have numerous ethnomedicinal applications including the treatment of coughs and 
colds, fevers, ulcers, diarrhoea, intestinal parasites, in  wound healing and also as an 
analgesic anti-inflammatory agent.26–28 
The in vitro antiplasmodial activity of SQTL reported by Becker et al indicated IC50 
values of approximately 1.9 µM and 4.1 µM against CQ-S D10 and CQ-R K1 P. 
falciparum strains, respectively (CQ IC50 0.038 and 0.2 µM, respectively). Gene 
expression studies on the SQTL-treated parasites revealed that the compound 
appeared to alter the expression of 572 unique genes, many of which were different 
from those affected by the antimalarial drug artesunate, suggesting that SQTL may 
have a novel mechanism of antiplasmodial activity.29 
The sample of SQTL used for all in vitro experiments in this work was obtained from 
the Council for Scientific and Industrial Research (CSIR), Pretoria, South Africa.  
 
3.4.4 Metergoline 
Metergoline (MTGN) is a semi-synthetic drug structurally 
related to the naturally occurring ergotamine, an ergot alkaloid 
first isolated from the fungus Claviseps purpurea.30 The 
synthesis and subsequent discovery of the serotonin antagonist 
effects of MTGN was first reported by Bernardi et al and 
Beretta et al in the 1960s.31 In addition, MTGN also acts as a 
dopamine agonist and is used clinically for the management of 
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migraine headaches and to suppress lactation via its bromocriptine-like 
pharmacological effects. MTGN has been reported to exhibit anti-fungal activity in 
vitro, inhibiting the growth of Candida krusei by triggering intracellular increase in 
reactive oxygen species and disrupting mitochondrial homeostasis.32 Very recently, 
MTGN has been identified as a moderately potent chemosensitizer with potential 
use in treatment of malaria by its enhancement of the sensitivity of resistant P. 
falciparum strains to chloroquine.33   
The sample of MTGN used for the in vitro assays in this work was purchased from 
Sigma Aldrich. 
 
3.4.5 Fusidic acid 
Fusidic acid (FSDA) is a naturally occurring steroidal 
antibiotic originally isolated from the fungus 
Fucidium coccineum and which has been in clinical 
use since the 1960s.34 FSDA is used for the 
treatment of infections caused by gram-positive 
bacteria and is formulated as tablets, oral 
suspensions, intravenous infusions and topical 
preparations.  FSDA has been reported to exhibit  high oral biovailability (91%) and 
long plasma half-life.35 As an antibiotic, FSDA has a relatively narrow spectrum of 
activity and is mainly active against staphylococci strains resistant to other classes of 
antibiotics such as the penicillins. However, the drug is reported to be generally well 
tolerated with a good safety profile and can be administered in large doses for 
prolonged periods of time.36,37 




Muzigadial (MZG), also known as canellal, is a sesquiterpene 
drimane dialdehyde present in plants of the genus Warburgia 
(family Canellaceae) that was first isolated from the bark of the 
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plant Warburgia ugandensis.38  MZG is also present in W. salutaris, the only species 
of the genus that extends into Southern Africa.39 Traditionally, W. salutaris has been 
used extensively for the ethnobotanical treatment of ailments such as headaches, 
gum inflammation, venereal diseases, abdominal pains, malarial fevers, skin 
complaints and stomach ulcers.40,41  
MZG and related drimane sesquiterpenoids have been reported to possess potent 
molluscidal, antifungal and broad spectrum antibacterial activity in addition to 
having anti-feedant effects against African army worms.42,43 MZG and other  drimane 
sesquiterpenes isolated from Canella winterana have also been reported to possess 
phytotoxic activity.44 MZG has also been reported to have potent in vitro 
antiplasmodial activity against the chloroquine sensitive D10 P. falciparum strain.  
However, its utility as an anti-malarial agent appeared to be limited by the fact that 
it showed poor selectivity when tested for cytotoxicity against Chinese Hamster 
Ovarian cells.45 
The sample of MZG used for in vitro experiments in this work was obtained from the 
Plants for Human Health Institute, North Carolina State University, USA.  
 
3.4.7 Muzi-04 
 Muzi-04 is a semi-synthetic semicarbazone 
derivative of muzigadial prepared from the reaction 
of the parent compound with semicarbazide 
(Scheme 3.1) to investigate the effect of substituting 
one of the aldehyde groups on the biological activity of the parent natural product. 
 
 
Scheme 3.1: Synthesis of Muzi-04 from muzigadial 
 
The sample of MUZI-04 used in this work was synthesized by Dr. Tzu-Shean Feng at 
the Department of Chemistry, University of Cape Town. 
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3.4.8 Cucurbitacin A, B and C 
 
The cucurbitacins are a group of highly oxygenated, tetracyclic triterpene 
phytosterols characterized by the presence of the cucurbitane skeleton, 19-(109β) 
abeo-10α-lanost-5-ene, and which were first identified in plants of the family 
Cucurbitaceae. To date, no fewer than twenty distinct cucurbitacins have been 
reported in the literature, each being assigned a different letter of the alphabet to 
distinguish between these structurally closely related compounds (i.e. Cucurbitacin 
A, B, C…etc.)46 Cucurbitacins have been reported to possess a wide range of 
pharmacological activities in vitro, with cucurbitacin B, D, E, I and Q being particularly 
notable for their cytotoxic activity against a variety of solid cancer cell types. The 
anticancer activity of this class of compounds is largely due to their potent inhibition 
of multiple cell signalling pathways crucial for cell proliferation and growth, resulting 
in fatal morphological and physiological changes in cancer cells.47 For example, 
cucurbitacin B (CUC-B) has been reported to inhibit the growth of Hep-2 human 
laryngeal cancer cells and K562 leukaemia cells through inhibition of STAT3 
activation leading to apoptosis and cell cycle arrest.48,49 CUC-B has also been 
reported to inhibit the proliferation of BEL-7402 hepatocellular carcinoma cells both 
in vitro and when administered orally to BEL-7402 xenografted nude mice. In this 
case, the mechanism of action appears to involve inhibition of a different signalling 
pathway, the activation of  c-Raf and not STAT3.50 Against different leukaemia and 
lymphoma cell lines, CUC-B has been reported to exhibit dose-dependent growth 
inhibition arising from cell cycle arrest, increased cellular multi-nucleation and 
abnormal enlargement of cancer cells but not apoptosis.51 In yet another study, CUC-
B has been found to inhibit growth of glioma cancer cells in culture, again by causing 
cell-cycle arrest, apoptosis, disruption of F-actin and the microtubule cytoskeleton, 
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thereby disabling the ability of cells to migrate. In these cells, CUC-B appeared to act, 
at least partly, through the activation of JNK signalling pathways.52 
The samples of cucurbitacin A, B and C used in this work were generously provided 
by Emeritus Prof. James Bull (Department of Chemistry, University of Cape Town). 
 
3.4.9 DC3 
The furanoterpernoid labdane compound designated DC3 is a semi-
synthetic tetraol derived from the natural product dubiin, first  
reported by Eagle and Rivett in the 1970s and originally isolated 
from the acetone extracts of the leaves of the southern African plant 
Leonotis dubia.53 DC3 was prepared through the synthetic reduction 




Scheme 3.2: Synthesis of DC3 from dubiin 
 
3.4.10 Leoleorin A 
Plants of the genus Leonorus from which dubiin and leoleorin A 
(DC14) are obtained are indigenous to tropical parts of the world 
and particularly common in southern parts of Africa where they 
have been used as components of traditional herbal remedies. L. 
leonurus commonly known as Lion’s Tail or Wild Dagga, is used as a 
herbal remedy for the treatment of fevers, headaches, dysentery, epilepsy, 
hypertension and snake bites. The plant is known to have mild psychoactive 
properties and its dried leaves and flowers have a calming effect when smoked. The 
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plant has subsequently been shown to be of potential benefit as an anxiolytic or 
antidepressant, possibly through modulation of the dopaminergic system.54  
 
The samples of DC3 and Leoleorin A (designated DC14) used for the in vitro assays 
reported in this work were a generous donation from Prof. Mike-Davies Coleman 
(formerly of Rhodes University, Grahamstown, South Africa and currently at the 
University of the Western Cape, South Africa). 
 
3.4.11 Jamaicin and Calopogonium isoflavone A 
 
Jamaicin (JMCN) is an isoflavone that was first isolated from root bark extracts of the 
plant Piscidia erythrina, commonly known as Jamaica Dogwood and from which the 
compound’s name is derived.55 Calopogonium isoflavone A (CLPG) is a closely related 
compound isolated from plants of the genus Millettia.   
In general, isoflavanoids have very limited distribution in the plant kingdom and are 
mostly found only in plants of the family Leguminoseae. JMCN, CLPG and other 
isoflavones are known constituents of herbal preparations that possess medicinal 
properties. Both compounds have, for example, been reported to exhibit moderate 
antiplasmodial activity in vitro against CQ-R Indochina 1 (W2) and CQ-S Sierra Leone 
1 (D6) strains of Plasmodium falciparum.56 
 
The samples of JMCN and CLPG used in this work were a generous donation from 
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Formononetin (FMTN) is an isoflavone also  isolated 
from plants of the family Leguminosae used as 
herbal medications. In Traditional Chinese Medicine 
preparations of the remedy Danggui Buxue Tang 
which comprises a mixture of Radix astragali and Radix angelicae, the content of 
FMTN and other isoflavanoids has been found to correlate with the biological 
activity of the preparation. FMTN content is therefore used as a quality control 
marker for Radix astragali preparations.57 FMTN from other plant species has 
similarly been reported to possess varying biological activities. For example, this 
compound from the bark of Dalbergia frutescens was found to exhibit significant in 
vitro antigiardial activity against the protozoan parasite Giardia intestinalis with IC50 
values superior to those of metronidazole, the current drug of choice (0.03 µg/mL vs. 
0.1 µg/mL). However, although FMTN was also found to be active against a murine 
model of giardiasis in vivo, only high doses were effective, suggesting possible ADME 
liabilities when the compound is administered orally.58 Isoflavones in general are 
well documented to possess phytoestrogenic biological properties, arising from their 
structural similarity to the hormone estrogen. FMTN has therefore been extensively 
studied to determine its effect on biological processes mediated in part by estrogens 
in vivo. For example it has been found to promote early healing of fractures in rats 
by activating angiogenesis and also been reported to promote endothelial repair and 
accelerate wound healing ex vivo and in a mouse model.59,60 In a study carried out in 
rats, FMTN was reported to cause aortic vascular relaxation via both nitric oxide 
dependent and endothelium-independent mechanisms involving activation of BKCa 
and KATP channels.
61 Very recently, it has also been reported that FMTN may play a 
neuroprotective role in rats subjected to traumatic brain injury through inhibition of 
intracephalic inflammatory response and oxidative stress.62 
 
The sample of FMTN used in this work was purchased from Sigma Aldrich.  
 
Prior to carrying out in vitro experiments, the identity and purity of the test 
compounds was confirmed using a combination of NMR spectroscopy, LC coupled 
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mass spectrometry (LC-MS) and melting point determination. Spectral data was 
compared to values reported in the literature. Semi-quantitative determination of 
the solubility of the test compounds in aqueous buffer was measured using 
turbidimetric analysis as a means of identifying potential challenges in conducting 
subsequent in vitro assays in aqueous buffer solutions. The experimental procedures 
used for these characterizations are described in detail in Chapter 6 and the results 
for each compound summarized in Appendix 1. 
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3.5 CYP450 Enzyme Inhibition Assays 
Inhibition of the enzymes involved in drug metabolism often presents as one of the 
mechanisms by which xenobiotics lead to toxicity either directly or more commonly, 
through adverse drug-drug interactions. As previously highlighted in Chapter 1, 
natural products present in foods or non-conventional herbal remedies can similarly 
inhibit the same drug metabolizing enzymes, resulting in clinically significant adverse 
food-drug or herb-drug interactions. Enzyme inhibition assays are therefore 
routinely conducted early in the drug discovery process to identify lead compounds 
that might interfere with the catalytic activity of the main drug metabolizing 
enzymes, particularly the CYP450 isoforms.  
For rapid high-throughput screening of large compound sets for CYP450 inhibition, 
assays based on the use of fluorogenic substrates and purified recombinant enzymes 
in microtitre 96-well plates are routinely used. These assays are based on the 
metabolism of the probe substrates to fluorescent metabolites when incubated in 
the presence of the drug metabolizing enzymes. Enzyme activity is proportional to 
the intensity of the measured fluorescence. If a compound that inhibits the activity 
of the enzyme is co-incubated with the probe substrate, there is a resultant decline 
in formation of the fluorescent metabolite, which can be determined through a 
measurable decrease in the fluorescence determined spectrophotometrically. 
Advantages of this assay set-up include its high speed, ease of application and low 
set-up cost without the need for elaborate compound separation or capital-intensive 
equipment since it is based on the measurement of fluorescence of known 
metabolites whose spectral properties are well established with regard to excitation 
and emission wavelengths. Furthermore, fluorescence readings are taken directly 
from the test preparation without the need for sample work-up or separation to 
isolate the fluorescent metabolites.  Because of the very simple setup of this type of 
assay, testing of compounds can be readily automated to facilitate high throughput 
screening. 
Although ideal for rapid early screening of potential enzyme inhibitors, this method 
suffers from the drawback of not being suitable for testing inhibition caused by 
compounds that fluoresce at the same wavelengths as the probe substrate 
metabolites detected or which quench the fluorescence of these metabolites. 
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3.5.1 CYP450 Inhibition Assay Procedure and Results 
In vitro CYP450 inhibition assays were carried out in 96-well microtitre plates based 
on the methods described by Crespi whereby test compounds were co-incubated in 
duplicate with purified recombinant enzymes in aqueous buffer to which the 
fluorogenic probe  substrates was also included.63,64 The test compounds were 
incubated at both 3 µM and 20 µM for 15 minutes at 37 °C at the end of which 
incubations were terminated by addition of an ice-cold solution of 20% 5 mM Tris in 
80% acetonitrile. Inhibition of enzyme activity in incubations containing test 
compounds was subsequently determined based on calculations of the fluorescence 
intensity measurements compared to control incubations in which no compound 
was present. Positive control incubations in which known specific inhibitors of the 
individual rCYP450 enzymes screened were also included in every assay. The general 
set-up conditions for the enzyme inhibition assays are summarized in Table 3.1 and 
described in detail in the Experimental Chapter. 
  
Table 3.1: CYP450 isoforms, probe substrates, fluorescent metabolites and spectrofluorometric 
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The fluorogenic probe substrates illustrated in Table 3.1 used to evaluate CYP450 
enzyme inhibition by the different compounds were synthesized, purified and 
characterised in-house as part of this work. However, evaluation of CYP2D6 
inhibition using MAMC as probe substrate was hampered by the unusually high 
flourimeter readings obtained from the inhibition assay samples. Although successful 
use of this probe substrate and structurally related analogues has been reported in 
the literature, 65 the readings observed in our case were thought to be due to 
spectral interference by other components present in the incubation matrix. The 
interference was most likely largely due to NADPH, which has almost identical 
maximum emission wavelength (λemm 460 nm) as that of the monitored metabolite 
(7-hydroxy-4-methylamino coumarin, λemm 470 nm).
66 Consequently, determination 
of CYP2D6 inhibition by the test compounds using the methods successfully 
employed for other isoforms as described in this Chapter was not possible, despite 
minimizing NADPH concentration. 
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3.5.1.1 Inhibition of CYP1A2 
 
 
Figure 3.1: rCYP1A2 inhibition assay results (Substrate: CEC 3 µM) 
 
rCYP1A2 appeared to be inhibited most significantly by the isoflavanoids CLPG and 
JMCN, both of which reduced enzyme activity to far less than 40% even at the lower 
assay concentration (3 µM). All other test compounds seemed to have little, if any, 
inhibitory effect on the activity of this isoform, with only metergoline and gedunin 
being noted to reduce activity to slightly less than 80% at 3 µM. This inhibition, was 
not, however, considered to be significant. 
The isoflavone formononetin (FMTN), though closely structurally related to both 
CLPG and JMCN did not appear to inhibit enzyme activity even at the higher assay 
concentration (20 µM), suggesting that inhibition of the enzyme might be, in some 
way, dependent on the presence of the unique dimethyl pyran ring substitution on 
the chromone nucleus in JMCN and CLPG.   
The three cucurbitacin compounds appeared to have no inhibitory effect on the 
enzyme.
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3.5.1.2 Inhibition of CYP2C9 
 
 
Figure 3.2: rCYP2C9 inhibition assay results (Substrate: MFC 85 µM) 
 
rCYP2C9 appeared to be substantially more prone to inhibition by the test 
compounds compared to rCYP1A2 with 7 of the test substances (FMTN, JSTN, MZG, 
MTGN, FSDA, CLPG and JMCN) being found to reduce enzyme activity by more than 
20% at 3 µM. The most potent inhibitors of this isoform were JSTN and MZG 
although neither seemed to reduce enzyme activity to as great an extent as 
observed with the most potent inhibitors of rCYP1A2 (i.e. JMCN and CLPG). Again, as 
also noted with rCYP1A2, none of the three cucurbitacins seemed to have any 
significant inhibition of rCYP2C9 enzyme at both assay concentrations, with only 
CUC-C exhibiting moderate inhibition at 20 µM. 
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3.5.1.3 Inhibition of CYP2C19 
 
 
Figure 3.3: rCYP2C19 inhibition assay results (Substrate: MFC 35 µM) 
 
GEDN and JMCN were the only compounds observed to inhibit rCYP2C19 to a 
significant degree at the lower assay concentration. Both reduced enzyme activity to 
less than 50% at 3 µM with GEDN being the more potent inhibitor. None of the 
remaining compounds reduced enzyme activity to below 50% although all fifteen 
appeared to exert greater inhibition at 20 µM in a manner largely proportional to 
activity at the lower concentration. The most notable exception to this behaviour 
was MZG - which at 3 µM only appeared to cause less than 25% inhibition of 
enzymatic activity, but was the most potent inhibitor at the higher assay 
concentration, reducing activity to less than 20%. As observed with rCYP2C19, such 
inhibitory activity was markedly absent in the semi-synthetic derivative Muzi-04. 
The cucurbitacin compounds were, as seen with rCYP1A2 and rCYP2C9, noted to 
possess very little, if any, inhibitory activity against this isoform, even when assayed 
at 20 µM.  
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3.5.1.4 Inhibition of CYP3A4 
 
 
Figure 3.4: rCYP3A4 Inhibition Assay Results (Substrate: BFC 400 µM) 
 
Of the CYP450 isoforms tested, rCYP3A4 appeared to be the most susceptible to 
inhibition by the test compounds. All fifteen compounds exhibited concentration 
dependent inhibition of this isoform, with greater inhibition of the enzyme at 20 µM 
compared to 3 µM. Seven (7) of the compounds reduced enzyme activity by more 
than 50% even at the lower assay concentration of 3 µM while only in the presence 
of FSDA at 20 µM was rCYP3A4 activity above 50% retained. GEDN, JSTN, MTGN, 
CLPG and JMCN were the most potent inhibitors, each being noted to inhibit enzyme 
activity by more than 60% at 3 µM. 
Although the cucurbitacins were very closely related structurally, and appeared to be 
uniformly devoid of inhibition against the other CYP450 isoforms tested, they were 
noted to possess different inhibitory profiles against rCYP3A4. Against this enzyme, 
CUC-B and CUC-C were appreciably more potent inhibitors compared to CUC-A, 
which was the only cucurbitacin that did not cause more than 50% enzyme inhibition 
at 3 µM. MZG was a moderate inhibitor of rCYP3A4 compared to its semi-synthetic 
derivative Muzi-04 which was only weakly inhibitory at 3 µM. Overall, GEDN, JMCN 
and JSTN, in that order, appeared to be the most potent enzyme inhibitors. 
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3.5.2 Time Dependent CYP3A4 Inhibition 
Time dependent inhibition (TDI) assays were performed to determine whether 
inhibition of rCYP3A4 was due to reactive metabolic intermediates of the test 
compounds resulting in mechanism based inhibition of this isoform. This enzyme 
was selected for TDI assays because it is the single most abundant and important 
CYP450 isoform involved in drug metabolism in vivo and also due to the fact that it 
appeared to be the most susceptible to inhibition by the test compounds. 
The TDI assay was performed by incubating test compounds in recombinant enzyme, 
in both the absence and presence of co-factor (NADPH) for a defined duration before 
re-incubating the test preparation in the presence of the fluorogenic substrate of the 
enzyme to determine the latter’s subsequent metabolism. If the test compound is a 
TDI, the pre-incubation is necessary to provide the enzyme adequate time to 
metabolize the compound. Presence of NADPH is a mandatory prerequisite for 
enzymatic metabolism. If the test compound is metabolized into chemically reactive 
species that in turn inactivate the metabolizing enzyme, this is detectable as a 
measurable decline in the fluorescence from metabolism of the fluorogenic marker 
substrate in the second incubation. If the test compound is not a TDI, the difference 
in the metabolism of the marker substrate in the test and control incubations is 
negligible and can be quantified by calculating  normalized inhibition ratios. 
In running the TDI assays, 2 known inhibitors of CYP3A4 were used as controls. 
Ketoconazole (KTZ) is a non-TDI compound (i.e. inhibits the activity of CYP3A4 but 
not irreversibly) and was therefore used as the negative control. Troleandomycin 
(TAO) is an irreversible inhibitor of the enzyme and acted as the positive control. 
Test compounds were incubated in duplicate at concentrations of 1 µM and 5 µM.  
From the measured fluorescence values, the normalized enzyme inhibition ratios of 
the test compounds were calculated using the equation shown below and results 
interpreted according to the criteria outlined by Thelingwani et al. 67  
 
Normalized Ratio =    
where R + I
+NADPH
 is the rate of reaction in the presence of both inhibitor and NADPH,  
R - I
+NADPH
 is the rate of reaction in the presence of NADPH but in the absence of inhibitor,  
R+ I
-NADPH 
is the rate of reaction in the presence of inhibitor but in the absence of NADPH, 
R - I
-NADPH
 is the rate of reaction in the absence of both inhibitor and NADPH 
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Compounds that gave normalized ratios greater than 0.9 were considered non-TDI, 
those between 0.7 and 0.9 were border-line while values less than 0.7 were 
considered to be a good indication of TDI activity. 
The results of the rCYP3A4 TDI assay using the three most potent inhibitors of the 
enzyme isoform (GEDN, JSTN, JMCN), CUC-B as representative of the cucurbitacins, 
and the control drugs ketoconazole (KTZ) and troleandomycin (TAO) are illustrated in 
Figure 3.5 below. 
 
Figure 3.5: Normalized ratios of rCYP3A4 inhibitors for determination of TDI 
 
 
Although all four test compounds had been observed to strongly inhibit rCYP3A4, 
their calculated normalized inhibition ratios at both assay concentrations were 
greater than 0.7, suggesting that enzyme inhibition activity was not mechanism 
based. For JMCN, the normalized ratios were calculated to be 0.91 and 0.90 at 1 µM 
and 5 µM, respectively. These values, by virtue of falling within the borderline region 
indicated that the possibility of JMCN being a mechanism-based rCYP3A4 inhibitor 
could not be entirely ruled out.  
 
3.5.3 Glutathione-Fortified rCYP3A4 Inhibition Assay 
The effect of incorporating reduced glutathione to the rCYP3A4 enzyme inhibition 
incubations was investigated by modifying the experimental protocol to include the 
endogenous redox scavenger. The four compounds tested for time dependent 
CHAPTER 3: IN VITRO EVALUATION OF NATURAL PRODUCT BIOACTIVATION 
 
NICHOLAS M. NJUGUNA - Ph.D. THESIS 2014 
 
106 
inhibition of the enzyme were evaluated once more using this strategy in the 
presence of 1 mM reduced L-glutathione (Figure 3.6). 
  
  
Figure 3.6: Effect of glutathione on inhibition of rCYP3A4 by selected natural products 
 
Glutathione appeared to have little influence on the inhibition of rCYP3A4 by GEDN, 
JSTN and JMCN in which incubations the remaining enzyme activity only increased 
by less than 2%, which was not considered to be significantly higher than the 
experimental error. In the case of CUC-B, however, the presence of glutathione 
appeared to have a more noticeable effect in reducing enzyme inhibition, increasing 
residual enzyme activity by approximately 8% and 6% at 3 µM and 20 µM inhibitor 
concentrations respectively.  
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This observation seemed to contradict the conclusion based on TDI data that showed 
CUC-B not to be an irreversible, time dependent inhibitor of rCYP3A4. On the other 
hand, the data from this assay for the other compounds supported the observations 
made from the TDI experiment that neither GEDN, JSTN nor JMCN seemed to form 
reactive metabolites that inhibited rCYP3A4.  
 
In order to establish more conclusively which of the test compounds screened for 
enzyme inhibition might act via formation of reactive metabolic intermediates, more 
comprehensive reactive metabolite trapping experiments were performed next.
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3.6 Reactive Metabolite Trapping Experiments 
In vitro reactive metabolite trapping experiments were conducted based on adopted 
assay protocols reported in the literature.68,69 The general procedure involved 
incubating test compounds at concentrations of 10 µM in aqueous phosphate buffer 
(pH 7.4) in the presence of hepatic microsomes and nucleophilic trapping agents. 
Metabolic reactions were initiated by the addition of NADPH and maintained at 37°C 
for 60 minutes then terminated by adding ice-cold acetonitrile. Sample preparation 
involved centrifugation of the quenched reaction mixture to separate precipitated 
microsomal proteins, followed by filtration of the resultant supernatant solution and 
analysis by LC-MS. For every trapping experiment, various controls in which either 
the test compound, trapping agent, NADPH or microsomes was excluded from the 
reaction were also incubated to aid in data interpretation.  
Prepared samples were analysed using reversed-phase HPLC coupled to mass 
spectrometry. Mass spectrometer ionisation and detection parameters for each test 
compound were manually optimised following direct infusion of the compounds 
using a syringe pump. Compound detection was carried out following ionisation 
using either electro-spray ionisation (ESI) as the preferred mode or, in a few 
instances, atmospheric pressure chemical ionisation (APCI). 
The following MS detection modes were used to analyse the incubation samples for 
trapped reactive metabolite adducts: 
i. Enhanced mass spectrum (EMS) scans in either or both positive and negative 
ionisation mode were the primary detection modes employed. The range of 
m/z values scanned was typically 150 – 900 and facilitated the scanning of 
full mass spectra on LC eluent samples using the increased sensitivity on the 
incorporated linear ion trap present in the mass spectrometer used. 
ii. Information dependent acquisition enhanced product ion scans (IDA EPI) 
were used to automatically detect and obtain mass fragmentation data of 
the most intense peaks observed from the initial EMS scans. By directly 
coupling this detection mode to the EMS scans, the need to rerun samples to 
obtain mass spectral fragmentation data was eliminated. 
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iii. Constant neutral loss (CNL) scans were used to detect reactive metabolite 
adducts of trapping reagents known to undergo characteristic fragmentation 
by losing neutral fragments having specific m/z values.  
iv. Precursor ion scans were used as an optional confirmatory detection mode to 
determine the presence of glutathione trapped reactive metabolites which 
are often observed to undergo collision-induced dissociation to yield 
fragment ions having m/z 272.09 in negative ion mode.   
 
3.6.1 Trapping Reactive Metabolites Using Cyanide 
Cyclic tertiary amines are principally metabolized by CYP450 or monoamine oxidase 
(MAO) enzymes via α-carbon oxidation that generates the corresponding endocyclic 
iminium ion. Alternatively, these compounds may also undergo oxidative N-
dealkylation via oxidation to the exocyclic iminium ion intermediate that is 
subsequently hydrolysed to form the corresponding secondary amine and an 
aldehyde. Unlike the exocyclic iminium ion intermediate, hydrolysis of the endocyclic 
iminium ion to the corresponding aminoaldehyde is reversible, allowing possible 
further metabolic processing of the former. Whereas the iminium ion intermediates 
of aliphatic tertiary amines are in equilibrium with carbinolamines that dissociate to 
aldehyde and secondary amine (i.e. via the N-dealkylation metabolic pathway), 
carbinolamine dissociation remains reversible for cyclic tertiary amines, increasing 
the effective lifetime of the iminium ion species. Endocyclic iminium ion 
intermediates are often oxidized by hepatic aldehyde oxidase to the biologically less 
active lactams. If special structural features are present in the substrate molecule or 
if the cyclic iminium ion intermediate is generated in extrahepatic tissue lacking 
aldehyde oxidase, these reactive intermediates may undergo alternative chemical 
transformations that can produce toxic products (Figure 3.7).70 
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Iminium ions are ‘hard’ electrophiles that cannot be effectively trapped using soft 
nucleophiles such as glutathione. Instead, in vitro trapping experiments make use of 
cyanide ions as the preferred trapping agent. In this reaction, it is hypothesized that 
the endocyclic iminium ions undergo reversible conversion to their corresponding 
cyclic α-carbocations which subsequently undergo nucleophilic attack by the cyanide 
anion to form stable cyano adducts (Figure 3.8). On LC-MS, successful cyanide 
trapping is evidenced by presence of substrate peaks having a net mass gain of +25 
Da corresponding to initial loss of hydrogen to form the iminium and carbocation, 
followed by addition of the cyanide ion (i.e. -1 then +26 Da). Following collision-
induced fragmentation of the cyanide adducts, the cyano group is relatively easily 
lost as hydrogen cyanide (m/z 27 Da). This characteristic can be used to confirm the 
presence of cyanide trapped intermediates by combining constant neutral loss scans 
in positive ion mode to detect the loss of the 27 Da and the EMS scans used to 
detect the intact cyano adduct. 
 




CHAPTER 3: IN VITRO EVALUATION OF NATURAL PRODUCT BIOACTIVATION 
 
NICHOLAS M. NJUGUNA - Ph.D. THESIS 2014 
 
111 
The drug rimonabant was used as a positive control to confirm that reactive iminium 
intermediates could be trapped and detected using LC-MS as reported in the 
literature.68 Rimonabant was incubated in both human (HLM) and rat liver 
microsomes (RLM) fortified with KCN to capture the iminium ion arising from 
suspected bioactivation of the tertiary N-atom in the piperidine ring (Figure 3.9). 
 
Figure 3.9: Hypothesized bioactivation of rimonabant and subsequent trapping of reactive 
intermediate using KCN 
 
In the RLM test incubation (Figure 3.10 and 3.11), extracted ion chromatograms 
(XIC) from the LC-MS EMS data generated clearly showed the presence of two 
distinct adduct peaks corresponding to mass shifts of +25 and +41 greater than the 
m/z value of the parent rimonabant (MH+ 463.1) and both eluting before the parent 
compound. 
Figure 3.10: XIC of T0 rimonabant incubation in presence of RLM fortified with KCN. As expected, no 
obvious degradation or metabolite peaks are observed in this incubation which illustrates compounds 
present at the start of the trapping experiment. 
CHAPTER 3: IN VITRO EVALUATION OF NATURAL PRODUCT BIOACTIVATION 
 
NICHOLAS M. NJUGUNA - Ph.D. THESIS 2014 
 
112 
Figure 3.11: XIC of rimonabant incubation in presence of RLM fortified with KCN after 60 min (T60) 
indicating presence of two suspected cyanide adduct peaks 
The peak having m/z 488.2 was suspected to be the direct cyanide adduct of the 
parent, especially since its fragmentation pattern was identical to that of rimonabant 
with the sole exception of a mass spectral signal corresponding to the protonated 
molecular ion at 488.2 not present in the parent. The peak with m/z 504.1 was 
suspected to be the cyanide adduct of the oxidized rimonabant resulting in the net 
mass gain of +41 (i.e. +16 then +25). 
In the HLM incubations, only the adduct peak corresponding to m/z 488.2 was 
detected, with no sign of the (suspected) oxidized rimonabant cyanide peak (Figure 
3.12). This variance was attributed to differences in the CYP450 composition of the 
HLM and RLM enzyme systems and suggested that perhaps rimonabant is preferably 
metabolized to reactive intermediates by an isoform of the CYPs that is more 
abundant/active in RLMs compared to HLMs. 
Figure 3.12: XIC of rimonabant incubation in HLM fortified with KCN after 60 min indicating presence 
of single suspected cyanide adduct peak (MH
+
m/z 488.1) 
Further proof that the peak with m/z 488.2 was a cyanide adduct was provided by 
the fact that fragmentation of the compound afforded a distinct loss of 27 Da as 
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revealed from its enhanced product ion (EPI) spectrum, consistent with collision 
induced loss of neutral hydrogen cyanide (Figure 3.13).  
 
Figure 3.13: EPI spectrum of suspected cyanide-trapped reactive rimonabant metabolite showing 
fragmentation involving loss of 27 Da hydrogen cyanide molecule. 
Metergoline was the only one of the test compounds that possessed a tertiary cyclic 
amine that could potentially undergo bioactivation to form a reactive iminium 
intermediate (Figure 3.14). The compound also contained a second structural alert in 
the form of a masked 3-methylindole moiety commonly implicated in the formation 
of reactive epoxide, iminium or quinone imine intermediates.2 To trap potential 
reactive iminium metabolites, KCN fortified trapping incubations were carried out on 
metergoline as performed on rimonabant in both RLM and HLM. 
 
Figure 3.14: Metergoline with structural alerts circled 
Contrary to the findings with rimonabant, incubation of metergoline in KCN fortified 
microsomes did not appear to result in the formation of cyanide trapped reactive 
metabolic intermediates. The 60 minute (T60) test incubation of metergoline in 
HLM+KCN revealed only the presence of the same compound/metabolite peaks as 
observed in the control incubation devoid of KCN (Figure 3.15). 
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Figure 3.15: XIC of T60 incubation of metergoline in KCN fortified HLMs indicating presence of 
metabolite peaks but no obvious cyanide adducts. 
The main peak observed at retention time 5.82 min had m/z 420.2 corresponding to 
a direct mono-oxidation of the parent (MH+ 404.2) which eluted at 6.54 min. Two 
other peaks were observed and suspected to represent minor metabolites of 
metergoline at m/z 418.2 (Rt 6.11 min) corresponding to a direct mono-oxidation 
possibly resulting in formation of a keto-group, and m/z 390.2 (Rt 6.47 min) thought 
to represent an N-demethylated metabolite. No peak appeared to result from the 
parent metergoline or any of the observed metabolites gaining 25 Da. 
 
3.6.2 Trapping Reactive Metabolites Using Glutathione 
Reduced L-glutathione (GSH) is the most commonly used in vitro reactive metabolite 
trapping agent. Its utility is based on the fact that in vivo this endogenous tripeptide 
(-L-glutamyl-cysteinyl-glycine) serves as a potent scavenger of reactive electrophilic 
species and toxic free radicals and acts as a crucial substrate for detoxification 
reactions. In the body, glutathione exists in both its reduced and oxidized forms 
(Figure 3.16) with the former being predominant and present in virtually all tissues 
at fairly high concentrations especially in the liver (5 - 10 mM).71 
CHAPTER 3: IN VITRO EVALUATION OF NATURAL PRODUCT BIOACTIVATION 
 




Figure 3.16: Reduced and oxidized forms of glutathione 
Glutathione serves as a substrate for Phase II metabolic conjugations catalyzed by 
the enzyme glutathione-S-transferase. In addition, however, GSH readily forms 
conjugates with soft electrophilic species spontaneously even in the absence of the 
conjugating enzyme. In the body, such conjugates may be directly excreted into 
urine or bile, or undergo further biotransformation to recycle the amino acid 
residues glutamic acid and glycine before forming mercapturic acid metabolites of 
the original substrates which are then excreted (Figure 3.17). 
 
Figure 3.17: Role of GSH in detoxification of reactive metabolites in vivo and the biochemical fate of 
resultant GSH conjugates 
GSH-fortified microsome in vitro trapping experiments were conducted on test 
compounds to determine if they might undergo bioactivation to ‘soft’ electrophilic 
reactive metabolites. As a positive control, the antimalarial drug amodiaquine was 
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used due to its reported bioactivation to a reactive quinone imine metabolite (Figure 
3.18).72 
 
Figure 3.18: Major metabolites of amodiaquine and GSH trapping of reactive quinone imine 
intermediate 
 
For LC-MS detection of GSH adducts, full survey EMS scans in either positive or 
negative modes were conducted as the primary detection mode and where 
necessary, followed by precursor ion scans for the parents of the m/z 272 Da 
fragment in –ve ion mode, for confirmation. In the EMS scans, direct GSH conjugates 
would be observed as substrate or metabolite peaks with a net mass gain of +305 Da 
(+/- H+ depending on polarity). Loss of the 272 Da fragment - a characteristic of GSH 
adducts, would provide further confirmation of the presence of the conjugates.73 
Constant neutral loss scans for peaks that showed a loss of 129 Da in positive ion 
mode also provided alternative proof of the presence of glutathione adducts. The 
origin of these characteristic glutathione fragments is illustrated in Figure 3.19. 
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Figure 3.19: Detection of GSH adducts and characteristic fragments using different MS scanning 
modes 
  
On the full survey EMS scans in both +ve and –ve ion mode, residual parent 
amodiaquine and its two main metabolites could be clearly observed as distinct 
peaks in the T60 incubation (Figure 3.20). 
Figure 3.20: XIC +ve ion mode EMS of T60 aliquot of amodiaquine incubated with GSH fortified RLM 
 
Whereas the expected amodiaquine-GSH conjugate was not observed in the +ve 
mode, it was distinctly visible in –ve ion mode at Rt 5.52 min albeit appearing to co-
elute with the desethylamodiaquine peak (Figure 3.21). 
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Figure 3.21: XIC of -ve mode EMS of T60 amodiaquine incubation in GSH fortified RLMs indicating 
presence of GSH-conjugate co-eluting with desethylamodiaquine 
Further proof that the peak at Rt 5.52 min was most likely that of a GSH-trapped 
conjugate was provided by re-analyzing the sample and detecting using a precursor 
ion scan of the 272 Da fragment in –ve ion mode (Figure 3.22). 
 
Figure 3.22: TIC of -ve ion mode precursor ion scan of m/z 272 Da fragment of T60 amodiaquine 
incubation in GSH fortified RLMs 
Constant neutral loss scans to detect the loss of a neutral 129 Da pyroglutamic acid 
fragment characteristic of glutathione-conjugated substrates did not yield conclusive 
data. The LC-MS peaks generated in this scan mode had very low intensity and could 
not be well distinguished from the baseline. By contrast, the PI scans in -ve ion mode 
were noted to have less noisy baseline signals owing to the fact that few compounds 
would be expected to form negatively charged ions under the analysis conditions 
used. Based on the observations from amodiaquine incubations, LC-MS detection for 
the subsequent test compounds for reactive metabolite trapping using GSH was 
conducted using +ve and/or –ve mode EMS scans followed by –ve mode PI scans for 
the m/z 272 fragment or +ve mode CNL scans of m/z 129. 
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Eleven compounds were incubated in human liver microsomes (mixed gender, 
pooled from 50 individuals) to determine their bioactivation to reactive metabolites 
and subsequent trapping with glutathione. The general incubation and LC-MS 
detection strategy employed with amodiaquine was used to analyze the incubation 
samples. A summary of the main diagnostic peaks detected for each sample with 
their corresponding m/z values and the conclusion drawn from LC-MS data is 
outlined in Table 3.2. 
 





Detection mode:   
Main Peaks (m/z) 
Comment 
Gedunin 482.23 ESI+: 483.2 No GSH-adduct observed 
Metergoline 403.23 ESI+: 404.2; 420.2; 418.2; 390.2 No GSH-adduct observed 
DC3 352.22 ESI+: 353.3 No GSH-adduct observed 
DC14 316.20 ESI+: 317.1 No GSH-adduct observed 
Justicidin A 394.11 ESI+: 394.8 No GSH-adduct observed 
Jamaicin 378.11 ESI+: 379.6  No GSH-adduct observed 
SQTL 244.11 ESI+: 245.2 (See below) 
CLPG 334.12 ESI+: 335.8 No GSH-adduct observed 
Formononetin 268.07 ESI-: 266.8 No GSH-adduct observed 
Fusidic acid 516.35 ESI-: 515.3; 513.1 No GSH-adduct observed 
Cuc-B 558.32 ESI+: 499.4; 866.3 (See below) 
Muzigadial 248.14 - (See below) 
Muzi-04 305.17 - (See below) 
 
Although the tested compounds all possessed structural alerts that were anticipated 
to undergo bioactivation to reactive species, none appeared to form intermediates 
that could be detected as GSH conjugates using the LC-MS detection modes 
established using amodiaquine which was used as the positive control in all assays. 
The results from incubations of SQTL and CUC-B were particularly interesting, 
however. Analysis of SQTL samples at the beginning of the incubation (Figure 3.23) 
clearly indicated the presence of the unmetabolized parent before addition of 
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NADPH to initiate the metabolic reaction as a peak eluting at Rt 6.88 min (ESI + MH+ 
m/z 245.2). 
Figure 3.23: XIC of SQTL peak only observed in incubation preparations devoid of GSH but absent in 
all incubations in which GSH was present 
 
The SQTL peak was, however, completely absent in all subsequent incubations to 
which GSH was present regardless of whether microsomes, NADPH or even 
acetonitrile had been added to quench the incubation beforehand. This 
phenomenon pointed towards the likelihood that SQTL was reactive enough even in 
its unmetabolized form to react with the trapping agent (GSH). The possibility that 
the SQTL peak disappeared owing to the compound being an unstable lactone that 
rapidly undergoes hydrolysis in aqueous medium was ruled out by the fact that scans 
to detect the hypothesized hydrolysis product were unsuccessful. Furthermore, 
when SQTL was incubated on its own in aqueous buffer devoid of microsomal 
proteins, NADPH or GSH for 90 minutes at 37 °C, the compound was easily 
detectable at virtually the same intensity as fresh solutions. However, although all 
the evidence pointed to a metabolism-independent reaction taking place between 
SQTL and GSH, the resultant product could not be detected on LC-MS.  
In the case of CUC-B, all incubation preparations in which GSH was present appeared 
to form adducts corresponding to a direct reaction between the substrate and GSH. 
The reaction appeared to be independent of enzymatic involvement and took place 
even in the absence of microsomal proteins. Unlike the case with SQTL, the 
suspected GSH adduct peaks were easily detected on LC-MS EMS scans and 
fragmentation data from EPI scans confirmed the presence of fragments commonly 
associated with glutathione adducts.   
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Reactive metabolite trapping incubations of MZG and its derivative Muzi-04 were 
not carried out owing to difficulties in optimising LC-MS detection parameters to 
attain the sensitivity required to detect trapped intermediates. Despite these 
compounds being readily separated and observed using HPLC-DAD detection, the 
mass spectral signal remained very weak, despite attempts to optimise compound 
ionisation by systematically altering ion source conditions (temperature, declustering 
potential, polarity etc.) and ionisation mode i.e. both ESI and APCI attempted.  
 
3.6.3 Trapping Reactive Metabolites Using Methoxylamine 
Furan and mono-substituted furan ring-containing xenobiotics are known to 
undergo bioactivation catalyzed by CYP450 enzymes resulting in opening up of the 
aromatic ring to form highly reactive aldehyde intermediates. Proposed 
mechanisms for this bioactivation hypothesize that ring opening is preceded by the 
formation of an epoxide intermediate. The final products of the bioactivation are 
dependent upon the substitutions on the parent furan ring. Substitutions at position 
2 of the ring may result in formation of a -keto-α-β unsaturated aldehyde whereas 
unsubstituted and 3-subsituted furans may form the corresponding highly reactive 
enedial metabolite (Figure 3.24). 
 
Figure 3.24: Proposed bioactivation of furan containing compounds to aldehyde intermediates 
Aldehydes, like iminium ions, are ‘hard’ electrophiles that cannot be reliably trapped 
using glutathione. GSH, as a soft nucleophile may, however, be capable of trapping 
the α-β unsaturated groups by conjugating via substitution at the unsaturated β-
carbon of the aldehyde or enedial. More reliable trapping agents for aldehyde 
reactive intermediates are available in the form of methoxylamine, as illustrated in 
Figure 3.25, and semicarbazide.74 
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Figure 3.25: Trapping furan-derived aldehyde reactive intermediates using methoxylamine 
Prazosin was used as the positive control to demonstrate bioactivation and 
detectable trapping of aldehyde intermediate thus formed using methoxylamine. 
The reported bioactivation of the furan ring in prazosin and its subsequent trapping 
is illustrated in Figure 3.26.  
Figure 3.26: Bioactivation of furan ring in prazosin and trapping of aldehyde intermediate using 
methoxylamine 
On LC-MS analysis of the incubation samples, successful trapping of the reactive 
aldehyde intermediates would be suspected from the presence of peaks 
corresponding to test substrates with a net mass gain of +45 or +74 on the EMS 
scans. These shifts in mass values were due to the initial oxidation of the furan ring 
to first form the short-lived epoxide and subsequently the ring opened aldehyde 
susceptible to methoxylamine addition that formed the O-methyl oxime species 
detected. 
The test incubations of prazosin containing pooled, mixed gender human or male rat 
liver microsomes, cofactor and trapping agent (methoxylamine) indicated the 
presence of a peak with the +45 mass gain not present in any of the control 
incubations in which one of these components was absent. Additionally, +ve mode 
EMS XICs revealed the presence of known metabolites of prazosin as reported in 
literature in the test incubation as well as in control incubation in which only 
trapping agent was absent (Figure 3.27 and 3.28).75 
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Figure 3.27: Prazosin and some of its known metabolites detected from trapping incubations 
 
 
Figure 3.28: XIC of +ve ion mode EMS of T60 incubation of prazosin in methoxylamine fortified RLM. 
The peak labeled ‘unknown component’ was unrelated to prazosin and present in all the incubation 
preparations 
 
Only the three compounds previously incubated with GSH containing furan rings in 
their structures (i.e. GEDN, DC3 and DC14) were further tested for reactive aldehyde 
metabolic intermediate trapping using methoxylamine. Evidence of successful 
trapping of the aldehyde from furan ring bioactivation was provided by +ve mode 
EMS scans which showed peaks having the expected mass shifts of +45 or +74. 
Fragmentation of such components, if present, on subsequent EPI scans to lose 32 
Da from the loss of neutral methanol molecule from the O-methyl oxime portion of 
the trapped adduct was considered further proof of successful trapping. 
Chromatograms of T60 test incubations of GEDN indicated two peaks (Rt 7.36 min 
and 8.46 min) with a mass gain of +45 and one with a shift of +74 (Rt 9.00 min)from 
the parent (Rt 8.57 min) but absent in the control incubations. Of the two m/z +45 
peaks, only the later eluting component at 8.46 min was intense enough to allow for 
controlled fragmentation and indicated the loss of a 32 Da fragment, strongly 
suggesting that it might represent a methoxylamine trapped aldehyde (Figure 3.29 
and Figure 3.30). 
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The peak suspected to represent a di-methoxylamine substituted adduct could not 
be confirmed to be such due to its low intensity and the fact that it appeared to co-
elute with a much more intense component (m/z 577) present as an artefact in all 
the incubated samples.  
 




Figure 3.30: Enhanced mass spectrum of peak in T60 GEDN incubation eluting at 8.46 min showing 
loss of 32 Da fragment from suspected methoxylamine trapped metabolite (MH
+
 m/z 528.0) 
Compound DC14 did not appear to form any reactive intermediates trapped using 
methoxylamine since no conjugate peaks on the EMS scans showed a m/z net gain of 
+45 or +74. 
Compound DC3 on the other hand appeared to be metabolized to a reactive 
intermediate trapped by methoxylamine and exhibited a very distinct m/z +45 
adduct peak at Rt 5.34 min from the T60 incubation sample (Figure 3.31). Proof that 
this peak represented a distinct compound was the fact that apart from forming the 
H+ adduct, it also formed both the Na+ (m/z 420.2) and K+ (m/z 436.2) adducts and 
was well resolved from the parent peak which eluted at Rt 6.74 min.  
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Figure 3.31: XIC of T60 DC3 incubation in methoxylamine fortified microsomes indicating presence of 
suspected trapped metabolite at Rt 5.34 min 
However, on enhanced product ion scans of the fragmented suspected adduct, no 
loss of the diagnostic 32 Da neutral fragment was observed, raising some doubt as to 
whether the component peak (m/z 398.3) actually represented a methoxylamine 
trapped aldehyde metabolite (Figure 3.32). 
 
Figure 3.32: EPI of suspected methoxylamine trapped metabolite (peak Rt 5.34 min, m/z 398.2) from 
T60 microsomal incubation of DC3  
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A set of natural products and selected semi-synthetic compounds were evaluated for 
clinical drug-drug interaction risk and in vitro metabolic bioactivation using both 
CYP450 inhibition assays and reactive metabolite trapping experiments. Of the 4 
main drug metabolizing enzymes tested, CYP3A4 was found to be the most 
susceptible to inhibition by a majority of the compounds. Time-dependent inhibition 
assays on the most potent inhibitor compounds of this isoform, however, suggested 
that none appeared to be a mechanism-based enzyme inhibitor. 
Data from the reactive metabolite trapping experiments revealed that two of the 
eleven compounds tested (i.e. DC3 and to a lesser extent GEDN) seemed to form 
detectable trapped metabolic intermediates using methoxylamine. On the other 
hand, no detectable enzymatically-mediated trapped intermediates from any of the 
compounds were observed when either reduced glutathione or potassium cyanide 
was employed as the trapping agent. CUC-B was observed to form detectable GSH 
adducts even in the absence of microsomal protein or co-factors, suggesting direct 
reactivity of this compound with GSH. It was postulated that the adduct might arise 
from a direct Michael-addition reaction involving the thiol group of GSH and the α,β-
unsaturated ketone on the side chain of CUC-B in a reaction that did not require 
enzymatic catalysis. 
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INVESTIGATING THE CROSS-REACTIVITY OF CHEMICAL INHIBITORS 
USED IN HEPATIC MICROSOMAL CYP450 ENZYME PHENOTYPING 
 
4.1 Summary 
In this Chapter, an overview of the different approaches employed by the 
pharmaceutical industry in enzyme phenotyping is presented as a primer to highlight 
certain drawbacks intended to be addressed by the work presented here. Detailed in 
vitro assays carried out to determine the extent to which chemical inhibitors 
routinely used in hepatic microsomal CYP450 phenotyping assays in early drug 
discovery exhibit cross-inhibition are described. Quantitative analysis of the data 
obtained from these assays and their application in improving calculations for 
determining the contribution of different CYP450 enzymes in drug metabolism is 
presented. 
The work described in this Chapter was carried out in the Drug Metabolism and 
Pharmacokinetics (DMPK) Department at the Novartis Institute of Biomedical 
Research (NIBR) in Basel, Switzerland. 
 
4.2 General Introduction 
In early DMPK studies, identification of the enzymes principally responsible for the 
biotransformation of lead compounds is crucial in understanding the metabolic fate 
and anticipating potential liabilities in the disposition of such potential drugs in vivo. 
The principle phase I oxidative enzymes involved in biotransformation of xenobiotics 
include the various CYP450 isoforms and the flavin-containing monoxygenases 
(FMOs) previously described in Chapter 1. The CYP450 enzymes are responsible for 
the biotransformation of more than 75% of drugs used clinically. Thus, investigating 
which of these enzymes are involved in biotransformation of potential new drugs, as 
would be expected, is often carried out early in the development process. ‘CYP450 
Reaction Phenotyping’ refers to the process of identifying the specific CYP450 
enzyme isoforms responsible for metabolism of xenobiotics and quantifying their 
individual contribution to overall metabolism. 
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CYP450 reaction phenotyping is important for several reasons: 
1. It allows for early detection of potential metabolic liabilities, including: 
 Identifying whether a compound is predominantly a metabolic substrate of 
major CYP450 isoforms such as CYP2C9, CYP2C19 or CYP2D6, which are 
known to exhibit phenotypic polymorphism in different human populations.1 
Such a scenario may necessitate consideration of different dosing strategies 
of such a compound in different patient populations. 
 Prediction of the major site (organ or tissue) of metabolism e.g. hepatic/ 
extra-hepatic. This is possible if the main metabolizing enzyme(s) are 
predominantly localized in specific tissues or organs and may aid in 
anticipating potential targets for toxicity related to compound metabolism, 
for example, via reactive metabolite formation. 
 Identification of whether a compound is metabolized by multiple isoforms 
and hence subject to metabolic switching in the event of inhibition of any of 
its metabolic pathways. Drugs significantly metabolized by more than one 
isoform might be more prone to drug-drug interactions when co-
administered with other xenobiotics. Additionally, depending on the 
individual isoform affinities for the substrate, this may also contribute to low 
metabolic stability for such compounds. 
2. By establishing the contribution of individual CYP450 enzymes to metabolism of 
a compound, one can more readily estimate the potential or risk and magnitude 
of undesirable drug-drug interactions in patients under concomitant medication 
with several drugs that are metabolised by the same enzymes. 
 
4.3 In vitro CYP450 Phenotyping Techniques 
There are several common in vitro techniques used in conducting early CYP450 
phenotyping studies: (1) phenotyping using pooled hepatic  microsomes and specific 
chemical inhibitors or monoclonal antibodies; (2) CYP450 isoform mapping using 
purified recombinant human CYP450 enzymes (rhCYP450);2 (3) a third, less common 
in vitro technique, involves correlation analysis based on statistical comparison of 
the rate of metabolism of test compounds to that of marker substrates in unpooled 
microsomes obtained from individual donors.3 
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4.3.1 Chemical Inhibition CYP450 Phenotyping 
This phenotyping method involves incubating the test compound in microsomal 
proteins to which inhibitors of specific CYP450 isoforms are also included. As a 
reference, incubations with no inhibitor serve as controls for standardizing 
metabolism. The incubation(s) in which compound metabolism is found to be 
significantly reduced by the presence of the included  inhibitor point to the fact that 
the CYP450 isoform(s) responsible for compound metabolism is/are the same one(s) 
inhibited by the chemical inhibitor (Figure 4.1). Thus, for example, if the compound’s 
metabolism is impaired in the presence of ketoconazole, it can be concluded that 
CYP3A4/5 is responsible for metabolism since ketoconazole is a known inhibitor of 
the CYP3A enzymes. The percentage decline in metabolism in the presence of 
inhibitor is considered to represent the fraction of the drug metabolised by the 
isoform in question (i.e. fm,CYP). A variation of this in vitro technique involves the 
use of monoclonal antibodies in place of chemical inhibitors to effectively inhibit the 
activity of specific CYP450 isoforms.4 Although this modified technique might give 
more accurate results, it is more expensive particularly for use in routine early 
phenotyping assays and therefore often only reserved for advanced phenotyping 




Figure 4.1: Schematic illustration of CYP450 phenotyping using chemical inhibitors or monoclonal 
antibodies. Decrease in metabolism with increasing inhibitor concentration reveals the relative 
contribution of the inhibited enzyme isoforms to compound metabolism. 
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4.3.2 CYP450 Isoform Mapping  
This technique involves incubating the test compound individually in a panel of 
specific purified recombinant human CYP450 isoforms and monitoring metabolic 
turn-over in each case (Figure 4.2). From the incubations, it is possible to directly 
determine which enzyme is involved in the metabolism of the substrate by 
calculating the percentage of drug remaining at the end of the assay or alternatively, 
quantifying the metabolites formed - if known or possible.5 
 
 
Figure 4.2: Schematic representation of CYP450 phenotyping data using recombinant enzymes. Only 
isoforms that show metabolism greater than control (i.e. red line in chart) are considered significant. 
 
In these assays, a control incubation of the test compound in the system used to 
express the recombinant enzyme isoforms (e.g. yeast cells or E. coli) must be 
included to determine and eliminate any inherent contribution of the expression 
system to metabolism of the test compound in phenotyping calculations.6 
CYP450 isoform mapping has the advantage of being simpler to perform and 
interpret data, since the incubation matrix is ‘cleaner’ and often has fewer 
confounding elements, such as reduced non-specific protein binding. It also allows 
for the contribution of CYP450 isoforms such as 1A1, 1B1, 2A3, 2B1, 2D4 and 4F that 
may not be present in hepatic microsomal fractions to be investigated unlike the 
case when using only liver microsomes or microsomes from other organs by 
including such in the panel of CYP450s to screen compounds with.7  
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4.3.3 Phenoyping Using CYP450 Correlation Analysis 
Correlation of CYP450 phenotyping involves the use of statistical analysis to establish 
a correlation between the metabolic rates of the test compound and marker 
substrates of specific CYP450 isoforms. The procedure entails incubating the test 
drug individually in microsomes obtained from a small number of human donors 
(typically ±10 donors) and comparing its metabolic rate to that of the probe 
substrates in incubations from the same set of donor microsomes to establish 
correlation.3 This method is prone to numerous sources of error and dependent on 
the precise control of numerous experimental procedures that render it unsuitable 
for routine use. Correlation analysis is therefore considered to be less accurate for 
CYP450 phenotyping but can serve as a useful tool in confirming the results obtained 
using recombinant CYP450s or chemical inhibitors.8 
 
4.4 Drawbacks of Current CYP450 Phenotyping Methods 
Although the phenotyping methods described above are used routinely in industry, 
there is often poor correlation between the data collected from them even when 
screening the same compound. In most cases, identification of the main 
metabolizing CYP450 isoforms can be unequivocally established, however, their 
individual relative contributions to overall metabolism (i.e. fm,CYP) as determined by 
each method may differ significantly.  
Accurate CYP450 isoform mapping using recombinant enzymes is often undermined 
by the fact that the enzymes used are often expressed using heterologous systems 
(e.g. yeasts, bacullo-virus infected insect cells, E. coli etc.) much different from the in 
vivo human/mammalian environment. Consequently, their metabolic activity may 
not necessarily be identical or representative of the endogenous CYP450s.9 Also, 
because test compounds are incubated in individual recombinant enzymes, possible 
enzyme competition that might be prominent in vivo may not be observed, leading 
to overestimation of the contribution of some isoforms to metabolism while at the 
same time underestimating that of others. In practice, data from CYP450 isoform 
mapping must be normalized, for example by applying intersystem extrapolation 
factors (ISEF), to take into consideration the different activities and abundances of 
specific isoforms, which might further complicate the use of this technique.10,11 
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On the other hand, the major shortcoming of CYP450 phenotyping using chemical 
inhibitors lies in the relative selectivity of the compounds used routinely as reference 
inhibitors for the different CYP450 isoforms.12 In practice, though the compounds 
used are known to inhibit specific enzymes to a high degree, they often demonstrate 
some extent of cross-inhibition resulting in the under- or over-estimation of the 
metabolic contribution of the affected CYP450 isoforms. Due to this cross-reactivity, 
it is not uncommon for phenotyping data to yield cumulative fm,CYP values that 
total more than 100%. Substituting chemical inhibitors with the use of monoclonal 
antibodies that inactivate specific CYP450 isoforms more selectively can significantly 
improve accuracy, but requires greater capital outlay and experimental complexity. 
Alternatively, more selective synthetic inhibitors than those used routinely could be 
identified and used. This is, however, complicated by the fact that existing 
compounds possess the advantage of having been studied over a long period of time 
under different settings and by different researchers, and are mostly compounds 
used clinically as drugs or which were originally designed as such. Furthermore, most 
chemical inhibitors in current use can also be used for in vivo studies. Replacement 
inhibitors would need to have undergone a similarly thorough evaluation prior to 
their acceptance and adoption for routine application. 
A more feasible approach in improving CYP450 phenotyping using chemical 
inhibitors lies in experimentally quantifying the actual extent to which such 
compounds exhibit cross-reactivity under particular assay settings. From such data, 
correction factors can be applied in CYP450 phenotyping calculations to more 
accurately determine fm,CYP. 
Such an approach has previously been reported by Lu et al. in a study aimed at 
predicting in vivo drug-drug interaction based on in vitro CYP450-phenotyping data 
determined using chemical inhibitors corrected for cross-reactivity.13 
The aim of the present study was to use a similar approach but in which the 
experimental protocols differed from the work carried out by Lu et al. by evaluating 
the cross-inhibitory effects of a greater number of chemical inhibitors in addition to 
maintaining in vitro incubation conditions aimed at ensuring linearity of enzymatic 
activity throughout. 
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4.5 Probe CYP450 Isoform Reactions and Chemical Inhibitors 
Ideally, CYP450 reaction phenotyping using human liver microsomes and chemical 
inhibitors would make use of probe substrates that are entirely metabolised by a 
single enzyme isoform through a metabolic transformation that can be monitored 
using an inhibitor that is wholly specific to that isoform. In practice, this scenario 
does not exist, instead, the compounds used routinely in CYP450 phenotyping are a 
collection of marker substrates predominantly metabolised by a particular isoform 
and chemical inhibitors considered to be highly, but not entirely, selective to the 
main drug metabolising CYP450 isoforms.14 
 
The eight (8) chemical inhibitors investigated for cross-reactivity in this work, specific 
CYP450 isoforms and the probe metabolic reactions monitored to quantify the 
extent of cross-inhibition are summarized in Table 4.1 and Figure 4.3 - Figure 4.5. 
 
Table 4.1: CYP450 isoforms, their respective probe substrates, metabolites and chemical inhibitors 
evaluated in this work 
CYP450 isoform Inhibitor Probe substrate Marker metabolite 




CYP2C19 (S)-mephenytoin 4’-Hydroxymephenytoin 
CYP2C9 Sulfaphenazole Diclofenac 4’-Hydroxydiclofenac 
CYP2C8 Montelukast Paclitaxel 6α-Hydroxypaclitaxel 
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Figure 4.3: Probe metabolic reactions of CYP1A2, CYP2B6, CYP2C9 and CYP2C19 and their respective 




Figure 4.4: Probe metabolic reactions of CYP2D6 and CYP2E1 and their respective chemical inhibitors 
evaluated for cross-reactivity 
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Figure 4.5: Probe metabolic reactions of CYP2C8 and CYP3A and their respective chemical inhibitors 
evaluated for cross-reactivity 
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4.6.1 Incubation Conditions 
Cross-inhibition of individual CYP450 isoforms was determined by incubating the 
specific marker substrates of each of the test CYP450s present in pooled, mixed 
gender human liver microsomes to which each of the inhibitors under test was 
included. The in vitro CYP450 inhibition assays were carried out in duplicate at 37 °C 
under optimized conditions with regard to microsomal protein concentration, probe 
substrate concentration and incubation duration (Table 4.2). Each inhibitor was 
incubated at a concentration 5 times greater than its reported Ki value to ensure 
maximal enzyme inhibition while probe substrate concentrations were at least 5 
times less than their reported Km values. Under these conditions, enzyme activity 
was expected to be linear and more reproducible. Incubation durations for each 
metabolic probe reaction were selected to ensure that not more than 20% of the 
probe substrate was metabolised, as recommended by Bjornsson et al.9 The 
optimized incubation conditions used are summarized below and the experimental 
procedure described in greater detail in the Experimental Chapter. 
 
Table 4.2: Summary of experimental probe substrate, chemical inhibitor and protein concentrations 
and experimental incubation duration 






CYP1A2 Phenacetin (2.0) Furafylline (10.0) 0.20 20 
CYP2B6 Bupropion (25.0) Ticlopidine (10.0) 0.10 20 
CYP2C8 Paclitaxel (1.0) Montelukast (2.0) 0.20 20 
CYP2C9 Diclofenac (1.0) Sulfaphenazole (5.0) 0.05 8 
CYP2C19 S-mephenytoin (10.0) Ticlopidine (10.0) 0.50 20 
CYP2D6 Bufuralol (5.0) Quinidine (2.0) 0.20 20 
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4.6.2 Quantification of Probe Metabolites and Inhibition of Isoform Activity 
Metabolic activity of each enzyme was determined in both the presence and 
absence of inhibitor by quantifying the amount of probe substrate metabolite 
formed at the end of each incubation. Detection and quantification of metabolites 
was achieved by LC-MS analysis of the incubation samples each spiked with a known 
concentration of the respective 13C or 2H radiolabelled metabolite to serve as 
internal standard. Metabolite concentrations were calculated from chromatographic 
peak areas determined using the MRM transitions of characteristic fragments of the 
analyte metabolite being intrapolated from peak area ratio vs concentration 
calibration curves from standard solutions of each metabolite. Each 7-concentration 
point metabolite standard solution (Table 4.3) was prepared fresh on the day of 
analysis and analysed before testing incubation samples on the same LC-MS system 
to ensure linearity of response. For all the probe metabolite calibration curves, a 
minimum concentration vs analyte/IS peak area ratio Pearson correlation coefficient 
(r2) of 0.98 was deemed acceptable for quantitative analysis (Figure 4.6).  
Metabolite concentration in the incubations devoid of any inhibitor was calculated 
to represent 100% enzyme activity. From this, the inhibition of enzyme activity was 
computed as a percentage fraction based on the metabolite content in the probe 
substrate incubations performed in the presence of the various inhibitors. 
 
Table 4.3: Metabolites analysed and concentrations used for plotting calibration curves 
CYP450 Isoform Analyte Metabolite 
Calibration Standard  
Concentrations  [ng/mL] 
CYP1A2 Acetaminophen 0; 1.0; 2.5; 5.0; 10; 25; 50; 100 
CYP2B6 Hydroxybupropion 0; 10; 25; 50; 100; 250; 500; 1000 
CYP2C19 4’-Hydroxymephenytoin 0; 0.4; 1.0; 2.0; 4.0; 10; 20; 40 
CYP2C9 4’-Hydroxydiclofenac 0; 10; 25; 50; 100; 250; 500; 1000 
CYP2C8 6α-Hydroxypaclitaxel 0; 1.0; 2.5; 5.0; 10; 25; 50; 100 
CYP2D6 1’-Hydroxybufuralol 0; 2.0; 5.0; 10; 25; 50; 100; 200 
CYP2E1 6-Hydroxychlorzoxazone 0; 0.4; 1.0; 2.0; 4.0; 10; 20; 40 
CYP3A 1’-Hydroxymidazolam 0; 4.0; 10; 20; 40; 100; 200; 400 
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Figure 4.6: Representative concentration vs response calibration curves of metabolite standard 
solutions used for LC-MS quantification of enzyme inhibition 
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4.7 Cross-Inhibition Assays Results 
4.7.1 Furafylline 
 
Figure 4.7: Inhibitory effect of furafylline on 8 different CYP450 isoform metabolic probe reactions 
 
The inhibitory effects of furafylline, a methylxanthine developed in the 1980s as a 
long acting antiasthmatic agent, on CYP1A2-mediated phenacetin O-deethylation is 
the basis for routine use of this compound in phenotyping metabolism mediated by 
CYP1A2.15 The inhibition is non-competitive and thought to involve mechanism-
based inactivation of the enzyme.16 
Cross-reactivity results from the assay using furafylline indicated that this compound 
exhibited very high inhibition of CYP1A2 as expected (89.0%), but also some 
significant suppression of CYP2E1-mediated chlorzoxazone 6-hydroxylation 
(approximately 50%). The remaining CYP450 isoforms appeared to be much less 
affected by furafylline with all six exhibiting less than 20% inhibition and in the case 
of CYP3A (0.5% inhibition), being virtually unaffected even by the relatively high 
concentration of inhibitor used. 
The relatively high selectivity observed with furafylline is perhaps not unusual 
considering that even its inhibition of CYP1A2 activity has been shown to vary 
significantly between reactions metabolised by the human enzyme compared to the 
same isoform in rat liver microsomes.17 Cross-inhibition of CYP2E1 by furafylline has 
been reported previously, albeit to a lesser degree than observed here.18 
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Figure 4.8: Inhibitory effect of ticlopidine on 8 different CYP450 isoform metabolic probe reactions 
 
Ticlopidine is a thienopyridine anti-platelet aggregation drug that acts as an 
antagonist at adenosine diphosphate receptors and which is used clinically in the  
management of conditions such as thromboembolic strokes and to prevent 
thrombus formation secondary to cardiovascular surgical procedures.19 
Ticlopidine has been reported to be a suicide inhibitor of CYP2C19, acting as a 
substrate of the enzyme,which undergoes biotransformation into a metabolite that 
then subsequently causes mechanism-based inhibition.20 Ticlopidine and related 
thienopyridines such as clopidogrel have similarly been reported to inhibit the 
metabolism of fluorogenic probe subtrates by CYP2C19.21 Ticlopidine is also a potent 
inhibitor of CYP2B6-mediated bupropion hydroxylation in vivo.22 In addition to its 
potent inhibitory activity against these two isoforms, in vitro studies have also 
revealed low selectivity and potential inhibition of other CYP450s.23 However, 
Walsky and Obach reported that ticlopidine was found to be markedly more 
selective to CYP2B6 when pre-incubated with hepatic microsomes prior to addition 
of probe substrates for other CYP450 isoforms.24 
In our cross-inhibition assays, ticlopidine was unsurprisingly found to markedly 
inhibit the probe metabolic reactions of both CYP2B6 (97.2% inhibition) and CYP2C19 
(86.8%) as anticipated. Ticlopidine was also found to inhibit both CYP1A2 and 
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CYP2D6 very strongly, reducing enzyme activity by more than fifty percent (66.7% 
and 54.4% inhibition, respectively). CYP 2C8, 2C9 and 2E1-mediated probe reactions 
appeared to be inhibited to an almost similar extent by ticlopidine (approximately 
20%) with only the CYP3A-mediated biotransformation of midazolam appearing to 




Figure 4.9: Inhibitory effect of montelukast on 8 different CYP450 isoform metabolic probe reactions 
 
Results obtained from the cross-reactivity assay for montelukast were consistent 
with CYP450 inhibition data reported by Walsky et al in which the compound was 
found to be a potent reversible inhibitor of CYP2C8 and to a lesser extent, CYP2C9-
mediated diclofenac-4’-hydroxylase activity and CYP3A-mediated midazolam 1’-
hydroxylation.25 Whereas the work by Walsky noted only marginal cross-inhibition 
with the other CYP450 isoforms, the cross reactivity of montelukast in our assays 
was quite significant with CYP2C9 activity being reduced to almost half (i.e. 49.0% 
inhibition) and CYP3A by one-third (33.6% inhibition). 
 With the exception of CYP2B6 (17.4% inhibition), however, the remaining CYP450 
isoforms all exhibited low susceptibility to cross-inhibition by montelukast (less than 
10%). 
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Figure 4.10:  Inhibitory effect of quinidine on 8 different CYP450 isoform metabolic probe reactions 
 
Quinidine is an isomer of the anti-malaria drug quinine used clinically as an anti-
arrhythmic agent and is a well established inhibitor of CYP2D6 first reported to 
suppress the oxidative metabolism of another anti-arrhythmic agent, sparteine, in 
the 1980s by Otton et al.26 Inhibition of recombinant CYP2D6 expressed from yeasts 
by quinidine and its related cinchona alkaloid dihydroquinidine has similarly been 
reported.27 Based on these and other reports of its well studied metabolic enzyme 
inhibition profile, quinidine is commonly used in chemical inhibition CYP450 
phenotyping to identify candidate substrates of CYP2D6. 
Cross-reactivity results of the effect of quinidine on the metabolism of probe 
substrates of the other CYP450 enzymes revealed consistently low cross-inhibition, 
with values of less than 10% against CYP1A2, CYP2B6, CYP2C8, CYP2C9 and CYP3A. 
Even though the cross-inhibition of CYP2C19 by quinidine was higher than for these 
five isoforms, it was still not considered to be significant at only 16.2%. 
On the other hand, in addition to its expected effect on CYP2D6-mediated 
metabolism (89.3% inhibition), quinidine was observed to strongly inhibit CYP2E1-
mediated chlorzoxazone hydroxylation (30.4%). 
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Figure 4.11: Inhibitory effect of sulfaphenazole on 8 different CYP450 isoform metabolic probe 
reactions 
 
Sulfaphenazole is a long acting synthetic sulphonamide originally developed in the 
1950s for the treatment of bacterial infections then subsequently discovered to be a 
potent inhibitor of CYP450 enzyme and now routinely used as a competitive and 
selective in vitro inhibitor of CYP2C9.28,29 
Cross-reactivity assays using sulfaphenazole confirmed its potent inhibition of 
CYP2C9 activity (89.1% inhibition) as reported in the literature. Inhibition of other 
CYP450 isoforms was low and ranged over 1.5% - 12.5% for CYPs 1A2, 2B6, 2C8, 
2C19, 2D6 and 3A. The only exception to this trend was CYP2E1 in which case 
sulfaphenazole reduced activity by 26.8%, which was considered low but 
nevertheless significant. 
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Figure 4.12: Inhibitory effect of diethylthiocarbamate on 8 different CYP450 isoform metabolic probe 
reactions 
 
Diethyldithiocarbamate was evaluated as the routine inhibitor used to establish the 
metabolic contribution of CYP2E1 and found to be the least potent of the 
compounds tested and by far the least selective. 
Despite significant loss of CYP2E1 activity (31.8% inhibition) in the presence of DETC, 
this value was considerably lower than inhibitions achieved with the other inhibitors 
on their respective probe reactions, all of which were typically in excess of 85%. 
Furthermore, DETC actually appeared to inhibit the activity of other isoforms to a 
slightly greater degree than observed with CYP2E1 i.e. CYP1A2 (33.7% inhibition), 
CYP2B6 (39.8%) and CYP2D6 (36.7% inhibition). The activities of both CYP2C8 and 
CYP2C9 were also significantly reduced by approximately 20% in either case and only 
CYP2C19 and CYP3A showed less than 10% inhibition. 
These somewhat idiosyncratic results for DETC inhibition potency and cross-
reactivity have previously been reported using recombinant cDNA-expressed human 
CYP450 enzymes by Chang et al., but contrasted with previous work by Guengerich 
et al. on the selectivity of DETC for CYP2E1 in microsomal preparations.30,31 
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Figure 4.13: Inhibitory effect of ketoconazole on 8 different CYP450 isoform metabolic probe 
reactions 
 
Ketoconazole was found to exhibit significant cross-inhibition of CYP2B6, CYP2C8, 
CYP2C9 and CYP2E1 in addition to its established mixed competitive and non-
competitive inhibition of CYP3A-mediated 1’-hydroxylation of midazolam.32 
The activities of CYP1A2 and CYP2D6 were both only reduced by about 10% while 
CYP2C19 activity appeared to be entirely unaffected following co-incubation with 
ketoconazole. In the case of both CYP2B6 and CYP2C8, ketoconazole accounted for 
approximately 40% loss in enzymatic activity, while CYP2E1 was comparatively only 
slightly less affected (35.8% inhibition) with CYP2C9 activity being reduced by 26.5%. 
The cross-inhibition findings with ketoconazole were not unexpected, particularly 
based on the large volume of information published regarding this and other azole 
antifungal drugs’ clinically significant drug-drug interactions with numerous other 
medications.33 It was, however, observed that the absolute rank order of in vitro 
cross-inhibition by ketoconazole (CYP3A > CYP2C8 ≈ CYP2B6 > CYP2E1> CYP2C9) 
differed from that reported by Obach et al (CYP3A > CYP2C9 ≈ CYP2C19 > CYP1A2 ≈ 
CYP2D6) particularly regarding CYP2C19, which was observed to be virtually 
uninhibited in our study.34 A possible explanation for these differences might be 
variance in experimental conditions e.g. protein and substrate concentrations.  
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Figure 4.14: Inhibitory effect of azamulin on 8 different CYP450 isoform metabolic probe reactions 
 
Azamulin is a synthetic azole derivative of pleuromutilin, a diterpene antibiotic first 
isolated from the fungus Pleurotusmutilis. This compound has been reported to be 
as potent an inhibitor of CYP3A isoforms as ketoconazole but more selective than 
the latter.35 
Results from the cross inhibition assay for azamulin were consistent with data from 
the literature. Compared to ketoconazole, azamulin was observed to be a 
significantly more selective inhibitor, reducing CYP3A-mediated metabolism of 
midazolam by more than 95% while generally reducing the activity of the other 
CYP450 isoforms by less than 20%. A notable exception to the selectivity of azamulin 
appeared to be its relatively high cross-inhibition of CYP2C9 (22.9% inhibition) which 
was comparable to the effect observed with ketoconazole (26.5% inhibition). 
Considering that the concentration of all inhibitors used in these experiments were 
deliberately higher than their Ki values, the data obtained for azamulin cross-
inhibition might suggest that in routine CYP450phenotyping assays, this compound 
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4.8 Compensating for Inhibitor Cross-Reactivity in CYP450 Phenotyping Data 
The same mathematical approach reported by Lu et al. was applied to recalculate 
CYP450 phenotyping data by taking into consideration the determined maximal 
cross-inhibition effects of the 8 inhibitors tested.13 
For this, a summary cross-inhibition matrix was generated as shown in Table 4.4: 
 
Table 4.4: Percentage inhibition of CYP450 isoform activity by different chemical inhibitors 
Inhibitor CYP1A2 CYP2B6 CYP2C8 CYP2C9 CYP2C19 CYP2D6 CYP2E1 CYP3A 
Furafylline 89.01 7.24 13.50 6.33 7.57 16.28 50.01 0.55 
Montelukast 0.82 17.37 87.17 49.00 3.93 9.09 -1.02 33.56 
Sulfaphenazole 12.57 1.56 10.04 89.14 11.10 7.42 26.84 8.02 
Ticlopidine 66.76 97.23 21.37 18.89 86.81 54.38 21.04 -13.55 
Quinidine -0.21 11.06 8.99 4.14 16.19 89.33 30.43 2.87 
DETC 33.74 39.81 21.33 20.02 8.05 36.72 31.81 6.62 
Ketoconazole 11.68 41.90 44.74 26.52 -2.64 9.16 35.79 94.64 
Azamulin -2.64 18.40 8.17 22.90 11.52 10.06 17.77 96.52 
 
Using the percentage cross-inhibition values determined for each inhibitor against 
the different CYP450 isoforms, it was possible to formulate simultaneous equations 
from data previously generated using conventional CYP450 phenotyping to more 
accurately represent the corrected contribution of different isoforms to compound 
metabolism.  
An example of how this was done is illustrated. In this case, assuming a test 
compound determined to undergo metabolism mediated by more than one CYP450 
isoform as follows:  
 
Table 4.5: Hypothetical CYP450 phenotyping data uncorrected for inhibitor cross-reactivity 
 CYP1A2 CYP2C8 CYP2C9 CYP2C19 CYP3A 
Test Drug 17% 13% 19% 35% 70% 
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Incorporation of the corresponding cross-inhibition matrix data for the CYP450 
isoforms involved in metabolism of such a compound would generate the following 
table and could be expressed in the form of an algebraic simultaneous equation as 
shown: 
 
 % inhibition by chemical Inhibitor   
 
CYP1A2 CYP2C8 CYP2C9 CYP2C19 CYP3A fm,CYP(%) 
Furafylline 1A2 89.01 13.50 6.33 7.57 0.55 17 
Montelukast 2C8 0.82 87.17 49.00 3.93 33.56 13 
Sulfaphenazole 2C9 12.57 10.04 89.14 11.10 8.02 19 
Ticlopidine 2C19 66.76 21.37 18.89 86.81 -13.55 35 
Ketoconazole 3A 11.68 44.74 26.52 -2.64 94.64 70 
 
 
Solving the equation can then be achieved using matrix calculations involving initial 








0.8901q + 0.135r + 0.0633x + 0.0757y + 0.0055z  = 0.17 
0.0082q + 0.8717r + 0.490x + 0.0393y + 0.3356z  = 0.13 
0.1257q + 0.1004r + 0.8914x + 0.111y + 0.0802z  = 0.19 
0.6676q + 0.2137r + 0.1889x + 0.8681y + 0.000z  = 0.35 
0.1168q + 0.4474r + 0.2652x + 0.000y + 0.9464z  = 0.70 
 
Where the variables q, r, x, y, andz represent the corrected fm,CYP values for CYP1A2, 
CYP2C8, CYP2C9, CYP2C19 and CYP3A, respectively. 
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The final step in calculating corrected fm,CYP is the determination of metabolic 
contributions of each isoform as a percentage of the sum total of all the solved 
variables whose magnitude is greater than 0. Solved variables with negative values 
are interpreted to represent nil metabolic contribution by the isoform in question.  
Thus, based on the foregoing correction calculation strategy, the corrected fm,CYP 
data for the hypothetical test drug is as tabulated below.  
 
Table 4.6: Unmodified and corrected fm,CYP data based on consideration of inhibitor cross-reactivity 
for a hypothetical drug 
 CYP1A2 CYP2C8 CYP2C9 CYP2C19 CYP3A 
Unmodified fm,CYP 17% 13% 19% 35% 70% 
Corrected fm,CYP 13.7% 0 7.6% 21.1% 57.6% 
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4.9 Application of Cross-Reactivity Correction to fm,CYP450 Data 
The calculation strategy described in the previous section was applied in determining 
the corrected fm,CYP values for 15 Novartis in-house development compounds 
(Table 4.7) previously phenotyped using both conventional recombinant CYP450 
mapping (Table 4.8) and pooled human liver microsomes with chemical inhibition. 
The uncorrected and modified chemical inhibition CYP450 phenotyping data for 
these compounds are summarised in Table 4.9. 
 
Table 4.7: Physico-chemical properties of 15 test compounds phenotyped for CYP450 metabolism 
using conventional in vitro methods 
Compound 
Physico-Chemical Properties 
Mwt pKa Log P Solubility (g/L) 
1 288.73 4.1/5.7 4.8 0.23 
2 560.49 8.2/3.5 4.6 0.02 
3 446.90 5.4/7.2 4.85 0.08 
4 403.40 7.1/10.6 1.6  0.02 
5 306.40 3.89/10.9 2.81 300 
6 453.54 5.2 3.2 0.2 
7 659.28 3.6/5.7 4.8 0.02 
8 453.60 3.4 2.0  0.20 
9 441.48 3.6/9.5 3.1 0.02 
10 443.54 8.52/5.63 1.954 9.5 
11 377.42 6.7/10.6 1.6 0.2 
12 444.00 7.9 5.1 0.34  
13 313.40 - 4.7 0.025 
14 516.60 3.3/8.6 1.8 0.868 
15 609.80 9.18 1.01 3.50 
 
CHAPTER 4: CHEMICAL INHIBITOR CROSS-REACTIVITY IN CYP450 PHENOTYPING 
 
NICHOLAS M. NJUGUNA - Ph.D. THESIS 2014 
 
160 
CYP450 isoform mapping using recombinant enzymes was performed by incubating 
the radiolabelled test compounds in a panel of 14 different recombinant human 
CYP450 (rhCYP450) enzymes expressed using bacullo-virus infected insect cells and 
quantifying the formation of metabolites by means of post-column radio-
fluorescence detection following HPLC analysis of incubation samples. 
 
Table 4.8: CYP450 phenotyping data from incubation of 15 Novartis test compounds in recombinant 
CYP450 isoforms 
Compound 
fm, CYP (%) using rhCYP450 
CYP1A2 CYP2C8 CYP2C9 CYP2C19 CYP2D6 CYP3A 
1 35.0 0 0 2.5 0.8 59.9 
2 0 0 0 0 0.1 97.5 
3 0.3 0 0 0 0.1 99.6 
4 0 0 0 8.2 0 91.6 
5 4.2 1.4 18.5 0.6 0.1 75.1 
6 0.7 0 0 0 0.4 98.9 
7 0 0 0 0 0 94.8 
8 0.6 0 1.7 0.1 0.1 96.3 
9 0.7 2.6 0 0.2 0 92.0 
10 1.1 0 0 0 0 98.2 
11 0 ND 0 ND 0 100 
12 0 0.4 0 0.6 88.6 10.5 
13 0 0.8 6.6 3.7 0.2 88.8 
14 0 1.7 79.2 0.1 0 18.5 
15 0 ND 0 0 0.4 99.6 
Note: “ND” indicates that values were Not Determined for this compound. Only the contribution of 
the main hepatic CYP450 enzymes is tabulated. 
 
All 15 test compounds were found to be substrates of rhCYP3A, which was the main 
enzyme contributing to the majority of metabolism in all except two cases (i.e. 
fm,CYP3A > 50%). 
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In the majority of cases, the contribution to metabolism of the other rhCYP450 
isoforms appeared to be marginal at typically less than 5%. Notable exceptions to 
this trend were compounds 1 (where fm,CYP1A2 = 35.0%), 4, (fm,CYP2C19 = 8.2%), 5 
(fm,CYP2C9 = 18.5%), 12 (fm,CYP2D6 = 88.6%), 13 (fm,CYP2C8 = 6.6%) and 
compound 14 (fm,CYP2C9 = 79.2%).  
Compound 5 was the only substrate found to be metabolised by 6 different isoforms 
to a quantifiable extent with most of the remaining compounds being metabolised 
by 2 to 4 different isoforms, with the exception of compound 7 which was only 
metabolised by CYP3A4 (fm,CYP = 94.8%) and extra-hepatic rhCYP450 enzymes (data 
not presented). 
 
Table 4.9: Original unmodified and modified chemical inhibition CYP450 phenotyping data for 15 
Novartis test compounds after correction for inhibitor cross-reactivity 
Cmpd CYP1A2 CYP2C8 CYP2C9 CYP2C19 CYP2D6 CYP3A* 
 Orig Mod Orig Mod Orig Mod Orig Mod Orig Mod Orig Mod 
1 56 71 - - - - 23 0 - - 33 29 
2 16 16 4 0 3 0 - - 12 11 77 74 
3 - - - - - - - - - - 80 100 
4 - - - - - - 23 25 - - 75 75 
5 17 14 13 0 19 8 35 21 - - 70 58 
6 - - - - - - - - 19 15 100 85 
7 - - - - 10 3 - - - - 88 97 
8 - - - - - - - - - - 99 100 
9 - - - - - - - - - - 100 100 
10 - - - - - - - - - - 75 100 
11 13 8 - - 21 9 - - 13 8 100 75 
12 - - 65 45 - - 37 0 49 36 55 19 
13 - - 19 0 32 26 - - 12 10 71 64 
14 - - 31 0 77 73 29 13 10 5 25 9 
15 - - - - - - - - 1 0 96 100 
*Note: fm,CYP3A values reported here were determined using ketoconazole as chemical inhibitor. 
‘Orig’ refers to the original fm,CYP450 values uncorrected for inhibitor cross-reactivity, ‘Mod’ denotes 
recalculated fm,CYP450 after correction for inhibitor cross-reactivity 
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Since metabolism by CYP3A4 appeared to be universally significant for all 15 test 
compounds regardless of which phenotyping method was used, data from this 
enzyme was plotted to determine if correlation between CYP450 isoform mapping 
and chemical inhibition phenotyping was improved by correcting for inhibitor cross-
reactivity (Figure 4.15 and Figure 4.16). 
 
 
Figure 4.15: Correlation plot of fm,CYP3A using rhCYP3A4 and HLM + ketoconazole 
before correction for inhibitor cross-reactivity 
 
 
Figure 4.16: Correlation plot of fm,CYP3A data using rhCYP3A4 and HLM + ketoconazole 
after correction for inhibitor cross-reactivity  
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The square of the Pearson correlation coefficient (r2) for fm,CYP3A data for the 15 
test compounds from phenotyping using recombinant enzymes and chemical 
inhibition with ketoconazole increased from 0.6305 to 0.8164 when corrected for 
cross-inhibition.  
Similar evaluation of the impact of cross-reactivity correction was carried out using 
data obtained when azamulin had been used as the chemical inhibitor to determine 
CYP3A contribution to metabolism. In this case, however, only 11 of the 15 test 
compounds had been phenotyped using azamulin, and therefore fewer data points 




Figure 4.17: Correlation plot of fm,CYP3A using rCYP3A4 and HLM + azamulin 
before correction for inhibitor cross-reactivity 
 
 
As observed with ketoconazole, cross-reactivity correction with azamulin also 
appeared to improve the correlation between rCYP3A and chemical inhibition 
phenotyping data, with the r2 value increasing from 0.2522 (Figure 4.17) to 0.6100 
(Figure 4.18). 
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Figure 4.18: Correlation plot of fm,CYP3A using rCYP3A4 and HLM + azamulin after 
correction for inhibitor cross-reactivity 
 
A final comparison of the effect of correcting for inhibitor cross-reactivity involved 
testing the improvement in correlation of fm,CYP3A among the same compounds 
from the test set for which  metabolic contribution of CYP3A isoform had been 
determined using both azamulin and ketoconazole. 
 
Table 4.10: Uncorrected fm,CYP3A values for compounds phenotyped using both azamulin and 
ketoconazole 
 fm,CYP3A (%) 
Compound 1 2 3 4 6 7 8 9 10 12 13 
Azamulin 24 72 92 78 99 94 100 100 54 62 80 
Ketoconazole 33 77 80 75 100 88 99 100 75 55 71 
 r2 = 0.8509 
 
Table 4.11: Modified fm,CYP3A values for compounds phenotyped using both azamulin and 
ketoconazole after correction for inhibitor cross-reactivity 
 Corrected fm,CYP3A (%) 
Compound  1 2 3 4 6 7 8 9 10 12 13 
Azamulin 29.9 70.1 100 74.5 84.8 97.5 100 100 100 36.2 63.9 
Ketoconazole 29.3 73.6 100 74.9 85.3 96.9 100 100 100 18.8 64.4 
 r2 = 0.9734 
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The uncorrected CYP3A chemical inhibition values for the 11 compounds showed a 
high degree of similarity even before the effects of inhibitor cross-reactivity were 
taken into consideration. The two sets of data had a correlation coefficient (r2) of 
0.8509 for fm,CYP3A. However, correction of the phenotyping data by factoring in 
the cross-reactivity of both ketoconazole and azamulin markedly improved the 
observed correlation to r2 = 0.9734, further illustrating the ability of the correction 
calculation to minimise differences in the data sets. 
 
4.10 Conclusions 
The cross-reactivity experiments described in this Chapter confirmed the CYP450 
enzyme inhibition activity of 7 out of the 8 chemical inhibitors routinely used in early 
CYP450 metabolic phenotyping assays. All the compounds tested exhibited varying 
degrees of cross-reactivity against different CYP450-mediated metabolic reactions 
both in terms of the absolute number of reactions (or enzyme isoforms) affected, as 
well as the degree to which the individual reactions were inhibited. Of the inhibitors 
evaluated, only diethyldithiocarbamate exhibited poor potency against its 
established marker metabolic probe reaction (i.e. conversion of chlorzoxazone to 6-
hydroxychlorzoxazone by CYP2E1). In contrast, all the other chemical inhibitors were 
found to reduce the activity of each of their respective marker probe reactions by 
between 86.8% and 97.2%. In addition, DETC was found to exhibit the highest 
relative cross-inhibitory effect against the other CYP450 isoforms, inhibiting CYP1A2, 
CYP2B6 and CYP2D6 to an even greater extent than its observed inhibition of 
CYP2E1. 
On the basis of absolute magnitude and number of cross-inhibitions observed from 
the compounds evaluated, furafylline and sulfaphenazole appeared to be the most 
selective of the CYP450 inhibitors tested. These two compounds were each found to 
inhibit only one other metabolic reaction by more than 20%, in addition to inhibiting 
their respective probe substrate biotransformations by almost 90%.  
Evaluation of the effect of correcting for inhibitor cross-reactivity on CYP450 reaction 
phenotyping data determined using different in vitro techniques for a set of 15 in-
house compounds was performed by calculating statistical correlation. Correction of 
ketoconazole and azamulin cross-reactivity appeared to improve the correlation in 
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CYP3A phenotyping data separately determined using rCYP450 and HLM with 
chemical inhibition. Additionally, it was also observed to improve the correlation of 
fm,CYP3A data from microsomal chemical inhibition individually determined using 
both ketoconazole or azamulin on the same set of test compounds. 
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SUMMARY, CONCLUSIONS AND RECOMMENDATIONS FOR FUTURE 
WORK 
 
5.1 Summary and Conclusions 
A virtual database of 335 natural products was designed, created and populated with 
compounds isolated from medicinal plants reported in the African Herbal 
Pharmacopoeia. The chemical space of these compounds was mapped by conducting 
statistical comparisons of their ‘drug-like properties’ against those for 608 
conventional drug molecules selected from the British Pharmacopoeia 2009. The in 
silico profiling data showed that the chemical space of the natural products was 
significantly different from that of synthetic drugs with regard to molecular weight, 
rotatable bonds and H-bond donor distributions but not with regard to lipophilicity 
(cLogP) and H-bond acceptor distributions. In general, the natural products were 
found to exhibit a higher degree of deviation from Lipinski’s ‘Rule-of-Five’. The 
observations based on evaluation of the five physico-chemical parameters outlined 
above were further confirmed using 2D principle component analysis based on a 
more comprehensive in silico prediction of 196 properties for the natural product 
and BP 2009 compound datasets. Again using in silico tools to identify structural 
alerts in the different compound sets, the natural products appeared to possess a 
slightly greater number of structural alerts per molecule (1.18) compared to 
conventional drugs (0.99), suggesting that they might be more prone to metabolic 
bioactivation.    
 
Although used principally as a repository for compound data from which predictions 
of physico-chemical properties of natural products could be made, the natural 
products database created in this work could conceivably serve as a starting point for 
a larger collection of compounds not restricted to monographs from the African 
Herbal Pharmacopoeia. Even in its current unexpanded format, the compounds in 
the database could be used in ligand or structure based virtual screening to identify 
potential hits against known pharmacological targets or in docking studies to predict 
binding to known protein drug targets. 
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Evaluation of a set of 15 natural product and natural product-derived compounds for 
in vitro bioactivation was conducted using a combination of CYP450 enzyme 
inactivation assays and reactive metabolite trapping experiments.  Of the major 
recombinant CYP450 drug metabolizing isoforms screened, CYP3A4 was found to be 
most prone to inhibition by the test compounds. This phenomenon was presumably 
due to the fact that the active site of CYP3A4 is relatively large and capable of 
accommodating a broad array of substrates possessing diverse chemical scaffolds. 
Among the compounds screened for enzyme inhibition, GEDN, JSTN and JMCN were 
the most potent CYP3A4 inhibitors with GEDN in particular also exhibiting potent 
inhibition of CYP2C19. Although the observed inhibition of CYP3A4 by these three 
compounds was significant, assays to determine their normalized inhibition ratios 
indicated that the reactions were not time-dependent and therefore unlikely to be 
due to reactive metabolite-mediated mechanism-based inactivation of the enzyme. 
These results were further validated by the fact that inclusion of reduced glutathione 
in the assays had no effect on the observed inhibition of the enzyme. Inhibition of 
the other main drug metabolising CYP450 isoforms (i.e. CYP1A2, CYP2C9 and 
CYP2C19) was markedly less pronounced, with only one or two compounds reducing 
enzyme activity by up to 50% at the lower assay concentration in all cases. 
 
Direct assessment of the formation of reactive metabolic intermediates was 
conducted by incubating 11 of the 15 compounds in microsomal preparations 
fortified with nucleophilic trapping agents. None of the test compounds appeared to 
form detectable reactive intermediates that could be trapped using reduced 
glutathione. On the other hand, however, using methoxylamine as the trapping 
agent, metabolic incubations of the monosubstituted furan ring-containing 
compounds GEDN and the tetraol DC3 were found to contain components strongly 
suspected to be trapped reactive metabolites. Despite its structural similarity to DC3, 
the α,β-unsaturated cyclic ketone DC14 did not appear to form reactive metabolic 
intermediates that could be trapped using methoxylamine. This observation was 
presumably partly due to the relatively lower ability of DC14 to interact with enzyme 
amino acid residues via H-bonding owing to the presence of far fewer hydroxyl 
groups compared to DC3. Only MTGN possessed the structural features necessary to 
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undergo bioactivation resulting in formation of reactive iminium ion intermediates. 
However, absence of detectable trapped adducts in microsomal incubations fortified 
with potassium cyanide as the trapping agent suggested that metabolic bioactivation 
did not occur as hypothesized. 
 
The results from in vitro bioactivation assays highlighted the difficulties of predicting 
reactive metabolite formation based only on the presence of structural alerts in 
substrate molecules. Despite most of the tested natural products bearing a potential 
structural liability that could easily be detected using in silico tools, their metabolic 
liability did not appear to be supported by in vitro results. In the case of DC14 and 
DC3, for example, in vitro data seemed to contradict the expected greater risk of 
bioactivation of DC14 compared to DC3 based on the greater number of structural 
alerts present in the former (2) compared to the latter (1). The set of compounds 
studied cannot realistically be used as a basis for drawing concrete conclusions 
regarding the bioactivation potential of natural products in general, owing to its 
limited size. However, the results obtained seemed to suggest that bioactivation 
risks might be more accurately predicted on the basis of the type of structural alert 
present on the test compound, rather than by the absolute number of structural 
alerts present in the molecule. 
 
Evaluation of the cross-reactivity of eight chemical inhibitors commonly used in early 
CYP450 phenotyping assays confirmed the relatively high selectively of furafylline 
and sulfaphenazole while conversely revealing the low selectivity of ticlopidine and 
diethyldithiocarbamate. These experiments also highlighted the particularly low 
potency of diethylthiocarbamate as the routinely preferred inhibitor for determining 
the contribution of hepatic CYP2E1 to xenobiotic metabolism. The data obtained 
provided good evidence for the need to identify and characterise a superior 
replacement inhibitor for CYP2E1 phenotyping.  
 
The compound data set used to test the hypothesis that factoring-in inhibitor cross-
reactivity in CYP450 phenotyping calculations could improve the correlation of data 
obtained from different phenotyping approaches was of limited size. Consequently, 
it was not possible to confirm the statistical significance of improvement in CYP450 
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phenotyping correlation for the majority of enzyme isoforms for which inhibitor 
cross-reactivity was evaluated. In the case of CYP3A4, however, there were 
sufficient, albeit few, data points to provide evidence that consideration of inhibitor 
cross-reactivity in fm,CYP3A4 calculations appeared to improve phenotyping data 
correlation. Improvement in the fm,CYP3A4 correlation was observed both between 
data values obtained using different CYP3A4 chemical inhibitors (i.e. ketoconazole 
and azamulin) as well as with hepatic microsome+chemical inhibitor-derived vs 
recombinant enzyme-determined fm,CYP3A4 values. 
 
From a pharmaceutical industry DMPK perspective, the potential to improve CYP450 
phenotyping by correcting for inhibitor cross-reactvity offers an opportunity of 
eliminating the need to use multiple phenotyping techniques as is currently the 
norm, when conducting routine CYP450 phenotyping. Having a single method that is 
validated to provide consistent and accurately correlated data would contribute in 
reducing the time, cost and effort needed to assess the metabolic fate of drug leads 
during development, without compromising on the accuracy of such assessments. 
  
5.2 Recommendations for Future Work 
Of the natural products tested for in vitro bioactivation in this work, GEDN, CLPG, 
JMCN and JSTN were each found to be potent inhibitors of at least one of the four 
CYP450 enzyme isoforms involved in drug metabolism (i.e. CYP1A2, CYP2C9, 
CYP2C19 and CYP3A4).  However, since the enzyme inhibition assays carried out in 
this project were designed more for use in rapid screening of large compound sets to 
identify potential bioactivation liabilities early, comprehensive determination of IC50 
values was not carried out. It might therefore be of interest to conduct further work 
aimed at determining the enzyme inhibition characteristics of these specific 
compounds and establish the mode in which they curtail enzyme activity i.e. is the 
observed inhibition competitive, non-competitive, uncompetitive or mixed.  
 
Although the natural products mentioned above inhibited recombinant CYP450 
enzymes in vitro, the actual impact of such inhibition in vivo is difficult to predict 
although the potential for herb-drug interaction exists. Based on data obtained in 
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this work, it might be of particular interest to investigate, possibly in vivo using an 
animal model, the effect of co-administration of these natural products on the 
metabolism of conventional drug substrates of the CYP450 isoforms affected. For 
example, the impact of inhibition of CYP2C19 and CYP3A4 by Gedunin in neem 
extract in patients also taking the prophylactic antimalarial proguanil, which is 
metabolised to its active form (cycloguanil) by these two isoforms, could be 
investigated both in vitro and in vivo using the pure natural product or the 
standardized crude plant extract. 
The trapped reactive intermediates detected from microsomal incubations of GEDN 
and DC3 with methoxylamine were hypothesized to arise from bioactivation of the 
furan-ring, based on cited literature. Isolation and actual characterisation of these 
intermediates using spectroscopic techniques such as NMR would provide structural 
data that could more conclusively shed light on the actual bioactivation mechanism 
involved and the molecular structure of the stable adducts detected using LC-MS. A 
key consideration in successful implementation of such an enterprise would involve 
the need to generate a sufficient amount of the trapped intermediate possibly 
through scaling-up of metabolic incubations to facilitate comprehensive structure 
elucidation.  
Another area for possible exploration regarding the formation of reactive 
metabolites from GEDN and DC3 would be to determine the specific enzyme 
isoform(s) responsible for the suspected bioactivation by conducting enzyme 
phenotyping assays modified to incorporate trapping agents. 
The consideration of chemical inhibitor cross-reactivity in routine in vitro CYP450 
phenotyping calculations offers potential advantages from a drug development 
perspective, not least in significantly reducing the time and effort taken to obtain 
reliable CYP450 phenotyping data without compromising accuracy and integrity. 
Inasmuch as the data obtained from this work showed promise in application, 
several other considerations require further investigation to develop this approach 
as a robust cross-reactivity compensation strategy. For example, testing the cross-
reactivity of the different inhibitors evaluated under a range of concentrations below 
and above their established Ki or IC50 values would provide greater insights on the 
actual impact of cross-reactivity. Furthermore, in order to gauge the true impact of 
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compensating for chemical inhibitor cross-reactivity, the correlation of a much larger 
data set of compounds tested using traditional CYP450 isoform mapping and 
uncorrected chemical inhibition would need to be compiled and computed, and 
preferably include as many of the main drug metabolising CYP450 isoforms as 
possible. 
The cross-reactivity data obtained in this work highlighted the particularly poor 
potency and low selectivity of diethyldithiocarbamate (DETC), underscoring the need 
to identify and characterise the enzyme inhibition properties of superior substitute 
CYP2E1 chemical inhibitors. Based on the potent enzyme inhibition activities 
observed from the few natural products studied in this work, it might be worthwhile 
to consider the search for new selective inhibitors for CYP2E1 phenotyping from 
among existing natural product libraries. 
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6.1 Reagents and Solvents 
All commercially available analytical grade chemicals and reagents were purchased 
from Sigma Aldrich. HPLC grade acetonitrile and methanol for mobile phase 
preparation were purchased from Romil Ltd (Cambridge, UK). Analytical grade 
solvents including hexane, dichloromethane, ethyl acetate, acetone, methanol and 
ethanol were purchased from Kimix Chemicals (Eppindust, South Africa) and used 
without further purification. Ultra purified water for in vitro assays was prepared in-
house using a Millipore Direct-Q®3 laboratory water purification system (Millipore 
SAS, Molsheim, France). 
 
6.2 Turbidimetric  Solubility1 
Solubility of the test compounds was determined using the turbidimetric method 
described by Bevan and Lloyd.2 Stock solutions of test and control compounds were 
prepared by dissolving an accurately weighed amount of each in HPLC-grade DMSO 
to a 10 mM concentration. 
Predilutions of the stock solutions, also in DMSO, were then prepared in clear, v-
shaped bottom 96-well polystyrene microtitre plates. For this, each stock solution 
was diluted serially in triplicate by first pipetting 20 µL DMSO into wells in row G on 
the plate and 50 µL DMSO to the wells in the rows above (i.e. rows F, E, D…A). 80 µL 
of the 10 mM stock solutions was then pipetted to the wells in row G and mixed to 
give a starting concentration of 8 mM (100 µL). Serial dilution of this solution was 
achieved by subsequently transferring 50 µL to the well in the row above (row F), 
mixing and then repeating this sequence to wells from row F through to B.  The final 
predilution concentrations obtained ranged from 0.25 mM (Row B) to 8.0 mM (Row 
G). All wells in row A contained only DMSO with no compound present, while those 
in row H contained the undiluted 10 mM stock solution as illustrated in Figure 6.1. 
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  Compound 1 (in triplicate) Compound 2 (in triplicate)… 
Conc (mM)  1 2 3 4 5 6 
0.00 A       
0.25 B       
0.50 C       
1.00 D       
2.00 E       
4.00 F       
8.00 G       
10.00 (stock) H       
Figure 6.1: Turbidimetric solubility assay pre-dilution plate set-up 
 
From each pre-dilution solution, secondary dilutions of the compounds in both 
DMSO and 0.01M pH 7.4 phosphate buffered saline (PBS) were prepared in a second 
96-well plate, also in triplicate (Figure 6.2). Wells in columns 1-6 contained the test 
compound dissolved in DMSO while those in columns 7-12 contained samples in PBS 
at similar nominal concentrations. Because compounds were tested in triplicate, only 




 DMSO 0.01M pH 7.4 PBS 
 Cmpd 1 (tripl) Cmpd 2 (tripl) Cmpd 1 (tripl) Cmpd 2 (tripl) 
 1 2 3 4 5 6 7 8 9 10 11 12 
0.0 A             
5.0 B             
10.0 C             
20.0 D             
40.0 E             
80.0 F             
160.0 G             
200.0 H             
Figure 6.2: Turbidimetric assay plate lay-out 
 
The final volume of solution in the assay plate wells was 200 µL, prepared by 
pipetting 4 µL each of solution from the pre-dilution plate to the corresponding well 
into both DMSO and PBS (both 196 µL). The final concentration of DMSO in the PBS 
aqueous buffer preparations was therefore 2% v/v. 
The concentrations of test compounds in DMSO served as controls for determining 
potential false turbidimetric absorbance readings arising from the compounds in 
solution absorbing radiation at the analysis wavelength. 
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The plates were covered and left to equilibrate for 2 hours at ambient room 
temperature. After incubation, UV-VIS absorbance readings were measured at 620 
nm using a SpectraMax 340PC384 microplate reader (Molecular Devices, Sunnydale, 
CA). Absorbance from the wells containing only DMSO and 2%v/v DMSO in PBS (i.e. 
denoted as 0.0 µM in plate layout, Row A) served as controls and blanks. 
Obstruction of incident radiation by particles of the test compounds that crashed out 
of solution at concentrations in excess of the limit of solubility, denoted by an 
increase in the apparent absorbance measurement, was used as the basis for 
determining approximate compound solubility. 
 
6.3 Physical and Spectroscopic Characterization 
Melting points were determined using a Reichert-Jung Thermovar hot stage 
microscope based on methods described by Kofler and Kofler and are reported as 
uncorrected values.3,4  
1H NMR spectral data was recorded on a Varian Mercury (300MHz), a Varian Unity 
(400 MHz) or a Bruker Ultrashield-Plus (400MHz) spectrometer. All NMR samples 
were dissolved in deuterated chloroform (CDCl3) or dimethylsulfoxide (DMSO-d6) 
with tetramethylsilane (TMS) as the internal standard. 13C NMR spectral data were 
recorded on the same instruments at 100 MHz. Chemical shifts (δ) are reported in 
parts per million (ppm) downfield with reference to the internal standard 
tetramethylsilane. Coupling constants (J) are reported in Hertz (Hz). The 
abbreviations used in assigning 1H-NMR signals are: d (doublet), dd (doublet of 
doublets), m (multiplet), q (quartet), s (singlet) or t (triplet). 
 
6.4 Chromatography 
6.4.1 Thin Layer Chromatography 
Preliminary natural product compound purity checks and reactions in the synthesis 
of CYP450 fluorogenic probe substrates were monitored on aluminium-backed, pre-
coated thin layer chromatography (TLC) plates and visualized under ultraviolet light 
at 254 nm and 366 nm or by spraying with a detection solution of ninhydrin in 
acidified ethanol. 
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6.4.2 Flash Column Chromatography 
Compound purification was achieved using automated low pressure flash column 
chromatography carried out on a Biotage Isolera™ Prime Flash Chromatography 
system (Biotage AB, Uppsala, Sweden). Compound separation and elution were 
monitored on the in-built dual wavelength UV-detector. Separations were achieved 
on 25 g Biotage SNAP™ cartridges packed with 40-65 µm diameter KP-Sil normal 
silica particles as stationary phase. 
 
6.4.3 High Performance Liquid Chromatography 
6.4.3.1 System 1 and 2 - Compound purity and molecular mass checks  
The purities of the synthesized fluorogenic enzyme probe substrates and natural 
products were determined using HPLC using either of two chromatographic systems. 
System 1 was a SpectraSERIES™ HPLC (Thermo Separations Products, Waltham, MA, 
USA) consisting of a SpectraSERIES P200 mobile phase pump, SpectraSERIES  AS100 
autosampler equipped with a 20 µL sample loop and a SpectraSERIES UV100  
variable wavelength UV detector. Data processing on this system was performed on 
an interfaced desktop PC running Delta Chromatography Data System software 
(version 5.0, DataworX Pty Ltd., Kangaroo Point, QLD, Australia).  
HPLC system 2 was used for both purity checks and low resolution molecular weight 
determination. This system consisted of an Agilent 1260 Infinity HPLC with a UV-
photodiode array detector and coupled to an Agilent 6120 single quadrupole multi-
mode ion source mass spectrometer (Agilent Technologies, Santa Clara, CA, USA). 
Instrument control and data processing on this system was achieved using an 
interfaced desktop PC running OpenLAB CDS Chemstation Edition software (rev. 
c.01.05, Agilent Technologies, Santa Clara, CA, USA). 
For purity determinations using either system, approximately 1 mg of test compound 
was dissolved in 1 mL HPLC grade MeOH, filtered through a 0.22 µm nylon syringe 
filter and the filtrate injected into the chromatograph for analysis. 
 
CHAPTER 6: EXPERIMENTAL 
 
NICHOLAS M. NJUGUNA - Ph.D. THESIS 2014 
 
182 
6.4.3.2 System 3 - Reactive metabolite trapping experiments 
Analysis of reactive metabolite trapping experiment incubation samples was carried 
out using LC-MS on system 3 comprising an Agilent 1200 Rapid Resolution HPLC 
system coupled to an API4000Q Triple Quadrupole Linear Ion Trap mass 
spectrometer equipped with a Turbo V® ion source with an installed electrospray 
interface (AB Sciex, Framingham, MA, USA). The liquid chromatography system 
consisted of a binary gradient pump equipped with a solvent degassing unit, an 
autosampler with a chilled sample tray maintained at 4 °C, column compartment set 
at 40 °C and UV-photodiode array detector programmed to scan UV wavelengths 
over 200 - 400 nm. Instrument control and data processing was achieved by means 
of an integrated desktop PC running AB Sciex Analyst™ software (ver. 1.5).  
 
6.4.3.3 System 4 - CYP450 phenotyping chemical inhibitor cross-reactivity assays 
Analysis of microsomal incubations to determine the cross-reactivity of CYP450 
isoform inhibitors was carried out using LC-MS on system 4 composed of a Rheos 
2200  microflow HPLC pump equipped with an online degasser (Flux Instruments 
GmbH & Co KG, Basel, Switzerland) coupled to a Triple Quadrupole Micromass 
Quattro Ultima Pt Mass Spectrometer detector (Waters Corporation, Milford, MA, 
USA).  Automated sample injection was achieved by means of a PAL HTS 
autosampler equipped with a 20 µL sample loop (CTC Analytics AG, Swingen, 
Switzerland) with the sample tray maintained at 14 °C. The chromatographic column 
was maintained at 30 °C by means of a heated column oven (Jones Chromatography 
Ltd, Mid Glamorgan, UK)  Programmable control of the gradient pump was achieved 
using an interfaced desktop computer running Janeiro II software while control of 
the mass spectrometer was performed using MassLynx software (v.4.1, Waters 
Corp., Milford, MA, USA). 
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6.4.3.4 HPLC and LC-MS chromatographic conditions 
The chromatographic conditions and methods used to analyse samples using each of 
the systems described above are summarized in Table 6.1. 
 
Table 6.1: Chromatographic method conditions used for HPLC and LC-MS sample analysis 
System 
Mobile Phase Gradient 
Flow Rate/  
Column A B 
Time 
(min) 






















Luna® C18, 150 x 4.6 mm, 
3 μm, 100Å (Phenomenex, 





























Zorbax Poroshell 120,  C18 2.7 
µm 3.0 x 50 mm  
(Agilent Technologies, Santa 


























Kinetex C18, 150 x 2.1 mm, 2.6 
µm, 100 Å  










Isocratic 70 30 
100 µL/min 
Micro-bore Luna® Phenyl-
Hexyl, 50 x 1.0 mm, 3 µm 
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6.5 rCYP450 Enzyme Inhibition Assays 
6.5.1 Direct CYP450 Inhibition Assay 
CYP450 fluorometric inhibition assays were conducted according to the method of 
Crespi et al.5 Purified isoforms of recombinant human CYP450 and CYP450-reductase 
enzymes co-expressed in Escherichia coli were obtained from Cypex Limited 
(Dundee, Scotland, UK). rCYP450 enzyme control inhibitors were purchased from 
Sigma Aldrich (St. Louis, MO, USA). The fluorogenic probe substrates for monitoring 
enzyme activity were synthesized as described in this work (see Appendices). 
Fluorescence readings were measured either using a Wallac Victor2™ Multilabel 
Counter (Wallac AB, Oxfordhuset, Upplands Vasby, Sweden) or Varian Cary Eclipse 
Fluorescence Spectrophotometer (Varian GmbH, Darmstadt, Germany). Both 
instruments were equipped with 96-well microplate readers. Test preparations were 
incubated at 37 °C in a Memmert INE 500 natural convection incubator (Memmert 
GmbH + Co. KG, Schwabach, Germany).  
Incubations were carried out in black 96-well Corning® Costar® microtiter plates for 
readings measured using the Wallac Victor2™ and in white 96-well Nunc™ microtitre 
plates for readings using the Cary Eclipse spectrophotometer.  
The following general procedure was used: An incubation master mix was prepared 
by adding ice cold ultra-pure water, 0.2 M pH 7.4 mixed potassium phosphate buffer, 
flourogenic probe substrate and recombinant enzyme, in that order, to a clean 
mixing tube. Solutions of 1000 µM and 150 µM test compound were prepared by 
appropriately diluting in 25% acetonitrile from 10 mM stock solutions of each 
prepared in DMSO. 
Aliquots of 186 µL master mix were transferred to all the 96 wells and 4 µL of either 
diluted positive control inhibitor, test compound solution or 25% acetonitrile solvent 
as blank was added to appropriate wells of the incubation plate. The plate was pre-
incubated for 15 min at 37 °C before adding 10 µL of 20 mM NADPH to all wells 
except the blanks to initiate the metabolic reaction. The final incubation 
concentrations for the test compounds were 3 µM and 20 µM in a volume of 200 µL 
per well. The plate was incubated for a further 30 min at 37 °C after addition of 
NADPH and the reaction terminated by adding 75 μL of an ice-cold solution of 1 mM 
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Tris in 80% AcN. 10 µL of 20 mM NADPH was added to the wells containing blanks. 
Fluorescence was measured at appropriate excitation and emission wavelengths.  
The final incubation plate setup was as illustrated in Figure 6.3. Detailed incubation 
preparations for the various CYP450 enzymes tested for inhibition are summarized in 
Table 6.2 - Table 6.5. 
 
Figure 6.3: Incubation plate set-up for rCYP450 inhibition assays 
 1 2 3 4 5 6 






3 µM  
Cmpd 1 
20 µM  






3 µM  
Cmpd 1 
20 µM  
C       
D       
E       
F       
G       
H       
Note: Incubations were performed in duplicate on adjacent rows. Only solvent containing no 
compound (25% AcN) was added to the master mix in wells marked blank and control. Different 
control inhibitors were used for different enzymes and incubated at a concentration greater than 
and lower than established IC50 value.  
 
Results of enzyme inhibition by the positive control were used as the basis for 
determining assay validity. The criteria used were as follows: at low positive control 
concentration, enzyme inhibition must not be > 25%, while at high concentration, 
inhibition was expected to be > 75%.  
 CYP3A4 inhibition assays in the presence of reduced glutathione were set-up exactly 
as described above with the only difference being that 5 µL of 40 mM GSH was 
substituted for the same volume of distilled water in each well.  
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Table 6.2: Summary incubation setup for CYP1A2 inhibition assay 

















Cmpd Hi NADPH 
Prepared as Master Mix 
α-naphthaflavone 
(in 25% AcN) Diluted in 25% AcN 
 Stock Concentration - 0.2 M 120 µM 13.3 pmol/µL 0.05 µM 0.5 µM 150 µM 1000 µM 20 mM 
Incubation Concentration - 0.1 M 3 µM 0.5 pmol/well 0.001 µM 0.01 µM 3 µM 20 µM 1 mM 
Blank Incubation 80.96 100.00 5.00 0.04 - - 4 (25% AcN) 10.00 
Control Incubation 80.96 100.00 5.00 0.04 - - 4 (25% AcN) 10.00 
Inhibitor Low 80.96 100.00 5.00 0.04 4.00 - - - 10.00 
Inhibitor High 80.96 100.00 5.00 0.04 - 4.00 - - 10.00 
Test Compound Low 80.96 100.00 5.00 0.04 - - 4.00 - 10.00 
Test Compound High 80.96 100.00 5.00 0.04 - - - 4.00 10.00 
Fluorimeter Settings Excitation/Emission λ (nm) 405/460 
 
Table 6.3: Summary incubation setup for rCYP2C9 inhibition assay 

















Cmpd Hi NADPH 
Prepared as Master Mix Sulphafenazole (25% AcN) Diluted in 25% AcN 
 Stock Concentration - 0.2 M 3.4 mM 2.1 pmol/µL 5 µM 50 µM 150 µM 1000 µM 20 mM 
Incubation Concentration - 0.1 M 0.085 mM 5 pmol/well 0.1 µM 1 µM 3 µM 20 µM 1 mM 
Blank Incubation 80.96 100.00 5.00 2.38 - - 4 (25% AcN) 10.00 
Control Incubation 80.96 100.00 5.00 2.38 - - 4 (25% AcN) 10.00 
Inhibitor Low 80.96 100.00 5.00 2.38 4.00 - - - 10.00 
Inhibitor High 80.96 100.00 5.00 2.38 - 4.00 - - 10.00 
Test Compound Low 80.96 100.00 5.00 2.38 - - 4.00 - 10.00 
Test Compound High 80.96 100.00 5.00 2.38 - - - 4.00 10.00 
Fluorimeter Settings Excitation/Emission λ (nm) 405/535 
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Table 6.4: Summary incubation setup for rCYP2C19 inhibition assay 

















Cmpd Hi NADPH 
Prepared as Master Mix Ticlopidine (in 25% AcN) Diluted in 25% AcN 
 Stock Concentration - 0.2 M 1400 µM 5.5 pmol/µL 50 µM 500 µM 150 µM 1000 µM 20 mM 
Incubation Concentration - 0.1 M 35 µM 2 pmol/well 1 µM 10 µM 3 µM 20 µM 1 mM 
Blank Incubation 80.96 100.00 5.00 0.36 - - 4 (25% AcN) 10.00 
Control Incubation 80.96 100.00 5.00 0.36 - - 4 (25% AcN) 10.00 
Inhibitor Low 80.96 100.00 5.00 0.36 4.00 - - - 10.00 
Inhibitor High 80.96 100.00 5.00 0.36 - 4.00 - - 10.00 
Test Compound Low 80.96 100.00 5.00 0.36 - - 4.00 - 10.00 
Test Compound High 80.96 100.00 5.00 0.36 - - - 4.00 10.00 
Fluorimeter Settings Excitation/Emission λ (nm) 405/535 
 
Table 6.5: Summary incubation setup for rCYP3A4 inhibition assay 

















Cmpd Hi NADPH 
Prepared as Master Mix Ketoconazole (in 25% AcN) Diluted in 25% AcN 
 Stock Concentration - 0.2 M 400 µM 3.9 pmol/ µL 0.5 µM 5.0 µM 150 µM 1000 µM 20 mM 
Incubation Concentration - 0.1 M 10 µM 2 pmol/well 0.01 µM 0.1 µM 3 µM 20 µM 1 mM 
Blank Incubation 80.96 100.00 5.00 0.51 - - 4 (25% AcN) 10.00 
Control Incubation 80.96 100.00 5.00 0.51 - - 4 (25% AcN) 10.00 
Inhibitor Low 80.96 100.00 5.00 0.51 4.00 - - - 10.00 
Inhibitor High 80.96 100.00 5.00 0.51 - 4.00 - - 10.00 
Test Compound Low 80.96 100.00 5.00 0.51 - - 4.00 - 10.00 
Test Compound High 80.96 100.00 5.00 0.51 - - - 4.00 10.00 
Fluorimeter Settings Excitation/Emission λ (nm) 405/535 
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6.5.2 Time-Dependent CYP3A4 Inhibition Assay 
The assay to determine time-dependent inhibition of rCYP3A4 involved two 
incubations as described here. 
6.5.2.1 Inactivation assay 
A volume of 85 µL master mix comprising 0.1 M mixed phosphate buffer and rCYP3A4 
was added to wells in a 96-well microtitre plate. A 5 µL solution of either test or 
control compound was added to wells in columns 1 - 4 and 7 - 8 of the plate in 
duplicate while plain solvent (25% AcN) was added to wells in columns 5, 6, 11 and 12. 
The plate was pre-incubated at 37 °C for 10 minutes before adding 10 µL of distilled 
water to all wells in columns 1 - 6 and 10 µL of 10 mM NADPH in wells in columns 7 - 
12.The plate was then further incubated for 15 min at 37 °C. Test and control 
compounds were incubated at final concentrations of 1 µM and 5 µM in wells 
containing 5 pmol of enzyme each (Figure 6.4). 
 
Figure 6.4: Inactivation assay plate lay-out for rCYP3A4 TDI assay 
 NO NADPH + NADPH 
 1 µM 5 µM - - 1 µM 5 µM - - 
 1 2 3 4 5 6 7 8 9 10 11 12 
A Cpd 1 Cpd 1 Cpd 1 Cpd 1 Cntrl Blank Cpd 1 Cpd 1 Cpd 1 Cpd 1 Cntrl Blank 
B Cpd 2 Cpd 2 Cpd 2 Cpd 2 Cntrl Blank Cpd 2 Cpd 2 Cpd 2 Cpd 2 Cntrl Blank 
C …etc …etc …etc …etc …etc …etc …etc …etc …etc …etc …etc …etc 
D             
 
6.5.2.2 Activity assay 
To a second 96-well microtitre plate, 170 µL of a master mix comprising 520 µM 
fluorogenic enzyme substrate BFC in 0.1 M mixed phosphate buffer pH 7.4 was added 
to all wells and warmed for 5 min at 37 °C. A 20 µL aliquot was transferred from each 
well in the inactivation assay plate, described in Section 6.5.2.1 above, to the 
corresponding well in the activity plate containing the fluorogenic substrate. A further 
10 µL aliquot of 20 mM NADPH solution was added to all wells except those marked as 
blanks and the plate incubated for 15 min at 37 °C. The incubation was terminated by 
adding 75 µL ice-cold stop solution to all wells and adding 10 µL NADPH to the wells 
containing blanks. Fluorescence measurements were taken at the specific wavelengths 
highlighted before and the results analysed as described previously to calculate the 
Normalized Inhibition Ratios.6 
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6.6 Reactive Metabolite Trapping Experiments 
Incubations to trap reactive metabolic intermediates were performed in 1.5 mL 
microcentrifuge Eppendorf® tubes using a generic procedure adopted from methods 
described previously in the literature.7–9 Human liver microsomes (20 mg protein/mL, 
mixed gender, pooled from 50 individuals) and rat liver microsomes (20 mg 
protein/mL, male, pooled from 400 individuals) were sourced from Xenotech LLC 
(Kansas, USA). Positive control substrates rimonabant hydrochloride and prazosin 
hydrochloride were obtained from Proactive Molecular Research (Alachua, FL) while 
amodiaquine hydrochloride dihydrate, potassium cyanide, reduced glutathione and 
methoxylamine hydrochloride were all purchased from Sigma-Aldrich Chemie GmBH 
(Schnelldorf, Germany). 
 
6.6.1 Microsomal Incubation Conditions 
Test compounds were dissolved in DMSO to prepare 10 mM stock solutions and 
incubated separately at a concentration of 10 µM in 0.1M mixed phosphate buffer pH 
7.4 containing 5 mM MgCl2, 1 mM nucleophilic trapping agent (KCN, GSH or 
methoxylamine) and 1 mg/mL human (or rat) liver microsomes. The metabolic 
incubations were initiated, following 5 min pre-incubation at 37 °C, by addition of 20 
mM NADPH to a final concentration of 1 mM. Total incubation volume per sample was 
200 µL. Incubations in which individual components were omitted from the 
preparation i.e. test compound, trapping agent, HLM or NADPH were included to serve 
as controls. The incubation tubes were maintained at 37 °C in a shaking water bath set 
at 50 rpm with the preparations exposed to atmospheric oxygen throughout. 
Metabolic reactions were terminated after 60 min by addition of 200 µL ice-cold 
acetonitrile to precipitate microsomal proteins. The incubation tubes were then placed 
on ice for 10 min and subsequently centrifuged at 14,000 rpm in a chilled centrifuge at 
4 °C for 15 min. The recovered supernatants was filtered through 0.22 um PTFE syringe 
filters and analysed on LC-MS.  
 
6.6.2 LC-MS Analysis of Trapped Reactive Metabolite Samples 
Filtered supernatant solutions of the incubation preparations were analysed using LC-
MS using the system and chromatographic conditions described in Section 6.4.3.4 
above. Detection of trapped reactive metabolites was carried out using different mass 
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spectral scanning modes including enhanced mass spectral (EMS) scans over a range of 
m/z values in either positive or negative ion mode, neutral loss and enhanced product 
ion scans for detection of glutathione adducts in particular. The ionisation source 
conditions were optimised by direct infusion of test compounds dissolved in 5 mM 
ammonium formate pH 3.0 in 50% AcN to a concentration of 0.5 µg/mL at a flow rate 
of 10 µL/min injected into the ion source using a HA11 syringe pump (Harvard 
Apparatus, Holliston, MA, USA). 
Optimised ion source conditions for the detection of test compounds are summarised 
in Table 6.6. 
 










Gedunin APCI + 500 - 111 
Metergoline ESI + 400 5500 111 
DC3 ESI + 400 5000 66 
DC14 ESI + 400 5000 86 
Justicidin A ESI + 550 5200 91 
Jamaicin ESI + 500 5000 116 
SQTL ESI + 500 5000 71 
CLPG ESI + 500 5000 91 
Formononetin ESI + 300 4000 66 
Fusidic acid ESI - 100 -3500 -105 
CUC-B ESI + 500 5000 51 
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6.7 CYP450 Phenotyping Chemical Inhibitor Cross-Reactivity Assays 
Microsomal incubations to determine the cross-reactivity of CYP450 phenotyping 
chemical inhibitors were performed in 1.5 mL polypropylene Eppendorf™ 
microcentrifuge tubes. Predilutions of probe substrates of each of the eight CYP450 
reactions monitored were prepared from stock solutions of different concentrations 
stored at -20 °C by diluting in water to working concentrations 40× higher than final 
incubation concentrations. For each incubation, 0.5 M pH 7.4 mixed phosphate buffer 
(BD Gentest, Oxford, UK) and 50 mM MgCl2 were both diluted to a working 
concentration of 0.1 M and 5 mM respectively by adding an appropriate volume of 
HPLC grade water. Human liver microsomes (mixed gender, pooled from 150 
individuals) were added to the buffer mixture to varying protein concentrations 
depending on the probe reaction and the pre-diluted (40×) probe substrate pipetted 
into the master mix. For test incubations, the chemical inhibitor under evaluation for 
cross reactivity was then added to the mixture while only the dilution solvent was 
added to the control incubations. The mixtures were pre-incubated at 37 °C for 10 min 
and the metabolic reactions initiated by addition of NADPH. All reactions were 
performed in duplicate and the tubes maintained at 37 °C while exposed to 
atmospheric oxygen by means of an Eppendorf ThermoMixer™ F1.5 benchtop 
incubator shaking at 300 rpm. The durations of the microsomal incubations were 
optimised for each probe substrate and selected to ensure that metabolism did not 
exceed 20%. 
Incubations were terminated by addition of 50% formic acid solution (10 µL per 100 µL 
incubation volume). A precise amount of 13C or 2H radiolabelled metabolite was added 
to the preparations to serve as internal standard and the samples subsequently 
purified using solid phase extraction. The purified eluents from SPE were loaded into a 
2 mL deep-well plate, evaporated to dryness under a stream of nitrogen at 40 °C and 
then dissolved in a mixture of 10% AcN in HPLC-grade water containing 0.1% formic 
acid. The resultant solutions were analyzed using LC-MS System 4 (Section 6.4.3.3) to 
quantify the probe metabolites. The mass spectrometer was operated in multiple 
reaction monitoring mode (MRM) at a source temperature of 120 °C and desolvation 
temperature of 300 °C. Analysis parameters for the different analytes are summarized 
in Table 6.7.  
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CYP1A2 Acetaminophen ESI + 152.1/110.1 [
2
H4] Acetaminophen 156.0/114.0 34 16 4A 
CYP2B6 Hydroxybupropion ESI + 256.0/139.0 [
2
H6] Hydroxybupropion 262.0/139.0 24 18 4B 





CYP2C9 4’-Hydroxydiclofenac ESI + 312.1/230.0 [
13
C6] 4’-Hydroxydiclofenac 319.0/237.0 20 32 4B 
CYP2C19 4’-Hydroxymephenytoin ESI - 233.05/190.05 [
2
H3] 4’-OH-mephenytoin 236.15/193.05 58 (56)
*
 15 4A 
CYP2D6 1’-Hydroxybufuralol ESI + 278.2/186.05 [
2
H9] 1’-Hydroxybufuralol 287.2/186.0 20 18 4B 
CYP2E1 6-Hydroxychlorzoxazone ESI - 183.9/119.95 [
2





CYP3A 1’-Hydroxymidazolam ESI + 342.1/203.5 [
2





 denote different cone voltage and collision energy values used to detect each metabolite and internal standard, respectively.  Values in parentheses are 
the settings used to detect the internal standard. In all other instances, the single values indicated were optimal for detection of both metabolites and internal 
standard. 
‡
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Gedunin 482.57 483.2; 505.1 96.9% 192 - 196 20 - 40 
Justicidin A 394.37 395.0; 417.0 99.5% 248 - 252 10 - 20 
Dehydrobrachylaenolide 244.29 267.1; 245.0 98.6% 225 - 228 > 200 
Metergoline 403.52 404.1; 426.1 97.9% 143 - 145 80 - 160 
Fusidic acid  516.71 539.2 97.3% 178 - 180 > 200 
Muzigadial 248.32 271.1 99.1% 125 - 128 > 200 
Muzi-04 305.37 306.1; 328.1 99.5% 249 - 252 20 - 40 
Cucurbitacin A 574.70 597.2; 613.1 96.5% 195 - 197 > 200 
Cucurbitacin B 558.70 581.2; 597.2 98.4% 172 - 175 > 200 
Cucurbitacin C 560.72 583.2 95.7% 198 - 201 > 200 
DC3 352.47 353.1 98.4% 218 - 220 > 200 
DC14 316.43 317.2; 339.1 97.9% 112 - 115 > 200 
Jamaicin 378.37 379.0; 401.0 96.2% 156 - 158 ND
‡
 
Calopogonium isoflavone 334.37 335.1; 357.0 96.3% 136 - 139 ND
‡
 
Formononetin 268.26 269.0; 291.0 98.9% 250 - 254 20 - 40 
Note: 
*







 = M+1 and [M+Na
+






Melting point values are uncorrected and reported as determined; 
‡
Not determined. Quantities of jamaicin and calopogonium isoflavone were insufficient for 








DESIGN AND SYNTHESIS OF FLUOROGENIC CYP450 PROBE SUBSTRATES 
 
Four fluorogenic probe substrates were synthesized, purified and characterised for 
use in testing inhibition of CYP450 enzymes by the natural products described in 
Chapter 3. 
 
7-Methoxy-4-(trifluoromethyl)coumarin (MFC) and 7-Benzyloxy-4-(trifluoromethyl) 
coumarin (BFC) 
The respective fluorogenic probe substrates for assessing inhibition of the 
recombinant CYP2C9 and CYP2C19 (MFC), and CYP3A4 (BFC) were each synthesized 
from commercially sourced 7-hydroxy-4-(trifluoromethyl)coumarin (HFC) via a single 
step Williamson ether synthesis as summarized in Scheme A.1. 
 
 
Scheme A.1: Reagents and conditions for the synthesis of MFC and BFC (i) Iodomethane, K2CO3, DMF, 
25 °C, 8h  (ii) Benzylbromide, K2CO3, THF, reflux, 12h 
 
7-methoxy-4-(trifluoromethyl) coumarin (MFC) 
Commercially sourced 7-hydroxy-4-(trifluoromethyl) coumarin (100 mg, 0.43 mmol) 
was dissolved in 3 mL anhydrous N,N-dimethylformamide and K2CO3 (125 mg, 0.90 
mmol) added. To the stirred mixture, iodomethane (55 µL, 127 mg, 0.89 mmol) was 
introduced using a micropipette and the solution stirred at room temperature for 8 
h. Progress of the reaction was monitored by TLC. The reaction was quenched by 
adding 15 mL distilled water and extracted with 3 x 25 mL portions of ethyl acetate. 
The combined extracts were dried over anhydrous MgSO4, concentrated in vacuo 
and purified in a silica gel cartridge using automated flash chromatography to obtain 
the target compound. 
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Pale yellow coloured crystalline powder (85.2 mg, 80.3%); m.p. 
98 - 101 °C; Rf (EtOAc:Hex, 1:1), 0.74; 
1H NMR (400 MHz, CDCl3) 
δ: 7.63 (d, J = 7.1 Hz, 1H, H-5), 6.92 (dd, J = 9.0 and 2.5 Hz, 1H, 
H-6), 6.88 (d, J = 2.5 Hz, 1H, H-8), 6.62 (s, 1H, H-3), 3.90 (s, 3H, -OCH3). HPLC purity 
95.2% (System 2; Rt = 3.54 min) 
 
7-benzyloxy-4-(trifluoromethyl) coumarin (BFC) 
Commercially sourced 7-hydroxy-4-(trifluoromethyl) coumarin (100 mg, 0.43 mmol) 
was dissolved in 10 mL anhydrous tetrahydrofuran and K2CO3 (123 mg, 0.90 mmol) 
added. To the stirred mixture, benzyl bromide (0.2 mL, 287 mg, 1.68 mmol) was 
introduced dropwise using a micropipette and the solution stirred under reflux for 
12 h. Progress of the reaction was monitored on TLC. The mixture was left to cool, 
then filtered under vacuum using a Buchner funnel and the filtrate washed with 3 x 
15 mL portions of distilled water. The organic layer was dried over anhydrous 
MgSO4, concentrated and adsorbed onto silica gel in vacuo then purified using 
automated flash chromatography to obtain the target compound. 
Off-white coloured crystalline powder (104.0 mg, 74.7%); 
m.p. 103 - 105 °C; Rf (EtOAc:Hex, 1:1), 0.83; 
1H NMR (400 
MHz, CDCl3) δ: 7.56 (d, J = 9.0 Hz, 1H, H-5), 7.37 – 7.28 (m, 
4H, Ar-H), 7.18 (d, J = 1.3 Hz, 1H, para Ar-H), 6.92 (dd, J = 
9.0 and 2.5 Hz, 1H, H-6), 6.87 (d, J = 2.2 Hz, 1H, H-8), 6.54 (s, 1H, H-3), 5.09 (s, 2H, -
CH2-, H-9). 
13C NMR (100 MHz, DMSO-d6) δ: 162.6, 159.3, 156.3, 141.4, 135.4, 128.8, 
128.5, 127.5, 126.4, 123.0, 120.2, 114.0, 112.3, 112.4, 107.3, 102.5, 70.7. Low 
resolution LC-ESI-MS (-ve ion mode): m/z 319.1 [M-H]-; HPLC purity 99.3% (System 2; 
Rt = 3.96 min). 
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CEC was synthesized as the probe substrate for monitoring the inhibition of CYP1A2. 
Preparation of this compound involved the initial synthesis, via a ‘green’ 
Knoevenagel condensation of malononitrile with 2,4-dihydroxybenzaldehyde in 
aqueous medium followed by Williamson etherification of the resultant 3-cyano-7-




Scheme A.2: Reagents and conditions for the synthesis of CEC (i) 0.05M aq. NaHCO3, 25 °C, 1.5h   
(ii) Conc. HCl, 90 °C, 1h (iii) Bromoethane, K2CO3, DMF, 25 °C, 12h 
 
3-Cyano-7-hydroxycoumarin 
To a 25 mL aqueous solution of 0.05M NaHCO3, 2,4-dihydroxybenzaldehyde (680 mg, 
4.92 mmol) and malononitrile (400 mg, 6.05 mmol) were added and stirred 
vigorously at room temperature for 1.5 h. 0.6 mL concentrated HCl was then added 
to the reaction and the heterogenous mixture heated at 90 °C for 1 h. The mixture 
was cooled and the desired compound recovered by filtration under vacuum using a 
Buchner funnel before drying at 50 °C to afford the target compound.  
Brown/red powder (842.4 mg, 91.4%); m.p. 269 - 272°C; Rf 
(EtOAc:Hex, 1:1), 0.18; 1H NMR (400 MHz, DMSO-d6) δ 11.29 (s, 
broad, 1H, -OH), 8.75 (s, 1H, H-4), 7.63 (d, J = 8.6 Hz, 1H, H-5), 
6.88 (dd, 1H, J = 8.6 and 2.3 Hz, H-6), 6.77 (d, J = 2.2 Hz, 1H, H-8). 13C NMR (100 MHz, 
DMSO-d6) δ: 165.3 (C-7), 158.0 (C-2), 157.1 (C-8’), 153.8 (C-4), 131.8 (C-5), 115.7 (-
CN), 115.1 (C-6), 110.8 (C-4’), 103.0 (C-8), 96.5 (C-3). Low resolution LC-ESI-MS (-ve 










3-cyano-7-hydroxycoumarin (200 mg, 1.07 mmol) was dissolved in 3 mL anhydrous 
N,N-dimethylformamide to which K2CO3 (300 mg, 2.17 mmol) was added. To the 
stirred mixture, bromoethane (0.2 mL, 292 mg, 2.68 mmol) was introduced using a 
syringe and the solution stirred at room temperature for 12 h. Progress of the 
reaction was monitored by TLC. The mixture was quenched by adding 15 mL distilled 
water and extracted with 3 x 25 mL portions of ethyl acetate. The combined extracts 
were dried over anhydrous MgSO4, concentrated in vacuo and purified in a silica gel 
cartridge using automated flash chromatography to obtain the target compound.  
 
Pale yellow coloured crystalline powder (122 mg, 53.2%); 
m.p. 201 - 204°C; Rf (EtOAc:Hex, 1:1), 0.41; 
1H NMR (400 
MHz, DMSO-d6) δ: 8.81 (s, 1H, H-4), 7.71 (d, J = 8.6 Hz, 1H, H-
5), 7.07 (d, J = 2.3 Hz, 1H, H-8), 7.03 (dd, J = 8.4 and 2.1 Hz, 1H, H-6), 4.19 (q, J = 7.0 
Hz, 2H, -CH2-), 1.35 (t, J = 7.0 Hz, 3H, -CH3). 
13C NMR (100 MHz, DMSO-d6) δ: 165.2 (C-
7), 157.9 (C-2), 157.1 (C-8’), 153.7 (C-4), 131.8 (C-5), 115.5 (-CN), 114.6 (C-6), 111.7 
(C-4’), 101.9 (C-8), 97.8 (C-3), 65.2 (C-9), 14.7 (C-10). Low resolution LC-ESI-MS (+ve 
ion mode): m/z 216.1 [M+H]+; 233.1 [M+NH4]
+; 238.0 [M+Na]+ HPLC purity 97.4% 








The synthesis of MAMC, the fluorogenic probe substrate for investigating the 
inhibition of rCYP2D6, was accomplished via a three step procedure (Scheme A.3) 
that involved initial Pechmann condensation of 3-methoxyphenol and ethyl-4-chloro-
3-oxobutanoate to form 4-chloromethyl-7-methoxycoumarin (a) which was 
subsequently converted to the corresponding azide (b) through a substitution 
reaction using sodium azide. The 4-azidomethyl-7-methoxycoumarin was then 
converted to the target primary amine via a Staudinger reduction. 
 
 
Scheme A.3: Reagents and conditions for the synthesis of MAMC (i) Amberlyst
®
-15, toluene, reflux, 




3-methoxy-phenol (500 mg, 4.02 mmol) and ethyl-4-chloroacetoacetate (695 mg, 
4.22 mmol) were added to 10 mL anhydrous THF and Amberlyst®-15 pellets (1 g) 
then added. The mixture was stirred under reflux for 12 h and progress of the 
reaction monitored on TLC. The mixture was allowed to cool and a minimum volume 
of DCM sufficient to dissolve the solid product formed added. This was then filtered 
to remove the Amberlyst® pellets and solvent evaporated from the filtrate in vacuo. 
The pure target product was obtained from the solid residue by crystallization using 
ethanol.  
Off-white coloured crystalline powder (843 mg, 93.6%); m.p. 
193 – 195 °C; Rf (EtOAc:Hex, 1:1), 0.58; 
1H NMR (400 MHz, 
CDCl3) δ 7.49 (d, J = 8.8 Hz, 1H, H-5), 6.83 (dd, J = 8.8 and 2.5 Hz, 
1H, H-6), 6.78 (d, J = 2.5 Hz, 1H, H-8), 6.33 (s, 1H, H-3), 4.55 (s, 
2H, -CH2-), 3.81 (s, 3H, -OCH3, H-9). 
13C NMR (100 MHz, CDCl3)  δ: 163.0, 160.7, 155.8, 
149.6, 125.1, 112.7, 110.8, 101.4, 101.3, 55.8. 41.3. Low resolution LC-ESI-MS (+ve 
ion mode): m/z 225.0 [M+H]+; HPLC purity 98.1% (System 2; Rt = 3.26 min). 
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4-chloromethyl-7-methoxy coumarin (275 mg, 1.2 mmol) was dissolved in 2 mL 
anhydrous DMF and sodium azide (90 mg, 1.4 mmol) added portion wise. The 
mixture was stirred at room temperature for 1 h and monitored by TLC. The reaction 
was quenched by adding 15 mL distilled water and the resultant solution extracted 
using 3 x 15 mL portions of ethyl acetate. The combined organic extracts were dried 
over anhydrous MgSO4 and the solvent evaporated under vacuum to afford the 
target compound.  
Reddish-brown powder (256 mg, 90.4%); m.p. 124 - 126 °C; Rf 
(EtOAc:Hex, 1:1), 0.52; 1H NMR (400 MHz, CDCl3) δ: 7.36 (d, J = 
8.7 Hz, 1H, H-5), 6.82 - 6.78 (m, 2H, H-6, H-8), 6.28 (t, J = 1.2 Hz, 
1H, H-3), 4.43 (d, J = 1.2 Hz, 2H, -CH2-), 3.81 (s, 3H, -OCH3, H-9). 
13C NMR (100 MHz, 
CDCl3) δ: 163.0, 160.6, 155.8, 148.6, 124.8, 112.7, 111.6, 110.8, 101.3, 55.8, 50.9. 
Low resolution LC-ESI-MS (+ve ion mode): m/z 232.0 [M+H]+; HPLC purity 96.4% 
(System 2; Rt = 3.27 min). 
 
4-methylamino-7-methoxycoumarin (MAMC) 
4-azidomethyl-7-methoxy coumarin (200 mg, 0.86 mmol) was dissolved in 5 mL THF 
to which triphenyl phosphine (450 mg, 1.72 mmol) and 0.5 mL H2O were added. The 
mixture was stirred under reflux for 2 h and monitored by TLC using both UV and 
ninhydrin detection. The solution was cooled then concentrated by evaporating the 
solvent under vacuum and the product purified by flash silica column 
chromatography to afford the target compound. 
 
Pale yellow coloured crystalline solid. (76 mg, 42%); m.p. 121 - 
124 °C; Rf (DCM:MeOH, 9:1), 0.51; 
1H NMR (400 MHz, DMSO-d6) 
δ: 7.67 (d, J = 8.8 Hz, 1H, H-5), 6.97 (d, J = 2.4 Hz, 1H, H-8), 6.92 
(dd, J = 8.8 and 2.4 Hz, 1H, H-6), 6.38 (s, 1H, H-3), 3.91 (s, 2H, -CH2-), 3.84 (s, 3H, -
OCH3), 1.98 (broad, s, 2H, -NH2). 
13C NMR (100 MHz, DMSO-d6) δ: 162.6, 161.2, 
158.6, 155.2, 125.9, 112.5, 112.1, 108.7, 101.3, 56.3, 42.1. Low resolution LC-ESI-MS 
(+ve ion mode): m/z 206.1 [M+H]+; HPLC purity 96.7% (System 2; Rt = 1.45 min) 
